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Abstract 
Signaling by growth factors from the TGF~/activin has a profound impact on 
cancer development. They can either negatively regulate tumor development by 
their ability to inhibit cell growth, induce apoptosis and limit the number of cell 
divisions through inhibition of telomerase activity, or positively promote cancer 
through the induction of angiogenesis, epithelial to mesenchymal transition, and 
the suppression of the immune response. These ligands bind to serine-threonine 
kinase receptors that phosphorylate the Smad proteins: Smad2 and Smad3. Once 
phosphorylated, Smad2/3 cooperate with Smad4 to activate or repress expression 
of TGF~ and activin target genes. It is the combined expressionlrepression of the 
numerous target genes that determine the physiological outcome of TGF~ and 
activin signaling. In this thesis, we have characterized the molecular mechanisms 
by which TG~ and activin repress two target genes that are often overexpressed 
in human tumors. First, we studied the inhibitory effects of TGF~/activin on cell 
growth and prolactin (PRL) production in pituitary lactotroph tumor ceIls, as 
prolactinomas are tu mors that secrete large amounts of PRL, causing endocrine 
and reproductive disorders. We showed that activin represses PRL expression 
through the Smad pathway and the tumor suppressor menin by downregulating 
the expression of Pit -1, a pituitary transcription factor essential for PRL 
expression. Second, we wanted to understand how TGF~ inhibits hTERT gene 
expression, the gene encoding for the protein component of telomerase. In 90% of 
cancers, telomerase is reactivated through the induction of hTERT, allowing 
cancer cells to become immortal. Using the keratinocyte HaCaT cell line, we 
showed that TGF~ rapidly increased E2F-l expression, through the Smad 
pathway, Erk and p38 kinases. We identify four binding sites for E2F as critical 
for hTERT inhibition by TGF~. Moreover, interfering with E2F activity also 
abolishes hTERT inhibition by TGF~. These data identify E2F-l as the 
intermediate factor required by TGF~ to repress hTERT expression. 
Understanding the mechanisms used by TGF~ and activin to regulate their target 
genes is important to improve our basic knowledge on how cancers progress. 
More importantly, it can create new avenues for cancer therapy development. 
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Résumé 
Les voies de signalisation du TGF~ et de l'activine jouent un rôle important dans 
le développement du cancer. Elles peuvent inhiber le développement des tumeurs 
en réduisant la prolifération cellulaire, en induisant l'apoptose et en limitant le 
nombre de division cellulaire potentielle en inhibant l'activité de la télomérase ou 
soutenir la progression du cancer en induisant l'angiogénèse, la transition des 
cellules épithéliales en cellules mésenchymales et en réprimant le système 
immunitaire. Ces ligands sont reconnus par des récepteurs possédant une activité 
sérine/thréonine kinase qui phosphorylent les protéines Smad2 et Smad3. Une fois 
phosphorylées, Smad2 et Smad3 interagissent avec la protéine Smad4 pour activer 
ou réprimer l'expression de centaines de gènes cibles. Les effets biologiques du 
TGF~ et de l'activine sont exécutés par la combinaison des nombreux gènes 
cibles exprimés. Pour cette thèse, nous avons caractérisé les mécanismes 
moléculaires par lesquels l'activine et le TGF~ répriment deux gènes cibles 
souvent surexprimés lors du développement des cellules cancéreuses. 
Premièrement, nous avons étudié les effets inhibiteurs du TGF~/activine sur la 
prolifération cellulaire et l'expression de la prolactine (PRL) chez les lactotropes 
cancéreux de l'hypophyse. Les prolactinomes sont des tumeurs qui sécrètent 
énormément de PRL, causant des troubles endocriniens et de fertilité. Nous avons 
montré que l'activine réprime l'expression de la PRL en utilisant les protéines 
Smad et menin, une protéine encodée par le gène suppresseur de tumeur MEN l, 
de façon à diminuer l'expression de Pit-l, qui est un facteur de transcription 
essentiel à l'expression de PRL. Deuxièmement, nous voulions comprendre 
comment le TGF~ diminue l'expression du gène hTERT, gène encodant pour le 
composant protéique de la télomérase. Dans 90% des cancers, la télomérase est 
réactivée par l'induction de l'expression de hTERT, ce qui permet aux cellules 
cancéreuses de devenir immortelles. Utilisant la lignée cellulaire de kératinocytes 
HaCaT, nous avons montré que le TGF~ induit rapidement l'expression du facteur 
de transcription E2F-I, par la coopération des voies de signalisation Smad, Erk et 
p38. Quatre éléments de liaison à l'ADN pour E2F jouent un rôle important dans 
l'inhibition de hTERT par le TGF~. Bloquer l'activité d'E2F inhibe l'effet du 
XVII 
TGF~ sur l'activité du promoteur hTERT. Ces données identifient E2F-I en tant 
que protéine intermédiaire requise par le TGF~ pour réprimer l'expression de 
hTERT. Une bonne compréhension des mécanismes utilisés par les ligands TGF~ 
et activine pour contrôler leurs gènes cibles est importante pour améliorer nos 
connaissances fondamentales sur la progression des cellules sur la voie 
cancéreuse. Plus important encore, ces connaissances pourront éventuellement 
créer de nouvelles pistes pour développer de nouvelles thérapies anti-cancer. 
XVIII 
Chapter 1: Introduction 
According to the Canadian Cancer Society, an estimate of 153,100 new cases of 
cancer will be diagnosed this year and 70,400 persons will die from cancer in 
Canada in 2006. Given the high incidence of cancer in the population, everybody 
knows somebody whose life was changed by a diagnosis of cancer, or more sadly, 
died from this disease. Clearly, the battle against cancer is far from over (119). 
However, research has revealed that cancer cells develop from normal cells that 
acquire seven new capacities, now called the hall marks of cancer: (1) self-
sufficiency from growth signaIs, (2) lack of sensivity to anti-growth signais, (3) 
evading apoptosis, (4) sustained angiogenesis, (5) immortality, and (6) tissue 
invasion and metastasis (157). Furthermore, cancer cells need (7) to escape the 
immune system surveillance in order to proliferate (l09). 
These seven hall marks are normal physiological processes that are not properly 
regulated in cancer cells. Cancer cells acquire these capacities progressively, and 
are characterized by at least five defects in the numerous intracellular signaling 
pathways that normally regulate these processes (112, 298). These defects have 
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been shown in many cases to be the underlying basis for cancer development. 
These signaling defects are mainly caused by mutations within the genome that 
can have several consequences: overexpression or gain-of-function affecting an 
oncogene and silencing or loss-of-function of a tumor suppressor gene. 
As described in the following review of literature, TGF~ superfamily members, 
more specifically TGF~ and activin, are involved in the control of most, if not aIl, 
of these hallmarks. As such, they can either negatively regulate cancer cell growth 
by their ability to inhibit ceIl growth telomerase activity, and induce apoptosis or 
positively promote cancer progression through the induction of angiogenesis and 
EMT, and the suppression of the immune response. Extensive studies have been 
undertaken to characterize the TGF~ signaling pathway, from the growth factors 
themselves, their receptors to their main intraceIlular mediators, the Smad 
proteins. Yet, to regulate ceIl homeostasis, TGF~/activin ligands require changes 
in the expression of hundreds of genes and it is the interplay between the proteins 
encoded by these genes that mediate the final outcome on the cell. One third of 
the target genes are repressed in response to TGF~ or activin stimulation. 
1 am specifically interested in TGF~ and activin's ability to inhibit cancer 
development through their negative actions on ceIl growth and on telomerase 
activity. The goal of this thesis is thus to characterize, at the molecular level, the 
mechanisms by which TGF~ and activin control the expression of two repressed 
genes, the Prolactin gene and the hTERT gene. Identification of the TGF~/activin­
regulated target genes, and more importantly, the intraceIlular signaling pathways 
that lead to their regulation will advance our basic knowledge in the causes of 
cancer progression. Indeed, defects in signaling cascades following TGF~ and 
activin stimulation could lead to improper regulation of target genes that then 
could play a role in tumor progression. 
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Chapter 2: Review of the literature 
1. Overview of the TGFWactivin signaling pathway 
The TGFf} superfamily is formed by a large group of growth factors, comprised of 
TGFf} , activins and BMPs, among others. TGFf} , activins and their respective 
receptors are expressed in most tissues during embryogenesis and throughout 
adulthood. At the cellular level, these ligands have important regulatory roles on 
cell proliferation, apoptosis, angiogenesis, immune response, extracellular matrix 
and epithelial to mesenchymal transition. All the se outcomes of TGFf}/activin 
signaling place these ligands as key regulators of cell homeostasis. Inappropriate 
control of TGFf} and activin signaling pathways is of central importance to human 
diseases (263). Reduced TGFf} signaling has been linked to hyperproliferative 
disorders and cancer development, inflammatory and autoimmune diseases, while 
increased signaling has been involved in immunosuppression and tumor 
metastasis. Interestingly, TGFf}/activin have a dual role on cancer progression. 
They initially repress tumor formation by inhibiting cell proliferation and 
inducing apoptosis. However, as tumor cells progress toward malignancy, the 
TGFf} growth inhibitory responses are often replaced by invasive and pro-
metastatic responses, involving the normal ability of TGFf} to induce 
angiogenesis, EMT and to repress the immune response. 
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Figure 1: Overview of the TGFWactivin signaling pathway. A) Ligand binding 
to the type II receptor triggers the recruitment of the type 1 receptor. B) The type 
II receptor phosphorylates the type 1 receptor. C) Activated type 1 receptor 
phosphorylates R-Smad. D) R-Smads associate with Smad4. E) Once in the 
nucleus, R-Smads-Smad4 complexes associate with transcription factors, co-
activators or co-repressor to regulate expression of hundreds of target genes. 
Adapted from Shi et al. (347) 
TGF~ and activins signal through different serinelthreonine kinase receptors but 
share the same signaling pathway. Once the ligand becomes available to the 
extracellular domain of the receptors, they bind to the type II receptor and this 
newly formed ligand-type II receptor complex triggers the recruitment of the type 
1 receptor (Fig. la). The type II receptor phosphorylates the GS domain of the type 
1 receptor (Fig. 1 b). This activates the kinase activity of the type 1 receptor and 
also promotes the recruitment of intracellular signaling molecules, named the 
receptor-regulated Smads (R-Smads). The type 1 receptor phosphorylates the Ser-
X-Ser motif of the R-Smads that is located at the C-terminus of the protein 
(Fig.lc). Once phosphorylated, R-Smads are released from the receptors and bind 
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to the Common-Smad (Co-Smad) or, as it is referred to, Smad4 and this complex 
then translocates to the nucleus (Fig.1d). R-Smads/Smad4 complexes interact with 
a multitude of DNA-binding factors, co-activators and/or co-repressors. These 
interactions are key determinants in the selection of hundreds of genes that are 
controlled by TGF~/ activin signaling (Fig. le). Several other signaling pathways 
(such as MAPKs pathway, Rho GTPase pathway, etc) are also activated following 
TGF~/activin stimulation. The activation of these pathways is highly cell and 
tissue specifie. 
2. TGF~ Superfamily 
a. Characteristics of the TGF~ superfamily of ligands 
TGF~ superfamily members are encoded by 42 open reading frames (ORFs) in 
humans,9 in Drosophila melanogaster and 6 in Caenorhabditis elegans (214). Of 
these 42 human ORFs, at least 29 encode for bona fide ligands (115). AlI TGF13 
family members are homo- or heterodimer complexes containing two 12-15kDa 
monomers. AlI monomers contain one cysteine residue involved in the inter-
subunit disulfide bond and six more cysteine residues that form three 
intramolecular disulfide bonds, creating the cysteine knot structure (Fig.2a). The 
cysteine knot is a motif that forces exposure of hydrophobie residues creating the 
dimerization interface (369). This results in a highly stable dimeric protein with a 
butterfly-shape structure, as illustrated by the crystal structure of TGFI33 (Fig.2b) 
(281,347). Each monomer is the C-terminal part of a precursor propeptide, which 
also contains a N-terminal peptide signal for secretion and a long propeptide of 
200-300 ami no acids residues (9). 
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b) 
Figure 2: The cysteine knot and structure of TGF~3. A) The structure of the 
TGF~ family cysteine knot monomer consists of two finger-like anti-parallel beta-
strand projections (gold), and an alpha-helical heel region (green). Two disulfide 
bridges complete a ring of covalent bonds that is penetrated by a third disulfide 
bond to form the knot. Reproduced from Peprotech Company. B) Monomers are 
colored blue and green, respectively. Red lines represent cysteine side chains and 
disulfide bonds. A disulfide bond links the di mer. Adapted from Shi et al. (347). 
Ligands are divided into two subfamilies: 1) TGF~s/activinsINodal family and 2) 
Bone Morphogenetic Proteins (BMPs)/ Growth and Differentiation Factor (GDF)/ 
Muellerian Inhibiting Substance (MIS) family (Table 1). These subfamilies are 
defined by sequence similarities and by the particular signal they induce. Between 
the different subgroups, sequence identity is 30%-50%. However, within the same 
subfamily, sequence homology increases to 60%-80% (381). 
Table 1: The TGF~ Superfamily. Adapted from Massagué et al. (259). 
Mammal Frog Fruitfly Worm 
(Homo sapiens) (Xenopus laevis) (Drosophila (Caenorhabditis 
melanogaster) elegans) 
BMP2 BMP2 
BMP4 BMP4 DPP DAF-7 
BMP5 
BMP6 (Vgrl) 
BMP7 (CP1) BMP7 GBB 
BMP8 (CP2) 
GDF5 
GDF6 (BMP13) GDF6 
GDF? (BMPI2) 
GDFl Vgl SCW 
GDF3 (Vgr2) 
GDF2 (BMP9) 
BMPlO 
BMP3 ADMP 
GDFlO 
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Mammal Frog Fruitfly Worm 
(Homo sapiens) (Xenopus laevis) ( Drosophila ( Caenorhabditis 
melanogaster) elelfans) 
Nodal Xnrl-4 
Activin ~A Activin ~A DACTIVIN 
Activin ~B Activin ~B 
Activin ~C Activin ~C 
Activin BE Activin BD 
TGF~1 TGF~5 
TGF~2 TGF~2 
TGF~3 
GDFll (BMP11) 
GDF8 MYOGLIANIN DBL-l 
BMP15 
GDF9 
AMH(MIS) 
Inhibin-a 
EBAF (Leftyl) Lefty-A 
Lefty 2 Lefty-B 
MAVERICK UNC-129 
Oneunamed Oneunamed 
b. TGF~s discovery and extracellular regulation 
TGF~ was initially described as an activity produced by retrovirally-transformed 
cells (322). TG~1 was first purified from human and porcine platelets (14), from 
human placenta (122) and from bovine kidneys (321). It is now obvious that 
TGF~s are expressed in most if not alI celI types and normal tissues from 
embryogenesis to adulthood. 
In humans, three TGF~ isoforms, products of three different genes, have been 
described: TG~I, TGF~2, and TGF~3. Each gene encodes for a protein 
containing a signal peptide for secretion, a large N-terminal pro-region, and the 
active peptide. TGF~ monomers can only form homodimers (261). In the Golgi, 
the propeptide is separated from the active TGF~ dimer by furin-type enzymes 
(102). However, the TGF~ propeptides, which are also named latency-associated 
proteins or LAPs, remain attached by non-covalent interactions with the TGF~ 
dimer. LAPs inhibit TGF~ from binding to its receptors due to their high affinity 
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interaction with TGFf3 (221). Before its secretion, the TGFf3-LAP complex forms 
disulfide bounds with the latent-TGF~-binding protein or LTBP, creating the 
secreted form of TGF~ that is called the TGFf3 large latent complex or LLC (130, 
284, 326). Moreover, once the LLC is secreted, LTBPs are covalently linked to 
proteins of the extracelIular matrix (ECM) via isopeptide bonds formed by the 
enzyme transglutaminase (Fig. 3) (299)(9). 
LAP1 
LLC 
-:===:::::::==; Extracellular Matrix 
(Y] LAP 
U TGFf\ 
;f Isopeptide Bond 
Figure 3: Schema of the TGF~ large latent complex. TGF~1 is in black, LAP1 
in red, and disulfide bonds in light blue. TGF~ and LAP are cleaved at the site 
indicated by the arrowhead. Adapted from Annes et al. (9) 
In order to be active, TGFf3 must dissociate from its LLC. Multiple activators of 
latent TGF~ complexes have been described. They all function by disrupting the 
interaction between LAPs and TGFf3s. For example, ECM degrading enzymes 
like plasmin (333), MMP-2 and MMP-9 (443) can induce the activation of latent 
TGF~. It also occurs through a direct interaction between the ECM protein 
thrombospondin-1 and LAP that disrupt LAP-TGF~ association (293). Integrin-
<Xv~6 was also proposed to mediate TGF~ activation through a direct interaction 
with LAP (291). AlI these activators share a common characteristic: they are 
indicative of ECM perturbations that are associated with phenomena like 
angiogenesis, wound repair and immune response, etc. 
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Annes and colleagues propose a model in which latent TGF~ complex is a 
molecular sensor that responds to specific signaIs modifying the ECM by 
releasing TGF~, which is known to have an important impact on ECM 
homeostasis, as described in section 8. In summary, the concentration of active 
TGF~ is regulated through its conversion of latent TGF~ to active TGF~ in the 
extracellular milieu and this conversion is necessary to generate cellular 
responses. 
Although each TGFf3 isoform seems to play a different role in a variety of 
responsive tissues, it has been extremely difficult to delineate specific functions to 
specific isoforms. Nevertheless, phenotype analyses of knockout mice of 
individual TGFf3 isoforms knockout mice reveal important information about the 
unique and overlapping functions of TGF~I, TGF~2, and TGF~3. TGF~1 
knockout mice die approximately four weeks after birth from a marked infiltration 
of lymphocytes and macrophages, resulting in tissue necrosis of the heart, lung, 
stomach, liver, pancreas, colon, among others (40, 70, 205, 206, 228, 353). As 
such, TGF~ 1 knockout mice are providing a good model for autoimmune disease 
and point for a role of TGF~l in the regulation of the immune system. Moreover, 
an embryonic phenotype is observed as 50% of the TGF~l-t- mice die at ElO.5 
due to defects in hematopoiesis and differentiation of extraembryonic tissue (101, 
227). 
TGF~2-t. mice are characterized by craniofacial, eye, spinal column, lung, limb, 
urogenital, and cardiac malformations. They die shortly before or during birth 
because of congenital cyanosis (331). Ablation of the TGFf33 gene results in death 
within 24 hours after birth. TGFf33·t. mice display a deft palate, and delayed lung 
development (190, 317, 378). No others organs malformations have been reported 
yet. 
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c. Activins discovery and extracellular regulation 
Activin and inhibin were first isolated from ovarian follicular fluid based on their 
ability to modulate Follicle-stimulating hormone (FSH) secretion from 
gonadotrophs in the pituitary (323, 391). Activin stimulates FSH secretion from 
the gonadotrophs of the pituitary, whereas inhibin antagonizes activin effect on 
FSH secretion. Activin was also purified independently as a factor produced by 
human leukemia cells that induce differentiation of erythroleukemia cells (111). 
Activin is also an important regulator of cell growth and apoptosis (68). 
Activin is a dimer with two ~ subunits, whereas inhibin is a heterodimer with one 
a subunit and one ~ subunit. There are four mammalian ~ subunits (~A, ~B, ~C, 
and ~E), products of four different genes and one a subunit. The ~ subunits share 
63% sequence homology (381). ~A, ~B and a subunits can homo-or hetero-
dimerize, leading to five different secreted proteins: activin A (~N~A), activin B 
(~B/~B), activin AB (~N~B), inhibin A (a/~A) and inhibin B (a/~B) (225). ~C 
and ~E subunits expression are restricted to the liver and their functions are not 
characterized. ~E subunit has been detected only in the mouse. Livers from ~C 
and ~E knockout mice show a normal development and phenotype (219), 
suggesting that activin ~C and ~E subunits are not essential for embryonic 
development or liver function, although it can also be due to compensation by 
others activin subunits. In vitro studies suggest that activin C stimulate growth of 
the liver cellline AML12 (398), whereas transgenic mice overexpressing human 
activin ~E subunit display reduced proliferation of pancreatic cells (161). A ~D 
subunit has been identified in Xenopus only and its function is currently unclear. 
Contrary to TGF~, activins are secreted in their processed and biologically active 
forms (159). Once outside the cell, activins are rapidly bound almost irreversibly 
by follistatin, which are soluble extracellular proteins. In fact, nearly aIl activins 
in the circulation are bound to follistatin (335). Follistatin blocks activins ability 
to bind to its receptors and initiate signaling. The observation that the activin-
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follistatin association is almost irreversible strongly suggests that activins act 
mainly in an autocrine/paracrine manner, as do TGF/3s, and not in an endocrine 
manner (411). Other molecules, like the pseudo type 1 receptor BAMBI, bind 
activins and thereby block their signaling pathways (303). 
Inhibin A and inhibin B antagonize most of activin's effects. Inhibins are able to 
bind to the type II receptor (265,266) with the help of the co-receptor betaglycan 
(229) and this blocks access of activin to the receptors complex. Indeed, activins 
and inhibins share the same binding site onto ActRII (142). 
d. BMPs discovery and extracellular regulation 
Bone Morphogenic Proteins (BMPs), as their name suggest, were identified based 
on their ability to induce bone and cartilage formation in rodents (249, 404, 416). 
Over 20 BMPs family members have been identified. They signal through 
different combinations of three type 1 receptors (BMPRIA, BMPRIB, and 
ActRIA) and three type II receptors (BMPRII, ActRII, ActRIIB) (Fig.4). 
Extracellular proteins, such as noggin, chordin, gremlin, cerberus, DAN and 
follistatin, also bind BMPs. Not surprisingly, these associations block BMP 
activity by preventing assembly of the receptor complex. Moreover, BMPs 
signaling is sensitive to the inhibin blockade since BMPs use ActRII, as does 
activin (159). BMPs signaling have a broad range of effects on cell behavior. 
They are highly important for embryogenesis: they control mesoderm patteming, 
left-right asymmetry, organogenesis of kidney, ear, gut, lung and limb, among 
others. On a cell basis, they regulate proliferation, differentiation and apoptosis 
(51). 
3. Signaling at the membrane 
a. Receptors and co-receptors 
TGFI} family ligands signal via 12 serine/threonine kinase receptors that represent 
the complete family of serine/threonine kinase receptors encoded by the human 
Il 
genome (252). The TOF~ receptors are divided into two subfamilies: five type II 
receptors and seven type 1 receptors (Fig.4). Both types of receptors are organized 
into aN-terminal extracellular ligand- binding domain, a single transmembrane 
domain, a cytoplasmic serine/threonine kinase domain and exist as homodimers at 
the membrane without ligand stimulation (144). Type 1 receptors lack C-terminal 
extension, whereas most type II receptors have a short C-terminal extension with 
unknown functions (261). The kinase activity of the type II receptor family is 
constitutively active (418). AlI type 1 receptors contain a glycine-serine rich 
domain, called the OS domain located at the juxtamembrane do main of the type 1 
receptor. Upon ligand binding, the type II receptor phosphorylates this OS 
domain, thus activating the type 1 receptor kinase (418). Tyrosine residues are 
also phosphorylated on type 1 receptor by the type II receptor, and their 
phosphorylation is important for signaling (220). In the absence of ligand, the 
proteins FKBP12 and/or FKBPI2.6 bind to the OS motif thereby blocking access 
to the phosphorylation sites (67, 86). Moreover, the crystal structure reveals that 
the FKBP12 binding to type 1 receptor ensure an inactive catalytic conformation 
of the kinase domain (177). This protects the cells from inappropriate activation 
of signaling in the absence of ligand. 
The model of TOF~/activin binding to their receptors is based on mutagenesis and 
structural analysis of different ligands, receptors and ligand/receptors complexes 
(142, 144,382). It involves the association of homodimers of type Ireceptors and 
type II receptors, thus forming a heterotetramer complex. TOF~s and activins 
bind to their respective type II receptors T~RII and ActRIII ActRlffi in absence of 
the type 1 receptor. Once the ligands interact with the type II receptor, this recruits 
type 1 receptors into the complex, probably through a conformational change 
exposing the ligand binding site to the type 1 receptors. To stabilize the 
heterotetramer complex, the ligand contacts the extracellular domains of both 
types of receptors (39, 145). Moreover, the extracellular domains of both types of 
receptors also interact together when mediating TGF~3 binding (160). 
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TGF-I~1 
TGF-112 
TGF-i33 
Activin 
Nodal 
Lefty 
f3MP2/tl 
BÎ'11P6 
BMP7 
MISI 
AMH 
ligand RII RI 
III 
MISRn 
R-Smad 
activation 
Smad1 
ALK1 _ Smad5 
Smad8 
(Alk4) 
ActRIB 
ALK7 
~ Smad2 
Smad3 
BMPRIA ~ ~~:~~ 
BMPRIB Smad8 
ALK2 
Smad1 
Smad5 
Smad8 
Figure 4: Ligands, their receptors, and the possible Smad combinations. 
Adapted from Feng et al. (115). 
It is worth noting that the number of ligands greatly exceeds the number of 
receptors. As illustrated in Fig. 4, both types of receptors combine to form several 
different complexes that respond to different ligands. Only a few combinations of 
receptors are competent to mediate specific ligand binding and signaling. 
Moreover, a single ligand is able to activate multiple type I1type II complexes. 
The components of the receptor complex define the signaling pathways that will 
be triggered following ligand stimulation. Thus, a ligand can induce different 
responses according to which type 1 receptors are activated (115). Typically, T~RI 
and ActRIIActRIB phosphorylate Smad2 and Smad3, while BMPRI activates 
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Smadl, Smad5, and Smad8 (Fig.4) (261). However, TGF~ can induce the 
formation of two different receptor complexes: the classical T~RIIrr~RI and 
T~RIIIALKI that phosphorylates SmadIlSmad5/Smad8 (140). These two 
pathways have opposing effects and define the balance in endothelial cell 
migration and proliferation (139). 
Two co-receptors have been described for TGF~s: betaglycan (also named 
T~RI1I) and endoglin, both sharing two similar regions within the N-terminal 
portion of the protein. Betaglycan is a membrane-anchored proteoglycan that 
contains a large extracellular domain, a single transmembrane domain and a short 
cytoplasmic tail. Betaglycan is crucial for TGF~2 binding to T~RII because it 
greatly increases the affinity of TGF~2 to T~RII (46, 244). T~RII phosphorylates 
the cytoplasmic part of betaglycan; this promotes the recruitment of ~-arrestin to 
the receptor and regulates TGF~ receptors complex internalization (64). 
Endoglin is an accessory component of the TGF~ receptors complex (19, 59), 
including receptors for activin-A, and is mainly expressed in vascular endothelial 
ceUs. The level of endoglin expression determines the outcome of TG~ 
stimulation. In the absence of endoglin, endothelial cells do not grow and ALKI 
signaling is blocked whereas ALK5 signaling is increased. The level of endoglin 
may thus function as a modulator of the balance between ALKI and ALK5 
signaling pathways in response to TGF~. Indeed, endoglin is necessary for TG~ 
signaling through the T~RIIIALKI complex in endothelial cells (224). ALKI 
signaling is thought to promote the activation of angiogenesis. TGF~ itself 
regulates endoglin expression (230), thus opening the possibility of a feedback 
loop control mechanism. 
b. Internalization of the receptors 
Internalization of membrane receptors, such as receptor tyrosine kinases (RTK), 
G-protein coupled receptors (GPCR) and T~Rs, can occur through two main 
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pathways: the classic clathrin-mediated endocytosis and the clathrin-independent, 
but lipid-raft caveolin-dependent endocytic pathway. Whatever the pathway used, 
internalization controls several aspects of receptor signaling. Internalization is 
important for degradation (or not) of the receptor complex, hence controlling the 
ability of a cell to respond to ligands. Moreover, internalized receptors mediate 
activation of signaling pathways that are not triggered by receptors remaining at 
the surface of the cell (222). 
T~Rs internalization occurs through clathrin-mediated AND caveolin-mediated 
endocytosis (99). T~Rn internalizes through clathrin-coated pits, perhaps in 
collaboration with betaglycan that binds to ~-arrestin2 (64). Importantly, 
interfering with the clathrin-mediated endocytosis of T~R receptors decreases 
Smad signaling. On the other hand, T~Rs are also internalized by clathrin-
independent mechanisms and detected in lipid rafts. Interestingly, the lipid raft-
bound T~Rs are associated with the Smad7-Smurf2-ubiquitin complex (described 
below). AIl together, these observations have led to a model in which the T~Rs 
internalized by the clathrin-mediated endocytosis mediate signaling, whereas the 
T~Rs internalized by the caveolarnipid rafts-dependent pathways promote 
degradation of the receptor complex (Fig.5). Clearly, increasing the prevalence of 
one internalization pathway over the other would have a strong effect on the 
signaling outcome. It is so far not known what signais control the TGF~ receptors 
partitioning between these two internalization pathways. Not much is known 
about the internalization of the activin receptor. One study demonstrates that Alk4 
can internalize but this internalization is not necessary for Smad2 phosphorylation 
and signaling (452). 
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Figure 5: Two T~R internalization pathways with different signaling etTects. 
A) Clathrin-coated pit intemalization of the receptors produces TGF~ signaling. 
B) Intemalization through the caveolae results in the degradation of the TGF~ 
receptor complexes. Reproduced from Le Roy, et al. (222). 
c. Phosphorylation of the Smads 
Following ligand stimulation, activation of the type 1 receptor leads to the 
phosphorylation of the Smad proteins (95, 172, 241). So far, Smads are the main 
characterized substrates of the type 1 receptors. They are transcription factors that, 
once activated, translocate to the nucleus and regulate target genes (264). The 
human genome encodes for eight Smad genes that can be classified into three 
categories: R-Smads, Co-Smad and I-Smads. The receptor-regulated Smads (R-
Smads) subfamily contains five members that are substrates for the type 1 
receptors. Among those, Smad2 and Smad3 are phosphorylated following 
TGF~s/activins/nodal treatment, while Smadl, Smad5, and Smad8 are the 
substrates of BMPs receptors and anti-Muellerian receptors. The Smad4 protein, 
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also termed Co-Smad, is a partner for aIl R-Smads. FinaIly, Smad6 and Smad7 are 
caIled the I-Smads (lnhibitory-Smads) because of their ability to antagonize TGF~ 
ligands signaling (264). 
Each Smad protein contains about 500 amino acid residues divided in two 
globular domains tethered by a linker region (Fig.6a). The MHl (Mad-Homology-
1) region is a DNA-binding domain stabilized by a tightly bound zinc atom (55). 
The MHl domain is conserved in Smad4 and aIl R-Smads, whereas I-Smads do 
not possess MHl domains. As revealed by crystal studies, the MHl domain of 
Smad3 associates with DNA through a characteristic ~-hairpin structure (55, 348). 
The amino acid sequence of the ~-hairpin structure is conserved in aIl R-Smads 
and Smad4, suggesting that they aIl bind to a similar DNA sequence. However, 
the most commonly spliced form of Smad2 is unable to bind DNA because it 
contains an insert encoded by exon 3 of the Smad2 gene that is located N-terminal 
to the ~-hairpin structure. This insert is though to disrupt the ability of the ~­
hairpin structure to bind DNA (348). 
a) R .. $mad 
s.n.d1, Smad2. 
Smad3, SmadS, Smadt 
a..lc HydroDbobk 
pocket corridor 
Co-Smad 
Sinad4 
I .. Smad 
Smad6 
Smacl7 
b) 
RSmad·Smad4 complex 
Figure 6: Schematic representations of the Smad family. A) R-Smads and co-
Smad bind DNA through the ~-hairpin (hp) structure in the MHl domain. The 
linker domain of R-Smads contains phosphorylation sites recognized by kinases 
other than T~RI, whieh phosphorylates the SXS motif and Co-Smad possesses a 
Nuc1ear Export Signal (NES) domain in the linker. PY motif binds SMURF 
proteins in the case of R-Smad and I-Smads. The MH2 domain mediates 
interactions with several different partners; in the case of R-Smads, sorne of them 
are through the hydrophobie corridor, as described in the text. FinaIly, co-Smad 
contains a Smad4 Activation Domain (SAD) important for transcription. B) R-
Smads and co-Smad interact together through direct binding of the 
phosphorylated SXS motif and the basic pocket of the MH2 domain. Adapted 
from Massagué, et al. (264). 
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The ami no acid sequence of the linker region is not conserved among the different 
Smads. In sorne Smads, it contains binding sites (PY motifs) for the Smurfll2-
ubiquitin ligase complex and several confirmed and putative phosphorylation sites 
for kinases other than the type 1 receptors. Finally, Smad4 linker region also 
contains a Nuclear Export Signal (NES) (Fig. 6a) (313). 
The MH2 (Mad-Homology-2) is a globular domain located at the C-terminus of 
proteins that mediate protein binding with multiple proteins. In R-Smads only, the 
MH2 domain contains the characteristic Ser-X-Ser motif at the very C-terminus of 
the protein (Fig.6a). These two serine residues are phosphorylated by the activated 
type 1 receptor (1, 362). Moreover, the MH2 domains of R-Smads contain a 
characteristic pocket lined with basic residues (Fig.6a) that mediate binding with 
the phosphorylated as domain of the type 1 receptor. Smad4 also possesses this 
basic pocket, which mediates the association with the phosphorylated tail of R-
Smads (Fig.6b). The crystal structure of the Smad2 MH2 domain also revealed 
the presence of a hydrophobic corridor (Fig.6a) (419) that can interact with 
several cytoplasmic or nuclear proteins, this will be described later. This 
hydrophobic corridor appears to be very important for R-Smads localization. 
Smad4 contains a Smad4 activation domain (SAD) that overlaps with the end of 
the linker region and the beginning of the MH2 domain (Fig.6a). Activation of 
transcription by Smad4 requires this SAD region (89). 
In their inactive form, type 1 receptors are associated with the FKBP12 repressor. 
The phosphorylation of the as box of the type 1 receptor promotes the release of 
FKBP12 allowing R-Smad binding to the as domain that is followed by 
phosphorylation of R-Smads by the activated type 1 receptor (67, 177, 178,419). 
However, as motif binding does not explain the specificity of the different type 1 
receptors to their respective R-Smads. This specificity is linked to the amino acid 
sequence of the type 1 receptor LA5 loop (66, 114). For example, T~RI and 
ActRIB lA5 loops are identical and they both exclusively activate Smad2 and 
Smad3. Compared to T~RI LA5 loop, the BMPRINBMPRIB lA5 loop differs in 
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four amino acid residues, while the Alkl and Alk2 lA5 loops differ in seven 
residues (115). As a result, these receptors only phosphorylate Smadl, Smad5, 
and Smad8. The lA5 loop of the receptor interacts directly with the L3 loop found 
in the MH2 domain of R-Smads (66, 242). Interestingly, the L3 loop of Smad2 
and Smad3 are identieal, but differs from the L3 loop found to be identical in 
Smadl, Smad5, and Smad8 (115). Thus, this lA51L3 loop association is 
responsible for the specificity receptorlR-Smad (66, 114, 242). In summary, the 
phosphorylated GS domain of the type 1 receptor drives R-Smads binding to the 
receptors, whereas the L45/L3 loop association is the key determinant for 
specificity of the interaction. Once phosphorylated, R-Smads are released from 
the receptor complex and are competent to signal. 
The I-Smads, as their names suggest, inhibit TGF~ and BMP signaling through 
different mechanisms. Smad7 appears to inhibit both the TG~ and BMP 
signaling pathways, whereas Smad6 primarily inhibits the BMP pathway. 
Inhibition mechanisms of the TGF~/activin signaling will he described later. 
d. Smads adaptors: SARA and others 
Several proteins have been suggested to function as R-Smads adaptors to facilitate 
phosphorylation by the type 1 receptor. The most studied of these putative 
adaptors is SARA (Smad Anchor for Receptor Activation) (387, 419). SARA 
contains an 80 amino acid Smad binding domain (SBD) and a FYVE domain that 
targets SARA mainly to early endosomes, and possibly to the plasma membrane. 
SARA thus restricts localization of Smad2/Smad3 at the plasma membrane and/or 
in early endosomes where T~RI is located. As SARA associates with both T~RI 
and Smad2/Smad3, this facilitates signaling (99, 164, 306). From crystallography 
study, the SBD of SARA contacts the hydrophobie corridor of the Smad2 MH2 
domain. When Smad2 becomes phosphorylated, its affinity for SARA decreases, 
which probably explains the release of phosphorylated Smads from the receptor 
complex (419). 
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Other proteins have been proposed to act as adaptors facilitating R-Smads 
phosphorylation by T~RI, such as HrslHgs (282), Disabled (169), TRAP-l 
(TGF~-receptor-associated protein) (423), TLP (TRAP-l-like protein) (113), 
Axin (124) and cPML (cytoplasmic form of the promyelocytic leukemia protein) 
(237). Interestingly, cPML interacts with SARA, Smad2/Smad3 and the T~Rs. 
This association appears to be critical for TGF~ signaling through the Smads. 
However, the physiological involvement of these different Smad adaptors needs 
to be analyzed in more detail (264). Genetic experiments, such as the creation of 
SARA knockout mice, would be of great help to understand the importance of 
these proteins in TGF~ signaling. For activin, TRAP-l and Dok-l has been 
described to bind the activin receptor and facilitate signaling from them (423, 
436). 
4. Smad proteins movement from the membrane to the nucleus 
a. Smad2, Smad3 and Smad4 nuclear import/export mechanisms 
Smad accumulation in the nucleus in response to TGF~ or BMP was the first 
observation that really defined the Smad proteins as effectors of the TGF~IBMP 
pathways (172, 241). Very interestingly, R-Smads and Smad4 are capable of 
translocation to the nucleus without the help of importins (429, 430). Classically, 
importin-a and importin-~ are key components of the nuclear translocation 
pathway for most cargo proteins. The nuclear localization signal (NLS) is 
recognized by importin-a. The importin-a-cargo complex then interacts with 
importin-~. Importin-~ associates to nuclear pore components to transport the 
cargo protein in the nucleus (431). On one hand, Smad2, Smad3 and Smad4 
interact directly with the nuclear pore components Nup153 and Nup214 through, 
again, the hydrophobic corridor of the MH2 domain (430). Blocking this 
interaction abrogates accumulation of the Smads in the nucleus. On the other 
hand, overexpressed Smad3 and Smad4 (not Smad2) directly associate with 
importin-~ (not importin-a), suggesting that these Smads translocate to the 
nucleus via an almost classical nuclear import process (208, 425, 426). However, 
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the efficiency of Smad3 nuclear import by the importin-dependent pathway 
appears to be weaker compared to the nuclear import via direct interaction with 
the nuclear pore (428). In brief, Smad2, Smad3 and Smad4 translocate to the 
nucleus through direct interactions with the nuclear pore. This process might be 
strengthened by interaction of importin-~ in the case of Smad3 and Smad4. 
Smad2 and Smad3 nuclear export is also mediated through direct interaction with 
the nuclear pore components (430). 
The classical CRMI-dependent nuclear export pathway, on the other hand, 
mediates Smad4 nuclear export (313). Treatment of cells with leptomycin B, a 
CRMI inhibitor, blocks Smad4 export while having no effect on Smad2 and 
Smad3 export (180, 430). The NES of Smad4 is thus important for its nuclear 
export. 
b. Retention in the cytoplasm versus retention in the nucleus 
Smad2, Smad3 and Smad4 are constantly moving from the cytoplasm to the 
nucleus and vice versa (Fig.7a) (431). This process occurs in the presence and in 
the absence of ligand stimulation (180). However, in the basal state, R-Smads 
appear to be retained predominantly in the cytoplasm (313, 408, 430). In the case 
of Smad3, the formation of high molecular weight complexes in the cytoplasm 
can explain the cytoplasmic retention (187). Furthermore, the Smad adaptors 
previously described may also function as cytoplasmic anchors for Smad proteins 
(Fig.7b). Indeed, upon R-Smads phosphorylation, the affinity of the hydrophobie 
corridor of R-Smads for SARA decreases, the hydrophobie corridor is thus free to 
interact with the nuclear pore components and R-Smads then translocate to the 
nucleus (430). Once in the nucleus, R-Smads interact with severa! DNA-binding 
partners and DNA. These in tum act as Smad nuclear retention factors (Fig.7c). 
Interestingly, sorne transcription factors, such as FoxHl and Mixer, interact with 
Smad through contact with the same hydrophobic corridor (318). As the Smad 
binding interface is the same for SARA, nuclear pore components and sorne 
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DNA-binding partners, the hydrophobic corridor is a key determinant for the 
localization of the Smad within the ceIl. 
Smad4 is located throughout the ceIl in the basal state and undergoes continuous 
shuttling between the cytoplasm and the nucleus (180, 313, 408). As R-Smads do, 
Smad4 accumulates in the nucleus foIlowing TGF~ treatment. Smad4 binds to 
phosphorylated R-Smads through its basic pocket (54, 420). Whether the 
interaction R-Smads/Smad4 oceurs before or after nuclear translocation is not 
weIl characterized. Whatever the case, Smad4 concentrates in the nucleus as a 
result of this association. R-Smads binding to Smad4 is thought to hide the NES 
of Smad4 from CRM1, thus protecting Smad4 from nuclear export (408). In 
contrast, when R-Smads are dephosphorylated, its NES becomes exposed and 
Smad4 is exported to the cytoplasm (Fig.7d) (180). 
Figure 7: Cytoplasmic shuttling of Smads. A) Smad2l3 continuously travels 
through the nuclear membrane. B) The adaptor SARA retains Smad2/3 in the 
cytoplasm in the absence of TGF~ stimulation. C) Following TGF/3 stimulation, 
Smad complexes are retained in the nucleus through binding to DNA and nuclear 
protein partners like transcription factors (Le. FOX). D) When Smad2/3 are 
dephosphorylated and free to go back to the cytoplasm or be degraded, Smad4 
protein is exported from the nucleus through the CRM1 pathway. Adapted from 
Xu, et al. (431). 
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In conclusion, Smads nucleocytoplasmic shuttling and nuclear dephosphorylation 
have been proposed as a mechanism allowing sensing of the receptor state 
(stimulated or not) at the membrane level (180), as illustrated in Fig.7. 
5. Smad pro teins in the nucleus 
a. Dogma: Smad-interacting partners and regulation of target genes 
As transcription factors, Smad4 and all R-Smads (except Smad2) are able to bind 
DNA. The sequence 5'-GTCT-3' or its complement 5'-AGAC-3' is the DNA 
sequence that is recognized with the highest affinity by Smad proteins, thus 
defining the sequence of the Smad Binding Element (SBE) (448). Indeed, several 
TGF~ target gene promoters do contain this sequence. The crystal structure of the 
Smad3 MHl domain-SBE shows that the second base of the SBE does not contact 
the MHl domain (348). So, substitutions of this base are not thought to affect 
DNA binding. Renee, Smad proteins bind severa! other sequences, such as the 
TGF~ Inhibitory Element (TIE: 5'-GGCTT-3') in the c-Myc promoter (62, 120) 
and GC-rich sequence in the promoters of Vestigial (197) and Tinman (432)in 
Drosophila. 
The SBE sequence is quite frequent in the genome and the affinity of the Smad 
proteins for their DNA binding sites is low (348). Rowever, TGF~ signaling 
induces very specifie and regulated gene responses. High affinity of Smad binding 
to DNA is achieved through the incorporation of other DNA-binding proteins into 
the R-Smads/Smad4 complexes on target gene promoters (264). Indeed, a rapid 
literature review demonstrates that Smad proteins interact with a wide range of 
transcription factors of several families, co-activators and co-repressors. This 
model provides a basis to explain how the selection of the target genes regulated 
by TGF~ in different cell types is achieved, as described below. 
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R-Smads/Smad4/DNA-binding partner complexes regulate the transcriptional 
outcome of TGF~ signaling in four ways. (1) DNA-binding partnerlSmads 
complexes bind to DNA with a much higher affinity than the Smad complexes 
alone. This implies that the SBE and the DNA binding element of the Smad 
partner are located in the right orientation and separated by the correct distance in 
the promoter of the target gene. (2) Sorne Smad partners are specifically binding 
to Smad2 and Smad3, while others bind to Smad1, Smad5 and Smad8. So, 
partners establish the pathway specificity for TGF~ and BMP gene responses. (3) 
Sorne Smad DNA-binding partners are only expressed in certain cell types; these 
specific Smads/partner complexes will thus regulate their target genes only in 
those cell types. (4) Finally, Smad proteins can recruit co-activators or co-
repressor complexes either directly or through their DNA-binding partner. In this 
way, target genes can either be activated or repressed following TGFJ3 signaling 
(264). In summary, Smad-interacting proteins determine which target genes is 
activated or repressed in which cell type in response to TGF~ or BMP signaIs. A 
list of the transcription factors, co-activators, and co-repressors that associate with 
the Smads can be found elsewhere (115, 392). 
b. Activation of gene transcription by TGF~ 
Microarray analysis revealed that about 75% of the TGF~ target genes are 
upregulated in the presence of TGF~ (61, 193, 445). A small number of these 
genes have been studied in detail. So far, induction of transcription involves at 
least two mechanisms. (1) R-Smads/Smad4 complex are capable of recruiting 
general eo-activators, such as p300/CBP (117, 316, 344, 384), P/CAF (183), and 
ARC105 (195) to promoters of target genes. This recruitment can be through 
Smad4 and/or Smad partners. Moreover, Smad complexes bind to more specific 
co-activators like MSG1, through the SAD of Smad4 (352, 433) and SMIF (17). 
Whether these specifie co-activators are essential for aIl TGF~ target genes 
induction remains to be shown. (2) In certain cases, Smad proteins displace 
transcriptional repressor complexes from the target promoter, thus allowing 
increased expression of the mRNA. In Drosophila, Dpp decreases the expression 
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of a transcriptional repressor, Brinker (256, 290). Brinker competes with Mad 
(Drosophila R-Smad) for DNA binding sites in the promoters of two genes: Zen 
and Ubx. When Brinker levels decrease, this favors the positive action of 
MadIMedea complexes, which trigger transcription of Zen and Ubx (200, 325). In 
conclusion, Smad proteins complexed with DNA binding partners can induce 
transcriptional activation through the recruitment of co-activators to the promoters 
of target genes. 
c. Repression of gene transcription by TGF~ 
TGF~ signaling also leads to repression of several target genes. A lot less is 
known about the molecular mechanisms underlying TGF~-mediated repression of 
gene expression. In certain cases, TGF~ inhibition of gene expression involves 
direct promoter binding by Smad complexes. TGF~ represses c-Myc expression 
in most cell types and its mechanism has been well studied as preventing c-Myc 
downregulation blocks TGF~ ability to inhibit cell cycle progression (61). c-Myc 
is rapidly repressed. The TGF~ inhibitory element (TIE) sequence within the c-
Myc proximal promoter is required for this inhibition. Smad3 interacts in the 
cytoplasm with heterodimers formed of E2F4 or E2F5 and DPI. This complex 
also contacts the pocket protein p107 that is known to recruit HDAC complexes. 
Upon activation of TGF~ signaling, this complex translocates to the nucleus, 
recruits Smad4, and bind to the c-Myc promoter, thus inhibiting its transcription 
(62, 120). Microarray studies revealed that Idl, Id2, and Id3 (inhibitors of 
differentiation) genes are repressed by TGF~ treatment. Repression of Idl 
requires cooperation between Smad3 and ATF3 proteins. TGF~ tirst increases 
ATF-3, which then interacts with Smad3 and together repress Idl expression 
through binding to the Idl promoter (193). In osteoblasts, Smad3 is also able to 
inhibit expression of the osteocalcin gene by the direct recruitment of HDAC4/5 
to Smad3IRunx2 complexes that bind to the Runx2 DNA binding element in the 
osteocalcin promoter (192). 
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On the other hand, Smad proteins are also able to repress gene expression by 
preventing the action of transcription al activators. TGF~ inhibits the 
differentiation of skeletal muscle and this effect has been proposed to be mediate 
by the binding of Smad3 to the transcription factor MyoD (240). In response to 
TGF~, Smad3 binds to MyoD. As a consequence, MyoD is unable to interact with 
its obligatory partner EI2147, thereby decreasing binding to E-box response 
element in genes important for myogenic differentiation. These examples point 
out that several more studies are required to fully understand how gene repression 
is mediated in response to TGF~. 
6. TerminationIDownregulation of TGF~ signaling 
a. Target genes and ubiquitination 
G-coupled receptor kinase 2 (GR[G) is one target gene induced by TGF~ that acts 
in a negative feedback loop to downregulate signaling. Upon TGF~ treatment, 
GRK2 binds to and phosphorylates Smad2 and Smad3 in the linker region. Once 
R-Smads are phosphorylated by GRK2, they are no longer competent for being 
phosphorylated by T~RI at the Ser-X-Ser motif. This results in the inhibition of 
target gene expression, cell cycle arrest and apoptosis (168). 
Two target genes have a repressive action on TGF~ ligands signaling: Smad6 and 
Smad7 genes. Smad7 expression is upregulated by TGF~/activin and BMP (21, 
182, 295) signaling while Smad6 is upregulated by BMP signaling only (4, 181). 
Smad7 transcriptional induction is rapid, occurring within one hour of ligand 
stimulation. I-Smads inhibit signaling in at least three ways. First, I-Smads 
interact with the activated receptor complex, thereby blocking access to the R-
Smads that cannot be phosphorylated (163, 295). Second, Smad6 can also 
associate with Smadl, creating a non-functional Smad complex (162). Finally, 1-
Smad are involved in the degradation of activated receptors through the 
recruitment of Smurf E3 ubiquitin ligases, as described below. I-Smads 
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upregulation is thus a negative feedback loop that ensures the proper duration of 
signaling. 
Smurfl and Smurf2 are HECT type E3 ubiquitin ligases, the HECT do main being 
responsible for its E3 ubiquitin ligase activity. Both Smurfs also contain WW 
domains that mediate the interaction with the PY motif found in the linker region 
of most R-Smads and I-Smads. Even though they are ubiquitously expressed, 
Smurfs must associate with their partners (R-Smads or I-Smads) to mediate their 
effects. Following TGF~ stimulation, Smad7 protein levels increase; 
consequently, Smad7 interaction with Smurf1l2 increases resulting in the nuc1ear 
export of the Smad7/Smurf1l2 complex. Smad7 brings Smurfl/2 proteins to the 
activated receptor and thus mediates the ubiquitination and degradation of both 
Smad7 and the activated receptors (106, 196,371,373). Altematively, Smad7 can 
recruit to the receptors other E3 ligases such as WWP-l (202) and NEDD4-2 
(207). A recent report suggests that p300 acetylates Smad7 onto two specific 
lysine residues in the N-terminal region. These residues are the same as those 
ubiquitinated by Smurf complexes. Therefore, Smad7 acetylation may serve to 
protect Smad7 and activated receptors from premature degradation (148). 
Activated Smad2 is targeted for ubiquitination and proteasomal degradation 
(243). The E3 ubiquitin ligase mediating the ubiquitination has not been 
identified. Activated Smad3 is also targeted for destruction following 
ubiquitination by the SCFlRoc1 E3 ubiquitin ligase complex (123). Finally, 
Smad4 is also targeted for ubiquitination and degradation; a role for the Jabl (Jun-
activating domain binding protein 1) protein has been suggested since 
overexpression of Jabl results in the ubiquitination and degradation of Smad4 
(401). Smad4 degradation also occurs through the formation of complexes 
between Smad4 and Smurfs via binding to Smad2 or Smad617 (285). 
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b. Transcriptional deactivation: TGIF, Evi-l, SkilSnoN 
TGIF is a homeobox transcription factor that associates with Smad2 and Smad3. 
TGIF represses Smad-activated transcription in two ways. First, TGIF recruits 
HDACs complexes through its interactions with mSin3 (414) and CtBP (276). 
This results in chromatin condensation and therefore repression of transcription. 
Second, when Smads are bound to TGIF, they are unable to interact with 
CBP/p300 coactivators (415). So, competition between coactivators and 
corepressors for Smad binding determines the level of the transcriptional 
response. 
Evi-l is a zinc finger transcription factor. The Evi-l gene is involved in 
chromosomal aberrations that lead to at least three different Evi-l fusion proteins 
implicated in the progression of leukemia. Evi-l interacts with Smadl, Smad2, 
and Smad3 (7). Evi-l can recruit CtBP and HDACs corepressor (185). This 
appears to be the main mechanism by which Evi-l inhibits TGF~, activin and 
BMP signaling (7), although previous studies suggested that Evi-l also inhibits 
Smad3 DNA binding (209). 
The oncoproteins Ski and SnoN interact with Smad2, Smad3 and Smad4 upon 
ligand stimulation. They are recruited to the SBE of promoters responsive to 
TGF~ ligands. The N-terminal region of Ski and SnoN is highly conserved and 
mediates the association with the Smad proteins (248). Three models have been 
proposed to explain the inhibition mediated by Ski and SnoN proteins on TG~ 
signaling. (1) The crystal structure of the Smad4-binding domain of Ski with the 
MH2 domain of Smad4 revealed that Smad4 uses approximately the same region 
to bind Ski and R-Smad (via the pSer-X-pSer motit). So, it is plausible that Ski 
and SnoN interfere with the formation of an active R-Smads/Smad4 complex and 
thus represses Smad transcriptional functions (421). (2) Ski and SnoN also 
interact with transcriptional co-repressors like mSin3 and HDACI. In this way, 
they promote the formation of transcriptional repressor complexes on TG~ 
responsive promoters. (3) Smad proteins are unable to associate with CBP/p300 
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when binding to Ski or SnoN (6, 421). Of note, these proteins seem to diminish 
transcription of genes that are activated in response to TGF~ stimulation. They do 
not seem to be involved in the TGFf3-mediated repression of genes, similar to 
TGIF and Evi-l. 
Interestingly, SnoN, but not Ski, is tightly regulated by TGF~ ligands. Upon 
TGF~ stimulation, SnoN interacts with Smad2 and Smad3. These R-Smads 
recruit E3-ubiquitin ligases (Smurf1l2 and/or the Anaphase promoting Complex 
APC) that promote the degradation of SnoN (41,367,370,402). However, TGFf3 
induces the transcription of the Sno gene within two hours (368). This increases 
the levels of SnoN proteins that are then thought to shut off TGF~ signaling 
through a negative feedback loop mechanism. So, the family of Smurf E3 
ubiquitin ligases seems to have a dual regulatory role on TGF~ signaling. In early 
phases following TGF~ signaling, Smurfs act in a positive way by mediating the 
degradation of the repressor SnoN. However, in later phases of signaling, Smurfs 
have a negative effect on signaling since they mediate the degradation of receptors 
complexes. 
c. Smads phosphatases! Receptor phosphatases 
As mentioned earlier, Smads are dephosphorylated in the nucleus. One study in 
Drosophila revealed that the pyruvate dehydrogenase phosphatase (PDP) directly 
dephosphorylated MAD, a Drosophila Smad. This inhibits the signal transduction 
of Dpp. Moreover, the mammalian PDPs are able to dephosphorylate mammalian 
Smads but are specific to activated Smadl white having no effect on Smad2 or 
Smad3 (63). Recently, the phosphatase PPMIA1PP2Ca was identified as a bona 
fide Smad2/Smad3 phosphatase that promote the nuclear export of 
dephosphorylated Smad2/Smad3, thus abolishing the antiproliferative and 
transcriptional responses induced by TGF~ (239). 
Two recent papers pointed out a role for protein phosphatase 1 (PPl) in the 
dephosphorylation of the type 1 receptors following ligand stimulation (26, 346). 
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ln a study using Drosophila as a model, Bennett and colleagues reported that the 
catalytic subunit of PPI (PPlc) is bound to the Drosophila homologue of SARA. 
Blocking this interaction or reducing PPlc activity results in the 
hyperphosphorylation of the type 1 receptor and enhanced expression of target 
genes (26). In mammalian cells, Smad7 is known to interact with GADD34, 
which is a regulatory subunit of PPI. Smad7/GADD34 recruits the catalytic 
subunit of PPI to dephosphorylate T~RI. Moreover, SARA increases the 
recruitment of PPlc to the Smad7-GADD34 complex. Importantly, the binding of 
the Smad7-GADD34-PPlc complex to T~RI inhibits TGF~-induced cell cycle 
arrest (346). This suggests one more mechanism by which Smad7 decreases 
TGF~ signaling: SARA and Smad7 target PPlc to the type 1 receptor for 
dephosphorylation, and thus negatively regulate signaling. 
7. Other signaling pathways activated by TGFp!activin 
TGF~ and activin also activate several other signaling pathways: MAPKs, PI3K, 
Rho, Rac1 and Cdc42, among others. Actually, sorne of these non-Smad pathways 
were known to be activated by TGF~ ligands before the Smad pathway was 
discovered. Sorne evidence suggests that TGF~ signaling is possible without the 
involvement of Smads proteins. First, in Smad4 knockout cells, TG~ stimulation 
can still induce sorne responses (359). Second, mutant T~Rl that is unable to 
activate Smad proteins is still mediating JNK phosphorylation (184). The overall 
role and importance of these signaling pathways vary between cell types. Sorne of 
these non-Smad signaling molecules often act as direct inhibitors of Smad 
function. The opposite is also true: Smad proteins can modulate non-Smad 
proteins whose functions are to transmit signaIs to other pathways. Finally, 
several non-Smad proteins can directly bind with or bec orne phosphorylated by 
TGF~ receptors. These proteins do not necessarily affect Smad functions. The 
role and importance of these pathways on biological action mediated by TGF~ 
and activin need more investigation. 
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a. MAPK: general overview and activation by TGFp and activin 
Activation of MAPK occurs through sequential phosphorylation events of three 
highly conserved kinases. Activation of a MAPK kinase kinase (MAPKKK) 
results in the phosphorylation and activation of a MAPK kinase (MAPKK), which 
in tum phosphorylates a MAPK (Fig.8). Once phosphorylated, MAPKs become 
active and phosphorylate effectors proteins such as nuclear kinases and 
transcription factors. MAPKs are divided in three main subfamilies: the 
extracellular signal-regulated kinases (Erkl and Erk2) , the c-jun N-terminal 
kinases (JNK1, JNK2 and JNK3), and p38 kinases (p38a., p38~, p38y, p38o) (71, 
126). 
Stimulus 
MAPKKK 
MAPKK 
.... "'PK 
Biological 
Responses 
Growth Factors 
Mitogens 
GPCR 
~ 
"~~. , 
;ij~K~r,~:; 
~ 
Growth 
Dlfferentlation 
Devcloprnenl 
Stress. GPCR 
Inflammator}/ Cytokines 
Growth Factors 
"" 
>MLKl,: 
"r~l 
OU<' 
• MKIO/6 
p38 
Inflammation 
Apoplosis, Growlh 
Differentiatîon 
Figure 8: General MAPK cascade components. MAPK are serine/threonine 
protein kinases widely conserved among eukaryotes and are involved in many 
cellular programs such as cell proliferation, cell differentiation, cell movement 
and cell death. MAPK cascades are organized hierarchicaIly: MAPKs are 
phosphorylated and activated by MAPKKs, which in tum are phosphorylated and 
activated by MAPKKKs. The MAPKKKs are in tum activated by interaction with 
small GTPases and/or other protein kinases, linking the MAPK module to 
receptors and extemal stimuli. 
GeneraIly, Erk1l2 activation is mostly involved in proliferation, differentiation 
and protection from apoptosis (455). JNK and p38 kinases are activated following 
stress stimuli, such as heat shock, radiation or DNA damage. They are primarily 
promoting apoptosis, although in sorne circumstances, they appear to play a role 
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in proliferation and differentiation as weIl. As described in Fig.8, Raf-l 
specifically activates MEKI and MEK2, which activates Erk1l2. Raf-l is 
activated by Ras following growth factors and cytokines stimulation. JNKs are 
substrates for MKK4 and MKK7; p38 kinases are phosphorylated by MKK3 and 
MKK6. These MAPKKs are activated by several MAPKKK, like TAKI and 
MEKKI (71, 126). 
TGF~ and activin have been shown to induce the phosphorylation and activation 
of Erk1l2, p38, and JNKs in different combinations in a cell-type dependent 
fashion. In sorne cens, phosphorylation of MAPKs is a slow event, suggesting that 
it is not mediated by a direct effect of TG~ receptors. In other cell types, 
activation is a direct consequence of receptor activation since phosphorylation is 
detected within 5-10 minutes after TGF~ stimulation (259). The signaling 
mechanisms underlying the activation of MAPK by the TGF~/activin receptors 
are currently poorly characterized. 
TGF~ induces the conversion of Ras to its GTP-bound active form. In epithelial 
cens, activation of Ras and MEKI is necessary for Erk activation by TGF~ 
(Fig.9). A model has been proposed to explain the strange role of Erk in cell cycle 
inhibition mediated by TGF~: following TGF~ activation of Ras, Erk and JNK 
are activated. These two kinases are necessary for the formation of AP-l complex 
(mainly junD and Fra-2) at the AP-l sites in the TGF~ 1 promoter. This in turn 
increases the expression of TGF~ 1, creating a positive feedback loop (289). 
Furthermore, several studies strongly suggested that the RaslMAPK pathway 
cooperates with the Smad pathway during tumor progression towards metastasis. 
This cooperation appears to be particularly important for EMT (226, 300, 340). 
Obviously, more studies are necessary to delineate the involvement of Erk 
activation in TGF~-mediated outcomes. 
Activation of Erk through signaIs other then TGF~ regulates the Smad pathway. 
In cens with active Ras (either following gain-of-function mutations or 
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amplification of upstream activators like ErbB2), Erk phosphorylates the linker 
region of Smadl and/or Smad2. This appears to block nuclear accumulation of 
Smads and Smad signaling (203). This inhibitory effect of Erk (activated by other 
growth factor like FGF8 and IGF2) was confirmed by in vivo studies in Xenopus 
embryogenesis (146, 260, 310). Of note, none of these studies involve TGF~­
mediated activation of Erk but rather activation of Erk through other signaling 
pathways. 
More details are known about p38 and JNK activation downstream of TGF~ 
receptors. Upon TGF~ stimulation, TAB 1 is activated. In tum, TAB 1 activates 
TAKI (349,435). TAKI is a MAPKKK that mediates activation of JNKs and p38 
in response to TGF~ (Fig.9). Interestingly, Smad7 interacts with TAKI. The role 
of this interaction is not clear. In one study, Smad7 blocks apoptosis dependent on 
TAKlIp38 activity in response to BMP (437). In another study, this Smad7ffAKl 
association is suggested to act as a scaffolding complex important for MKK3/p38 
activation by TAKI (107). These two kinases are important for inducing 
apoptosis in response to TGF~ ligands (287). Moreover, our laboratory showed 
that p38 kinase activity is important for cell growth inhibition in breast cancer 
cells (72) and for the inhibition of Pit-l promoter activity in pituitary cells (90). 
XIAP, an E3 ubiquitin ligase, was identified as a bridging molecule between 
TAB 1 and the TGF~IBMP receptor and serves as an acti vator of T AKI signaling 
and JNK signaling (Fig.9) (31, 434). However, XIAP might not be the only 
protein mediating TGF~ activation of TAKI since XIAP-deficient mice respond 
to TGF~ (158). Interestingly, another mechanism involves XIAP in apoptosis 
mediated by TGF~: TGF~ induces the relocalization of the pro-apoptotic protein 
ARTS from the mitochondria to the cytoplasm where it interacts with XIAP. This 
leads to decreased XIAP protein levels, caspase-3 activation and ultimately 
apoptosis (138, 217). Another connecting protein, Daxx, binds to the cytoplasmic 
tail of T~Rn. Daxx was shown to be important for induction of apoptosis through 
the JNK pathway in B cell lymphoma and hepatocyte cell lines (311). Daxx 
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interacts with and is phosphorylated by the homeodomain-interacting protein 
kinase 2 (HIPK2). This event results in the activation of MKK4 and MKK7, 
which are the upstream activators of JNK (Fig.9) (170). 
b. Other signaling pathways activated by TGF~ ligands 
In polarized epithelial cells, T~RI is localized to tight junction complexes. The 
association of T~RI with the protein Occludin is important for this localization, 
where T~RI also associates with the polarity protein PAR6. Upon TGF~ 
stimulation, both T~RI and T~RII are localized to tight junctions where T~RII 
phosphorylates PAR6. Phosphorylated PAR6 remains attached to the receptor 
complexes and recruits the E3 ubiquitin-ligase Smurfl to tight junction where 
Smurfl stimulates the ubiquitination and the degradation of the small-GTPase 
RhoA (Fig.9). RhoA is important for the maintenance of tight junction structures. 
As a result, the localized diminution of RhoA activity would favor the loss of tight 
junction, an important step towards EMT (42, 305,405). 
Nevertheless, TGF~ also promotes the activation of the GTPases RhoA, Rac1 and 
Cdc42 (Fig.9), which are normally implicated in cytoskeleton organization and 
cell movement. Activation of these GTPases can be mediated by Ras activation in 
response to TGf13. Moreover, these GTPases are known activators of p38 and 
JNK, and they might mediate their activation following TGF~ treatment (15, 18, 
288). The mechanism by which these signaling proteins are engaged in the 
physiological effects of TGF~ is unclear. TGF~-mediated RhoA activation also 
leads to the activation of the downstream effector ROCKI kinase, which 
phosphorylates and inactivates the phosphatase CDC25A, whose activity is 
necessary for activation of the cyclin-dependent kinases and progression through 
the cell cycle (Fig.9) (29). The same pathway (RhoA-ROCKl) is also important 
for EMT (30). Activation of RhoA and Cdc42 are necessary to promote 
membrane ruffling in response to TGF~, probably through p38activation (108). 
Finally, in response to TGF~, ROCKI also activates Limk2 and subsequent 
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inhibition of cofilin and this lead to polymerization of actin, a step toward EMT 
(Fig.9) (393). 
TGF~ can also activate PI3K: the regulatory p85 subunit of PI3K indirectly 
interacts with the TGF~ receptor complexes and both receptors are needed to 
induce PI3K activity following TGF~ stimulation (Fig.9) (442). In human 
keratinocytes and hepatoma cells, TGF~ induces PKCa. activity. PKCa. 
phosphorylates the SlOOC/AII protein, which cooperates with SpI to induce p15 
and p21 gene expression (327). Finally, TGF~ receptors associate with the Ba. 
subunit of the phosphatase PP2A (composed of Ba., A~, and Ca. subunits) in a 
ligand-dependent manner (147). This leads to the association of the three subunit 
of PP2A with p70S6K and its inactivation (Fig.9), leading to cell cycle arrest 
(312) as p70S6K is necessary for cell cycle progression (216). 
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Figure 9: Overview of TGF~-activated pathways. For detailed informations, 
see the text. 
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To conclude, TGF~ ligands activate several signaling pathways upon stimulation 
of their receptor complexes. These different pathways play a role, although not 
yet well defined, in all TGF~ physiological outcomes such as cell cycle arrest, 
apoptosis, EMT, etc. These effects are highly cell-type specifie. Whether sorne 
pathways are Smad-dependent or truly Smad-independent remains to be 
determined. 
8. Outcome of the TGFWactivin signaling effect: physiological roles and 
target genes 
TGF~ ligands play a central role in a plethora of physiological events. However, 
the molecular mechanisms by which these ligands regulate cell growth, apoptosis, 
angiogenesis, EMT and immune suppression are not equally well characterized. 
ln this part, 1 will focus on the TGF~ target genes that are mediating the 
physiological effects of the TGF~/activin. 1 choose to concentrate on aspects that 
have a direct implication in the development of cancer cells, as described in the 
next section. When available, 1 describe the components of the Smad complexes 
together with Smad partners that are responsible for the expression of target 
genes. 
a. Cell cycle Arrest 
The cell cycle is a tightly regulated process. In order to divide, a cell must go 
through the four phases that define the cell cycle. In G1 phase (Gap 1), cells 
accumulate mass and prepare for DNA replication, which occurs during the 
following phase, the S (Synthesis) phase. The Gl/S checkpoint controls the 
passage between these two phases. Two cyclin-dependent kinase complexes, 
CDK4/6-cyclin D and CDK2-cyclin E, and the transcription complex including 
pRb-E2F proteins are key regulators of the G l/S checkpoint. CDKs-cyclin 
complexes catalyze multiple phosphorylation events on the protein pRb. When 
hyperphosphorylated, pRb releases the E2F transcription factors that mediate the 
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transcription of genes necessary for S phase progression. Once the DNA is 
replicated, the ceUs are in G2 phase (Gap 2), which is followed by mitosis or the 
M phase (105,258). 
TGF~ stops the cell cycle in most epithelial, immune and neuronal cells (354). 
For endothelial celIs, the balance between AlkllAlk5 activation controls whether 
ceUs proliferate or not. The mechanism by which TGFf3/activin inhibits 
progression through the ceU cycle is the most characterized physiological effect of 
TGF~ in terms of target genes involved. AlI of the proteins encoded by these 
target genes result in sorne way in the inhibition of pRb phosphorylation. So, 
TGF~ activates the transcription of at least two CDK inhibitors (CDKI): pI5 and 
p2I genes. Moreover, TGFf3 stimulation decreases the expression of the 
oncogenes c-Myc as weU as IdI, Id2, Id3, which are transcription factors that 
favor proliferation. Epithelial ceUs of at least the skin, the mammary gland and the 
lung share these target genes. 
CDKI are proteins that associate with CDK-cyclin complex. CDKI can be divided 
into two subfamilies: the CIP/KIP family containing p21, p27, and p57, and the 
INK4 family that includes p15, p16, p18, and p19 (345). In dividing ceUs, the 
proximal promoter of the pI5 and p2I genes are bound by the c-MyclMIZI 
complex that ensures inhibition of their transcriptions. Upon TGF~ stimulation, a 
decrease in c-Myc protein levels relieves pI5 and p2I inhibition of transcription 
(337, 339, 363). Additionally, Smad3/Smad4/FoxO complexes that are formed 
onto a more distal region of the promoters activate transcription of pI5 and p2I 
(Fig. 1 Oa) (338). Sp 1 transcription factors also cooperate with Smad2, Smad3 and 
Smad4 for activation of the pI5 (116) and p2I (307). p15 specificaUy inhibits 
CDK4/6-cyclin D kinase activity by inducing an inhibitory kinase conformation 
and cyclin binding. On the other hand, p27 binding to CDK4/6-cyclin D does not 
always inhibit kinase activity; these complexes are thus reservoirs of p27 proteins 
(33). Interestingly, p15 competes with p27 for association with the CDK4/6-
cyclin D complex. As a result, the TGFf3-induced p15 protein displaces p27 from 
37 
the CDK4/6-cyclin D complex; p27 then redistributes to the CDK2-cyclin E 
complex, causing inhibition of the latter (314). So, by increasing expression of 
one gene, TGF~ mediates the inhibition of the two CDKs important for G liS 
transition. 
c-Myc expression is repressed upon TGF~ stimulation in several cell types. 
Although it has been known for a while that c-Myc expression correlates with 
proliferation, its exact role in promoting proliferation remains to be characterized. 
TGF~ inhibits c-Myc expression by promoting the recruitment of a preexisting 
cytoplasmic Smad3-E2F4/5-DP1-p107 to the TIE sequence within the promoter 
region of c-Myc (Fig. lOb) (62). 
The Inhibitor of Differentiation or Id family is composed of Id1, Id2, and Id3 
proteins. These proteins are transcriptional regulators that promote cell 
proliferation and prevent differentiation. Upon TGF~ treatment, Smad signaling 
activates the transcription of the gene ATF3 within 1-2 hours. Once upregulated 
by TG~, ATF3 transcription factor associates with Smad3 and is essential to 
TGF~ to mediate its inhibition of Idl gene transcription (193). Thus, TG~ 
induces the expression of a Smad transcriptional partner, ATF3, which targets Idl 
for repression in collaboration with Smad complexes (Fig. lOb ). TGF~ also 
repress Id2 expression in several epithelial cells (Fig. lOb). This correlates with the 
induction of the transcription factor Mad2 and Mad4. Repression of Id2 can thus 
be explained by (1) decreased formation of c-Myc/Max complexes as c-Myc 
expression decreases in response to TG~, and (2) replacement of c-Myc/Max 
complexes with MadIMax complexes on the Id2 promoter (356). 
Furthermore, other genes are involved in cell cycle regulation in a cell-specific 
manner. The gene encoding for the phosphatase CDC25A is downregulated 
following the TGF~-mediated increase of E2F4-p130-HDAC complexes that bind 
to the E2F DNA binding site in the CDC25A proximal promoter specifically in 
keratinocytes (179). Moreover, the E2F transcription factors, with the cooperation 
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of the pocket protein p107 and p130, are important for the induction of cell 
growth arrest by TGF13 (232, 449), suggesting that E2Fs are involved in the 
regulation of several genes following TGF13 stimulation. 
A) Activation BI Repression 
Figure 10: Target genes of TGF13 for cell cycle arrest. A) Expression of p2! 
and p!5 requires binding of SmadIFoxO complexes and removal of Mizl/c-Myc 
complexes from the promoters. B) Smad and E2F transcription factors cooperate 
to repress c-Myc expression. Control of Id! and Id2 requires the previous 
upregulation of ATF3 and Mad2/4, respectively, to be repressed by TGFj3 
treatment. 
b. Apoptosis 
Two major pathways in mammalian cells induce apoptosis: the death receptor 
pathway (mainly TNF-a. and FasL) and the mitochondrial pathway. These two 
pathways activate caspases, which are the enzymes producing the morphological 
and biochemical changes that characterize an apoptotic cell: DNA degradation, 
nuc1ear membrane breakdown and plasma membrane blebbing, etc (47). 
TGF13/aetivin induces apoptosis in several different cell types. However, the 
pathways and the target genes that control this phenomenon are far from being 
completely resolved. Actually, apoptosis seems to occur in a cell-type and context 
specifie fashion. So, it is not possible to delineate a group of TGF13 target genes 
that are responsible for apoptosis in a large variety of celllineages (354). JNK and 
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p38 activation have been implicated in TGF~-mediated apoptosis in sorne cell 
lines but not others (287). Intrigingly, the activation of these pathways by TG~ 
treatment are also cell-type specific. 
In hematopoietic cens, TGF~/activin activates transcription, through the Smad 
pathway, of SHIP. Accumulation of SHIP protein results in the inhibition of Akt 
phosphorylation and thus promotion of apoptosis of the immune cens (390). In 
hepatoma cens, TGF~ induces the transcription of the DAPK gene through the 
action of Smad2, Smad3 and Smad4. No Smad partners have been described so 
far for DAPK regulation. DAPK protein expression induces apoptosis white 
DAPK inhibition using dominant negative DAPK blocks TGf13-mediated 
apoptosis (186). In pancreatic epithelial cens, TGF~ induces the expression of the 
TGF~-inducible early gene or TIEGJ; its overexpression leads to apoptosis 
(Fig.lIA) (167,372). No mechanism has been described that explains how TGF~ 
regulates the expression of TIEG J. TIEG 1 transcription factor seems to promote 
cen death by favouring the formation of reactive oxygen species (3). TIEG 1 
inhibits Smad7 expression by binding to a repressor element in the Smad7 
promoter, thus having a positive effect on Smad signaling (188). 
Another TGF~ target gene that has been implicated in apoptosis is Smad7 in 
prostate cancer cens (215), and mesangial cells (302). In kidney cells, 
overexpression of Smad7 in cens treated with TGF~ 1 produce a stronger 
apoptotic response than TGF~ treatment alone; in these celIs, Smad7 seems to 
inhibit NF-1d3 anti-apoptotic activity by blocking its nuclear translocation (212, 
334). Moreover, Smad7 activates the JNK cascade, which results in apoptosis in 
MvLul, MDCK and COS7 cens (274). Smad7 can also act as a scaffolding 
protein to activate p38-dependent apoptosis (107). Upon TGF~/activin 
stimulation, the Srnad3-Smad4 complex binds to two palindromic SBE (5'-
GTCTAGAC-3') found in the Smad7 promoter, (92, 294, 397). In the human 
promoter, an E-box element that binds TFE3 synergies with Smad cornplex to 
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promote the activation of Smad7 transcription (174). In the mouse Smad7 
promoter, binding sites for the transcription factors AP-l and SpI are important 
for TGF~-induced activation of the Smad7 promoter (Fig.11A) (45). 
The protein levels of Smad3 and Akt have been proposed as regulating the 
sensitivity of cells to TGF~-mediated apoptosis (75, 320). Once activated by 
survival-promoting factors (like insulin), Akt directly interacts with Smad3; this 
prevents the phosphorylation of Smad3 by T~RI by reducing the pool of Smad3 
available for T~RI binding. This results in decreased Smad3 phosphorylation that 
leads to inhibition of Smad3 transcriptional activity and apoptosis. According to 
the proposed model, a high Smad3/ Akt ratio would favor apoptosis folIowing 
TGF~ treatment, whereas a ratio favoring Akt would inactivate Smad3-dependent 
induction of apoptosis. 
Finally, TG~ regulates the expression of sorne Bel-2 family members, which can 
either exert a pro-apoptotic effect (Bax, Bad, Bak, Bid, Bim, etc.) or an anti-
apoptotic influence (Bel-2, Bel-XL, Mel-l, etc.). The ratio of pro- versus anti-
apoptotic proteins determines whether a celI undergoes apoptosis or not. Pro-
apoptotic proteins forms pores in the outer membrane of the mitochondria to 
ultimately induce caspase activation. On the other hand, anti-apoptotic proteins 
prevent pore formation by sequestering pro-apoptotic proteins. TGF~ decreases 
Bel-2 protein levels in numerous celI types (118, 154, 383). In other celIs, TGF~ 
reduces Bel-XL protein levels (Fig.11B) (23, 69, 336, 350). On the other hand, 
TGF~ increases the level of Bax (379) through an uncharacterized mechanism. In 
gastric epithelial celIs, Bim pro-apoptotic gene expression is also increased in 
response to TGF~ through the involvement of the transcription factor Runx3 and 
Smad proteins (Fig.11A) (441). 
Of note, TGF~ signaling protects celIs from apoptosis in certain systems (176, 
351). Although these observations are hard to reconcile with the above studies, it 
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is a common feature of TGFp signaling to have a dual effect on the final 
physiological output. 
A) Activation B) Repression 
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Figure 11: Target genes of TGFp for apoptosis. A) TGFp increases, in a cell-
type dependent fashion, Bim, SHIP l, DAP K, TIEG l, and Bax genes. In certain 
cell types, Smad7 universal target genes play a role in apoptosis. B) TGFP 
represses Bel-2 and Bel-XL anti-apoptotic genes. 
c. Angiogenesis 
TGFp stimulates the formation of new blood vessels or angiogenesis. First, 
TGFp/activinA increase the transcription of VEGF, a ligand well known for its 
angiogenic effect. R-Smads/Smad4 complexes cooperate with the transcription 
factor Sp 1 to enhance VEGF transcription (22, 399). Moreover, TGFp and 
hypoxia cooperate to induce VEGF transcription through a direct interaction 
between Smad3-Smad4 and HIF-Ia. on the VEGF promoter (328). Under the 
same environment (hypoxia and TGFP stimulation), Smads-HIF-la. complexes 
are also involved, together with other transcription factors, in endoglin (329) and 
erythropoietin (330) upregulation (Fig.12). This is of particular interest for cancer 
development, since cancer cells and the surrounding endothelial cells are under 
hypoxic conditions and in the presence of high TGFp concentrations. 
Second, knockout mice of several components of the TGFp pathway are affected 
by vascular defects, inc1uding TGFpl, endoglin, TPRI, and TPRII, as detailed in 
the appendix 1. These observations highlight the importance of tightly regulated 
42 
TGF~ signaling on angiogenesis. Moreover, TGF~ ligands have a profound 
impact on ECM, as discussed below. This TGF~-induced remodeling of ECM 
promotes a favorable microenvironment for endothelial migration that is 
necessary for blood vessel formation. 
TGF~ induces CTGF expression in both epithelial cells and fibroblasts. Several 
studies have been performed to understand the regulation of CTGF in response to 
TGF~. CTGF upregulation is mediated by Smad3 and Smad4 proteins (Fig.12) 
(171). Moreover, a consensus TEFffEAD binding element is essential for the 
TGF-ê induction of CTGF, suggesting that TEF transcription factors family could 
cooperate with Smad proteins to regulate CTGF (223). Several other signaling 
pathways are also involved in this regulation, such as PKC, Erk, p38, JNK, but 
their roles seem to be highly cell type dependent (65, 389). CTGP is a secreted 
protein that plays important roles in TG~-mediated angiogenesis, ECM 
synthesis, cell migration, and cell adhesion (286). 
Figure 12: Target genes of TGF~ for angiogenesis. Cooperation between RIF-
1 a. and Smad3/Smad4 complex is important for at least three genes involved in 
angiogenesis, with the cooperation of others transcription factors. TGF~ also 
increases expression of the CTGF gene. 
d. Extracellular matrix regulation 
TGF~ regulates the expression of several genes that affect the extracellular matrix 
(ECM) composition (262). It normally increases the production of ECM by 
stimulating the expression of ECM components (collagen, fibronectin, laminin), 
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decreases the expression of matrix degrading enzymes (MMP) white increasing 
MMP inhibitors expression, such as PAI-l and TIMP-l. It induces the promoter 
activity of several collagen genes (COLlAl, COLlA2, COL3Al, C0L5A2, 
COL6Al, and C0L6A3) that lead to deposition of ECM components (396). In 
particular, Spl-Smad3-Smad4 proteins bind to the COLlA2 proximal promoter 
and synergize to mediate TGF~ upregulation of alpha2(1) collagen (315, 450). 
Moreover, CBP/p300 activity is required for optimal activation of COLlA2 
transcription (Fig.13A) (128). TGF~ negatively regulates MMP-l expression 
through cooperation between Smad3 and AP-l DNA binding element (Fig.13B) 
(156,444). 
TGF~ increases the transcription of proteins that inhibit ECM-degrading enzymes. 
The best-characterized gene of this class is the plasminogen activator inhibitor-l 
(PAI-l) gene. Indeed, the 3TP-Iux construct used in almost every TGF~/activin 
study, is formed of three copies of the TGF~1 response element from the PAI-l 
promoter (417). Induction of PAI-l requires Smad3 binding to a SBE (93) that is 
separated by three bases of an E-box element, which binds TFE3 (175). Not 
surprisingly, two GC-boxes, which are SpI binding sites, are required for TGF~­
induced PAI-l expression (85). The TGF~-mediated induction of TIMP-l also 
depends on Smad3 (Fig. 13A) (396). 
Al Activation 6) Repression 
Figure 13: Target genes of TGF~ for ECM production. A) TG~ increases 
COLIA2, PAI-l and TIMP-l genes. B) TGF~ represses MMP-l gene. 
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e. Epithelial to mesenchymal transition 
Epithelial to mesenchymal transition (EMT) is the process by which epithelial 
cells show reduced cell-cell contacts, acquire fibroblast-like properties and 
increased motility. It is a normal process during embryogenesis. Unfortunately, it 
is also the mechanism used by cancer cells to invade surrounding tissues and form 
metastases (446). As mentioned above, the PAR6 pathway is an important player 
in the early step of EMT induced by TGF~ as it is involved in the dissolution of 
tight-junctions (20, 305). Moreover, TGF~ decreases cellular adhesion through 
the downregulation of the E-cadherin gene. TGF~ induces the expression of 
Smad-interacting protein-l or SIPI (74), which collaborates with Smad 
complexes to mediate E-cadherin downregulation (Fig.14B). The transcription 
factors Snail and Slug, two potent repressors of E-cadherin expression, are 
induced upon TGF~ treatment directly through Smad3 (447). The MAPK and 
PI3K signaling pathways are required for Snail promoter activation induced by 
TGF~ (Fig.14A) (309). 
TGF~ also increases the expression of aIl/Pl integrin that is associated with 
invasion (129), possibly through Ets transcription factors (194), and vimentin 
(305), which is a marker of mesenchymal cell (Fig.14A). A recent paper 
established that the CUTLI gene is activated by TGF~, through Smad4 and p38 
kinase cooperation, and is a mediator of the TGF~ migratory effect (Fig.l4A). 
CUTLI transcription factor activates several genes involved in cell motility (278). 
A great amount of studies were reported to elucidate the pathways mediating 
EMT downstream of TGF~ receptor complexes: Smad, PAR6, PI3K, Erk, Akt, 
RhoA and p38 pathways that are activated by TGF~ stimulation (see previous 
section) have been implicated in EMT regulation (446). In conclusion, TGF/3 
activates several signaling pathways that synergize to induce the initiation and the 
progression of EMT. 
45 
Al Activation 8) Repression 
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Figure 14: Target genes of TGF~ for EMT regulation. A) TGF~ induces 
expression of Snail, Slug, SIP-I, CUTLI, vimentin, alllPI integrin. B) TGF~ 
represses E-cadherin expression. 
f. Immune Response 
Several studies using animal models strengthen the importance of TGF~ in the 
immune system regulation to both pathogens and autoimmunity. TGF~ 1 knockout 
mice that are bom alive, die within 3-4 weeks due to extensive autoimmune and 
inflammatory responses (206, 353). Smad3 knockout mice also show an extensive 
autoimmune response and die within a couple of months following birth (87, 
439). TGF~ signaling has a potent regulatory effect of the proliferation, 
differentiation and survival of most, if not aIl, immune cells. TGF~ effect has 
been studied mostly in cells from Iymphoid lineages: the B and T lymphocytes. 
However, TGF~ also plays an important role in myeloid cells, like dendritic cells, 
macrophage and mast celIs, etc (233). In general, TGF~ seem to be particularly 
important for inhibition of inappropriate activation of the immune response. 1 will 
focus on the role of TGF~ in T cells homeostasis. 
i. Antiproliferative effect on immune cells 
Several studies have been published that describe the antiproliferative effect of 
TGF~ signaling on T cells. The antiproliferative effect of TGF~ on primary T 
cells is mainly due to its inhibition of interleukin-2 production (IL-2: essential for 
T-cell proliferation) (Fig. 15). Although the murine IL-2 promoter activity is 
decreased upon TGF~ treatment via inhibition of an octamer-binding element, the 
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protein complexes mediating this effect are not characterized (43). Promoter study 
of the human IL-2 promoter reveal that Smad2/3 in association with Smad4 and 
the transcription factor Tob bind to a SBE on IL-2 proximal promoter, and inhibit 
IL-2 expression in non activated T cells. Interestingly, upon T cell activation, Tob 
protein levels decrease, thus relieving inhibition of IL-2 (388). Moreover, Smad3 
is a central player in the downregulation of IL-2 since Smad3-1- T lymphocytes 
(CD4+ and CD8+) are unable to repress IL-2 expression in response to TGF13 
(275). 
TGF~ also blocks expression of c-Myc, cyclin D2 and cyclin E, in T celllines and 
CDK4 in primary CD4+ T cells, as observed in epithelial cells (233). Importantly, 
TGF~ inhibits naive T cell proliferation while having a minimal effect on 
activated T cells (81). Both transgenic mice models expressing DN-T~RII, under 
the control of T-cell specific promoter (CD2 or CD4 promoters), display 
infiltration of lymphocytes into tissues and unstimulated T-cell activation (135, 
246). So, the CUITent model is that TGF~ inhibition of T cell proliferation is a key 
mechanism to prevent uncontrolled T cell activation. 
ii. T cell differentiation 
Naïve T cells can differentiate into effector T-cell subsets: helper T lymphocytes 
(TH) expressing CD4+ and cytotoxic T lymphocytes (CTL) that are expressing 
CD8+. TH cells can differentiate into two main subsets of effector cells expressing 
cytokines that mediate their specific effector functions. TH 1 cens express 
interferon-y, IL-2, IL-12 and lymphotoxin-a. These cytokines regulate cells 
involved in immune responses to intracellular pathogens. TH2 cens express ILA, 
IL-5, IL-10 and IL-13 that drive optimal antibody production from activated B 
cells to combat extracellular pathogens (136, 233). 
TGF~ decreases the expression of most effector cytokines in CD4+ T cells. TGF~ 
represses differentiation of CD4+ T cens into T H2 cells by inhibiting the 
expression of GATA-3(Fig.l5) (134, 166). GATA-3 is a transcription factor 
47 
required (in collaboration with ST A T6) for expression of all T H2 specific 
cytokines, and is thus important for proper differentiation of naïve cells into T H2 
cells (451). The mechanism by which TGF~ decreases GATA-3 expression is far 
from being resolved. One study reports that TGF~ interferes with the nuclear 
translocation of NFAT and that this correlates with decreased GATA-3 expression 
(60). Intriguingly, GATA-3 and Smad3 appear to interact together upon TGF~ 
stimulation and induce activation of the IL-5 promoter (37). The in vivo 
significance of this observation remains to be characterized. 
TH 1 cell differentiation is blocked by TGF~ in part through its ability to block IL-
12Rf32 (137) and T-bet expression (mRNA and protein levels) (133). T-bet is the 
mirror protein of GATA-3 for THI differentiation as it is a necessary transcription 
factor for expression of THI specific cytokines. Since T-bet activates IL-12Rf32 
expression, it is probable that the reduced IL-12Rf32 expression is a consequence 
of decreased T-bet expression following TGF~ stimulation (Fig.15). T-bet 
expression is dependent on IFN-y signaling; it also induces IFN-yexpression 
resulting in a positive feedback regulation. How TGF~ suppresses T-bet 
expression and whether it is involving IFN-y downregulation is not known. 
Once activated, CTLs act by producing inflammatory cytokines like IFN-y. They 
kill the target cells that they contact through two mechanisms: 1) CTLs express 
perforin and granzymes proteins. Perforin mediates the formation of pores that 
allow delivery of pro-apoptotic granzymes (GzmA and/or GzmB) in the target 
cell. (2) CTLs express Fas Ligand (FasL) that induces apoptosis following its 
binding to its receptor, Fas. 
CD8+ T cells activated in the presence of TGF~ do not display cytotoxic activity 
(319). Indeed, TG~ inhibits the expression of FasL through a possible role of c-
Myc downregulation in this process (Fig.15) (127). Downregulation of the 
transcription factor T-bet by TGF~ is associated with a decrease in IFN-y 
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production from CD8+ T cells (5). A recent paper provides information on the 
molecular mechanisms suppressing CTLs differentiation in response to TGF~ 
(380). In activated mouse T lymphocytes, TGF~ represses the expression at the 
mRNA and protein levels of five gene products: perforin, GzmA, GzmB, FasL and 
IFN- r. Inhibition of GzmB and IFN- y expression involve the association of 
Smad2/3 and ATF-l transcription factors on their respective DNA binding 
elements on the GzmB and IFN-y promoters. Moreover, ATF-I expression is 
increased following TGF~ treatment (Fig.15). The inhibition of cytotoxic genes is 
independent of TGF~-induced ceU growth inhibition. AU together, these 
observations suggest that TGF~ acts through two separate mechanisms to inhibit 
proliferation and effector functions of CTLs. 
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Figure 15: Target genes of TGF~ in the immune system. TGF~ inhibits T cell 
proliferation by repressing IL-2 expression through Smad3. TGF~ inhibits TH! 
and TH2 differentiation by decreasing expression of T-bet and GATA-3 
transcription factors. In CTL, TGF~ induces ATF-I, which cooperates with 
Smads, to repress expression of CTL effector proteins. 
9. TGF~ and cancer 
a. Hallmarks of cancer and dual role of TGF~ signaling in cancer 
Tumor progression requires successive rounds of mutations that allow cancer cells 
to acquire a minimum of seven hall marks (Fig.16). These characteristics are (1) 
proliferation in the absence of growth factors stimulation, (2) ability to escape 
growth inhibitory signaIs, (3) resistance to apoptosis, (4) immortality, (5) ability 
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to induce angiogenesis, (6) metastasis and invasion of other tissues (157). 
Moreover, tumor cells have the capacity to (7) evade recognition and destruction 
by the immune system (109). These acquired modifications are the result of 
defects in the signaling pathways controlling normal cell proliferation and 
homeostasis and are usually caused by mutations in the DNA, since a general 
property of cancer cells is genomic instability. The TGF~ signaling pathway is 
involved in every aspect of tumorigenesis by acting on the tumor cell itself and 
the microenvironment in which the tumor cells live, including the extracellular 
matrix and surrounding cells (endothelial and immune cells). 
TGF~ signaling has been described to function as a tumor suppressor through its 
effects on cell growth arrest, apoptosis and inhibition of telomerase activity, and 
as a tumor promoter via its effect on cell motility (thus invasion and metastasis), 
angiogenesis and the immune system. Several mice studies support this dual role 
for TGF~ in cancer development (84, 377). For example, mice with targeted 
expression in the breast of constitutively active T~RI crossed with mice 
expressing an oncogenic form of ErbB2 (an EGFR family member) have a longer 
primary tumor latency, supporting a tumor suppressor role for TGF~. However, 
once these mice develop tumors, they exhibit an enhanced frequency of lung 
metastases. On the opposite, mice expressing DNT~RII crossed with mice 
expressing activated ErbB2 have shorter primary tumor latency, but more 
importantly, exhibit less lung metastases (355). 
To divide in an uncontrolled manner, cancer cells become resistant to 
antiproliferative signaIs like TGF~ and divide without growth factors stimulation. 
Epithelial-derived tumors (carcinomas) represent more than 85% of all human 
tumors; virtually an of those cancer cells exhibit a resistance of the growth 
inhibitory effect of TGF~ (109). In sorne cases, this resistance is due to mutations 
in either TGF~ receptors, Smad2 or Smad4 (see next section). However, for most 
human cancers, the mechanisms of selective resistance to the antiproliferative 
effect of TGF~ are poorly defined. Moreover, TGF~ is able to induce the 
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proliferation of sorne cancer cells. Again the mechanism underlying this 
phenomenon is poorly understood, but might involve the ability of TGF~ to 
induce mitogenic growth factor production (such as PDGF, CTGF, etc.) and/or to 
collaborate with oncogenes, as observed with oncogenic Ras on human colon and 
prostate cancer cells (109). 
Tumor suppressor Tumor promoter 
Figure 16: Acquired hallmarks of cancer cells and TGF~. For details, see text. 
Furthermore, TGF~ inhibits telomerase activity through repression of hTERT 
gene expression, and by doing so, probably limits the number of divisions a ceIl 
can undergo. With the new discovered role for telomerase in promoting cell 
proliferation (described below), inhibition of hTERT expression by TGF~ might 
be important for its ability to block cell proliferation. Supporting this hypothesis, 
overexpression of hTERT in human mammary epithelial cells lacking p16, results 
in resistance to TGF~-induced cell growth arrest (364). As mentioned earlier, 
TGF~ is recognized as a pro-apoptotic agent. The ability to resist to apoptosis 
induced by TGF~ might be important for cancer cells arising from tissues like the 
liver, in which TG~ strongly induces apoptosis. Moreover, the ability of TG~ 
to induce apoptosis of immune cells could be partially responsible for the ability 
of cancer cells to escape the immune system. 
The tumor environment is characterized by high levels of TGF~ in the 
extracellular milieu. The tumor cells themselves usually produce this TGF~. 
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lncreased levels of TGF~ correlate with the severity of tumor grade (94). The 
tumor-derived TGF~ influences cells that are in proximity of the tumor mass. 
Since TGF~ normally inhibits T cell proliferation and differentiation, high levels 
of tumor-derived TGF~ contribute to the ability of cancer cells to escape immune 
recognition and destruction. Indeed, mice models and sorne clinical studies have 
demonstrated that blocking TGF~ signaling effectively restores the ability of the 
immune system to recognize and destroy cancer cells (103, 104). 
TGF~ normally induces angiogenesis. Since cancer cells are growing under 
hypoxic conditions, they must induce angiogenesis, which is facilitated by the 
high TGF~ levels around the cancer site. Interestingly, expression of endoglin 
(also known as T~RIII) is highly upregulated on endothelial cells during tumor-
induced blood vessel formation (50). The upregulation of endoglin is particularly 
intriguing since it allows the cells expressing it to become even more responsive 
to TGF~. Moreover, TGF~ has been described as a strong promoter of metastasis, 
probably through its ability to regulate cell motility, cellular adhesion and ECM 
production. In particular, TGF~ frequently increases the ability of cancer cells to 
degrade the ECM by increasing the expression of MMPs (96), thus facilitating 
movement of cancer cells. 
Two models have been proposed to explain the dual effect of TGF~ signaling on 
cancer development (Fig. 17). The prevailing model suggests that TGF~ acts as a 
tumor suppressor at the beginning of tumor development, as TGF~ inhibits 
proliferation (through ceIl growth arrest or apoptosis) and telomerase activity in 
normal cells. Later in tumorigenesis, tumor ceIls become resistant to cell growth 
inhibition by TGF~. The promoting effect of TGF~ is through its action on the 
surrounding tumor environment as it is inducing angiogenesis and 
immunosuppression. However, this model does not explain the increased ability 
of the tumor cells to invade and to undergo metastasis in response to TGF~. This 
might occur as the cancer ceIls undergo EMT. TGF~ induces EMT either al one or 
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ln collaboration with oncogenic Ras. Whether EMT is a Smad-dependent or 
Smad-independent process is a very controversial topic. Since TGF~ has a very 
different effect on mesenchymal cells compared to epithelial cells, EMT is a 
plausible model that explains the observed switch in TGF~ responsiveness of 
cancer cells. 
1 TGF-~ 1 
Tumor 1 \ Tumor Suppressor Promoter 
EplthelialCelis Stromal CeUs 
• Growth jnllibHion • Induction of angiogenesis 
• hTERTrepressiOn • Immunosuppression 
• IndlJ<:tion of apoptosis • Promotion 01 metastasis 
Epithélial CeUs 
Tumor Suppressor EMT Tumor Promoter 
• Inhibils growth ........ • Enhancesmotility 
• Promotes differentiation? • Promotes migration 
• Induces apoptoSÎS • Incraases InvasiOn 
Smaq.~nt? Smad..fndapel'ld.m? 
Figure 17: Two models explaining the dual effect of TGF~ on tumorigenesis. 
Reproduced from Elliot, et al. (109). 
b. Mutations affecting the Smad pathway in cancer 
Numerous studies reveal that components of the TGF~/Smad pathway are 
mutated in cancers. The table summarizes the data for the five most prevalent 
human cancers that together account for more than 50% of diagnosed cancers 
(109). These mutations are found in the TGF~ receptors, Smad2 or Smad4. To 
date, no Smad3 mutations have been associated with cancer. In the coding region 
of the extracellular domain, the T~RII gene contains a lObp polyadenine repeat 
that constitutes a microsatellite. Mutations in this region result in truncated 
inactive T~RII proteins and are the result of rnicrosatellite instability (MSI) often 
observed in the sporadic or hereditary form of colon and gastric cancers (254, 
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255). Importantly, reintroduction of wt T~RII restores TGF~-mediated cell 
growth inhibition and reduced tumor formation when these T~RII-expressing 
cells (colon and gastric cancer cell lines) are injected in mice (58, 406). On the 
other hand, T~RI gene is inactivated in 1/3 of ovarian cancers (403). Smad4 was 
initially identified as DPC4 (deleted in pancreatic carcinoma locus 4) and is 
deleted or mutated in 50% of pancreatic carcinomas (155) and 20% of metastatic 
colon tumors (283). Smad2 inactivation is detected in 6% of colon cancer (110). 
Smad7 is overexpressed in 32% of gastric carcinomas (199) and 50% of 
pancreatic cancers (201). 
Table 2: Mutations of TGFptSmad components in prevalent cancers. Adapted 
from Elliot, et al. (109) and references therein. 
Cincel", Taru[g~~){: ~ ~:~i:ij~~B!gè,D~.:.;!~·;;;· ~Smad4'enê . '.~. g, . 
Frequently Mutated in 2% Mutated in 7% 
Lung downregulated, but NSCLC NSCLC 
rarely mutated 
Mutated in 58%- Mutated in 6% Mutated in 20% 
Colon 82% of tumors with invasive tumors and MSI, and 15% of 5% non-invasive 
tumors with no MSI tumors 
Pancreatic Mutated in 4% No mutations Mutated in 50% detected in 100% 
Frequently No mutations No mutations 
Breast downregulated, but detected in detected in 
rarely mutated approximately 100% approximately 100% 
T~RII protein not No mutations No mutations 
Prostate detected in 24% detected in 100% detected in 
approximately 100% 
c. Mutations in oncogenes/tumor suppressors that act by 
inhibitinglactivating TGF~ signaling 
TGF~ signaling is tightly controlled to limit the activity of Smad transcriptional 
activity. Two proteins that interact with the Smad proteins and inhibit their 
transcriptional activity were first described as oncogenes. It is thought that 
increased levels of negative regulators result in the blockade of TGF~ signaling 
and thus relieves the cells from TGF~-mediated cell growth inhibition. 
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Ski/SnoN proteins are overexpressed in many human tumor cell lines derived 
from breast, lung, stomach and prostate. Furthermore, overexpression of wt 
Ski/SnoN results in transformation of cells (248). The transforming ability of Ski 
and SnoN is dependent on their capacity to inhibit TGF~ signaling since mutant 
Ski or SnoN are unable to associate with the Smads and fail to promote oncogenic 
transformation (165). This suggests that overexpression of SkilSnoN is 
contributing to tumor development by blocking TGF~ signaling. 
Another oncogene, Evi-l, was first described as an oncoprotein involved in the 
development of myeloid leukemia. The Evi-l gene is the target of chromosomal 
rearrangements that lead to overexpression of fusion proteins, such as MDS-Evi-l 
and AML-Evi-l. Since Evi-l appears to be a general repressor of Smad 
transcriptional activity, the overexpression of the fusion protein could transform 
cells by blocking TGF~ signaling (264). 
On the other hand, the protein menin is a Smad3 partner encoded by a bona fide 
tumor suppressor gene, MENl, which is located on chromosome llq13 (56). 
More then 300 mutations within this gene have been described in patients 
suffering from multiple endocrine neoplasia type 1 or MENI (151). The 
syndrome is classically characterized by a triad of neoplasia affecting the 
parathyroid glands (90% of patients), pancreatic endocrine tumors (30% to 80%) 
and pituitary adenomas (15%-50%) (57). Most of these pituitary adenomas are 
prolactinomas (49). 
Menin is a nuclear protein of 610 amino acid residues without any homology to 
any other known protein or functional do mains (56, 152). The exact function of 
menin is still unclear, yet its role in cell proliferation suppression is thought to be 
mediated through its interacting partners (151). Menin interacts with multiple 
proteins involved in different signaling pathways or cellular functions, such as the 
cytoskeleton, GTPase, DNA processing and many transcription factors (257). 
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Menin is a Smad3-binding protein. When menin expression is blocked, TGFp and 
activin are no longer able to activate transcription (191) or to repress transcription, 
as it will be described in Chapter 3. Loss of menin disrupts Smad3 binding to its 
consensus sequence (191). This might explain the tumor suppressor activity of 
menin in the pathogenesis of MEN 1 disease. 
lO. Mechanisms of regulation of prolactin and Pit-l genes in the pituitary 
a. Prolactin (PRL) 
The pituitary gland is a critical organ for the regulation of normal homeostasis, 
growth and reproduction. In most species, the pituitary can be divided into three 
lobes: the posterior lobe, the intermediate lobe and the anterior lobe. In adult 
humans, the posterior lobe is composed of neural cells and is called the 
neurohypophysis, white the intermediate lobe is almost inexistent (153). The 
anterior lobe, also called adenohypophesis, contains epithelial cells responsible of 
the secretion of several hormones, such as luteinizing hormone (LH), growth 
hormone (GH), FSH and PRL. PRL is produced by lactotrophs and 
mammosomatotrophs, which also produced GH. Lactotrophs form 20%-50% of 
the cellular population of the adenohypophysis, the percentage varying according 
to the sex and the reproductive status. PRL regulates several aspects of 
reproduction, such parental behavior and, of course, lactation, among others. PRL 
have also been shown to be involved in immune response, osmoregulation and 
angiogenesis. Furthermore, other organs and tissues in the body, like the brain, the 
uterus, the mammary gland and lymphocytes, produce PRL (121). 
In humans, PRL is encoded by a single gene, composed of five ex ons and four 
introns for a total size of lOkb (79, 385). Two independent promoter regions 
control the transcription of PRL. The first 5000bp region directs the specific 
expression within the pituitary (28), while a more distal promoter region is needed 
for expression outside of the pituitary (27). As most hormones, PRL is first 
synthesized as a prohormone that contains a signal peptide of 28 amino acids and 
56 
the mature human PRL is composed of 199 amino acids (357). The rat mature 
PRL is composed of 197 amino acids (80). The homo1ogy between human and rat 
PRL is 56% (357). Active PRL is a single chain of amino acids that contains three 
intramolecular disulfide bonds (79). Several variants of pituitary PRL have been 
described in many mammals, including humans. These are the results of 
alternative splicing, proteolytic cleavage and post-translational modifications of 
the ami no acid chain. The physiological functions of these PRL variants are 
currently unclear (121). 
b. Pit-! and features of the rat PRL promoter 
The rat PRL gene promoter contains two important regions important for 
induction of the expression of PRL in the pituitary. The proximal promoter 
sequence is located between -422 to +33, and the distal enhancer/promoter 
element is located between -1831 to -1530 (see Fig.6 of Chapter 3) (141). The 
proximal promoter contains three DNA binding elements for the transcription 
factor Pit-l, while the distal region contains four DNA binding elements for Pit-l. 
Pit-1 is responsible of the commitment of three pituitary cell lineages: the 
lactotrophs, the somatolactotrophs, and the thyrotrophs (8). 
Pit-1 was the first transcription factor reported to have an critical role in the 
development of the pituitary (236). Pit-l, which is exclusively expressed in the 
pituitary, is a 33-kDa protein formed of an 80-amino acid N-terminus that 
functions as a transactivation domain and a C-terminal POU domain that is 
responsible for DNA-binding, homodimerization, and other protein-protein 
interactions (8). To regulate PRL gene expression, Pit-1 was shown to bind to Pit-
1 DNA binding sites that are found in the PRL promoter (251, 296). Pit-l DNA 
binding elements in the proximal promoter are necessary to confer pituitary-
specifie expression (247, 251, 296). Finally, the Pit-l DNA binding sites and 
flanking sequence found in the distal enhancer/promoter region restrict rat PRL 
expression to the lactotrophs (82). 
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c. PRL gene regulation in the pituitary 
PRL production and secretion is under the control of several molecules 
originating from the central nervous system, with the hypothalamus being the 
main regulator, the pituitary itself and peripheral organs. 1 will give one ex ample 
for each of them. For a review of aIl the regulators of PRL, an extensive review is 
available elsewhere (121). Increase of PRL production and secretion is mostly 
stimulated by suckling, stress and increased levels of ovarian steroids, mainly 
estrogen (121). AlI these stimuli impinge on the. hypothalamus, which is the main 
regulator of PRL production. 
Lactotrophs have constitutively high PRL secretory activity. The neurotransmitter 
dopamine, which is produced by the neurons of the hypothalamus, is the main 
inhibiting factor of PRL secretion. In the lactotrophs, dopamine signaIs through 
D2 receptors, a GPCR. Dopamine inhibits within seconds the release of PRL from 
secretory granules. Within hours, dopamine suppresses PRL gene expression and 
within days, dopamine blocks lactotrophs proliferation (25). Dopamine 
diminishes PRL gene expression primarily by decreasing intracellular cAMP 
levels (213). Reduction of cAMP levels lowers PKA activity and it is the 
suppression of PKA activity that produces many of the dopamine effects in 
lactotrophs (25, 100). Dopamine has also been reported to inhibit Pit-I expression 
(25). 
Within the pituitary, several factors have an effect on PRL expression and 
secretion, like PRL itself, EGF, TGFp and activin. These factors act in an 
autocrine/paracrine manner to regulate PRL expression. Administration of TGFp 1 
in the pituitary decreases cell proliferation, PRL production, and circulating PRL 
in the plasma (279). TGFp and/or activin decrease basal secretion and production 
of PRL in ceIl culture (2, 91, 292, 376). The molecular mechanisms by which 
TGFp and activin control PRL expression in the pituitary is the subject of the 
chapter 3 of this thesis. Interestingly, a recent paper proposes that the growth 
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inhibition due to dopamine is mediated, in part, by induction of TGF~ 1 
expression (332). 
Estradiol is mainly produced by the ovaries and is thus acting through an 
endocrine mechanism to control PRL expression. Estradiol activates the 
expression of the PRL gene by binding to its nuclear receptor, the estrogen 
receptor (ER), which is then competent to bind DNA and induces transcription. 
There is an estrogen-responsive element in the promoter of the PRL gene that 
synergizes with the transcription factor Pit-l, probably through direct interaction 
between Pit-l and ER (88,386,409). 
d. Pituitary tumors 
Fifteen percent of intracranial tumors are pituitary tumors, usually non-metastatic. 
They are causing serious disorders and even death in two ways. When they grow 
rapidly and form an important mass, they can squeeze surrounding brain 
structures, leading to headaches and visual problems. By their ability to secrete 
pituitary hormones in excess, they can disrupt the functions that are normally 
controlled by these hormones, which can translate into mood disorders, sexual 
dysfunction, infertility, hypertension, diabetes mellitus and accelerated heart 
disease (12). 
In humans, the most common form of pituitary tumors is prolactinomas, 
accounting for 35%-40% of the pituitary tumors (12). These tumors secrete large 
amount of PRL, commonly causing reproductive and sexual dysfunction. As 
dopamine is a potent inhibitor of PRL production, several dopamine receptor 
agonists, like bromocriptine, are used to treat patients affected by prolactinomas. 
However, about 15%-20% of prolactinomas resist to dopamine effect, probably 
due to a 10ss of the dopamine receptors or defective signaling cascade (24). Other 
approaches to treat prolactinomas are needed for these patients. 
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11. Mechanisms of regulation of hTERT gene in normal and cancer cells 
3. Telomeres 
Telomeres are specialized structures formed of repeated DNA sequences and their 
associated proteins at the end of linear chromosomes. Telomeres protect the end 
of chromosomes from recombination, end-to-end fusion, and recognition as 
damaged DNA. This protective effect is due to the invasion of the G-rich 3'-
overhang in the double-stranded region of the telomere to form the so-called T-
loop (Fig. 18a). In humans, the telomeric DNA sequence TI AGGG extends from 
2 to up to 50kb, the average length being 1O-15kb (35). Telomeric DNA 
associates with the telomere repeat binding factors 1 and 2 (TRFI and TRF2), 
which are themselves capable of binding other proteins, forming large protecting 
complexes. Functional telomeres require three essential factors: a minimal length 
to TIAGGG repeats, integrity of the 3'-overhang and telomere-binding proteins. 
In most cells, the telomere shortens by 50-200 nucleotides with each cell division 
simply because the conventional DNA polymerase is unable to completely 
replicate the 3'end of the lagging strands of linear DNA. This is called the end-
replication problem, as illustrated in Fig.18b. 50 normal somatie cells divide a 
limited number of times and the shortening of the telomere appears to function as 
a clock that monitors the proliferation history of the cells. When the telomeres are 
too short, they trigger either replicative senescence or apoptosis to avoid genomie 
instability and loss of important chromos omal DNA (78). 
The telomeres have to be maintained long enough to ensure unlimited cell 
division. Telomerase is the enzyme that elongates telomeres. It is expressed in 
cells that need a high proliferative capacity such as germ line cells, stem cells, 
activated lymphocytes and cancer cells. Telomerase is formed of two main 
components: the telomerase reverse transcriptase (TERT) and the telomerase 
RNA template (TER). TER contains a sequence complementary to the telomeric 
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Figure 18: Telomeres. A) The "end-replication problem". DNA polymerases 
synthesize DNA in the 5'-73' direction and cannot begin synthesis de novo. The 
leading strand can he continuously synthesized (green). DNA polymerases use an 
8-12bp RNA primer (red) for extension of the lagging strand (blue). Removal of 
the 5'-most RNA primer generates an 8-12-base gap. Failure to fill in this gap 
leads to a small DNA loss in each round of DNA replication. Adapted from(395). 
B) T-loop model of the telomere. Three essential factors of functional telomeres. 
Reproduced from Blasco (34). 
DNA, thus providing a template for reverse transcription by TERT for new 
telomeric DNA repeat (Fig. 19). Most somatic cens do not have detectable 
telomerase activity. This is due to a strong repression of the hTERT component of 
telomerase (277), whereas hTER expression seems to be constitutive (16). 
Although telomerase activity is regulated at several levels: mRNA splicing, 
modifications of hTER and hTERT and access of telomerase to the telomeres, 
several studies have demonstrated that the transcriptional regulation of hTERT 
expression is the limiting step in the apparition of telomerase activity in most 
cens, including cancer cens (76, 173, 277, 375). 
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Figure 19: Telomerase in action. 
b. Features of the hTERT promoter and its regulation 
Since the cloning of the hTERT gene in 1999 (76, 173, 375, 412), hundreds of 
studies have been done to understand how the hTERT gene is regulated at the 
transcriptionallevel in normal and in cancer ceUs. 
The human TERT gene is located on the short arm of chromosome 5 (5pI5.33) 
(277). It consists of 16 exons and 15 introns spread over 40kb (76, 412). The 
minimal promoter sequence for activity is contained within the 330bp upstream of 
the A TG. The promo ter is characterized by the absence of TATA or CAA T boxes, 
but is highly GC-rich (77%). This creates a large CpG island around the 
translation start site, suggesting that DNA methylation might be important for 
hTERT gene repression but no consistent results about a role for DNA 
methylation on gene repression have been reported (97, 98). When transfected in 
cultured ceUs that do not express hTERT, the hTERT promo ter is inactive. 
However, in ceUs that exhibit telomerase activity, the hTERT promoter is highly 
active. This suggests that repression is dominant over activation (78). 
Computer analysis of the hTERT promoter reveals hundreds of putative 
transcription factor binding sites (Fig.20). The presence of so many DNA binding 
elements suggests that the hTERT gene is under multiple levels of regulation and 
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Figure 20: Human TERT promoter region. A) Schematic representation of a 
fragment of 2kb of the hTERT promoter; +1=ATG. B) Detailed representation of 
the hTERT core promoter region (-330bp to +lbp). 
is most probably controlled by different factors in a cell specific manner. Indeed, 
several transcription factors have been described to participate in hTERT gene 
expression. Sorne of them are positive regulators; others are negative regulators. 
However, it is important to keep in mind that most of these candidate 
transcription al regulators still have to be proven as physiological regulators. More 
is known about the mechanism of the upregulation of hTERT in cancer cells than 
its repression in a normal cell context. 
The hTERT core promoter contains two E-boxes confirmed to be DNA binding 
elements for c-MyclMadIMax family members. The relative contribution of each 
E-box varies depending on the cell Hne used (143, 211, 422). In many cases, c-
Myc expression parallels hTERT expression, in that it is increased in highly 
dividing cells and downregulated during differentiation. Overexpression of c-Myc 
increases hTERT promoter activity and this is dependent on E-boxes integrity. On 
the other hand, Mad overexpression results in decreased hTERT promoter activity 
(150). Both c-Myc and Mad proteins can dimerize with the ubiquitously 
expressed Max protein. The c-Myc/MadIMax network constitutes a molecular 
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switch where the amount of c-Myc- versus Mad-containing dimers determines 
whether a gene is expressed or not. For example, when HL-60 cells differentiate 
into granulocytes, the c-myc protein level decreases and Mad protein level 
increases, resulting into the disappearance of c-MyclMax dimers on the hTERT 
promoter and the apparition of MadIMax complexes. This ultimately leads to a 
decrease of hTERT mRNA and protein levels (427). E-boxes are also bound by 
Upstream Stimulatory Factor (USF1I2) transcription factors; overexpression of 
USF-l decreases hTERT mRNA level, telomerase activity and hTERT promoter 
activity (189). 
The hTERT core promoter contains five GC-boxes that are potential binding 
elements for Sp 1 transcription factors. These sites are located between the 2 E-
boxes. The mutation of aIl GC-boxes results in a 90% loss of hTERT promoter 
activity suggesting that these GC-boxes could function as Initiator elements. 
These elements are particularly important in promoting TATA-less promoter 
activation. SpI cooperates with c-Myc to activate hTERT transcription; mutations 
ofthe GC-boxes abrogate the positive effect of c-Myc overexpression (211). 
Several studies demonstrate that HDACs are important for hTERT gene 
repression in normal cells. Trichostatin A treatment (HDAC inhibitor), results in 
the appearance of telomerase activity (77, 407). The transcription factor Madl 
was shown to recruit HDAC activity to the hTERT promo ter. Importantly, HDAC 
complexes were also shown to be recruited to the hTERT promoter via 
uncharacterized factors; SpI and/or Rb/E2F being plausible candidates. Recently, 
an elegant study demonstrates that the assembly of complexes formed of E2F, 
pocket proteins and HDAC regulates hTERT gene expression in normal human 
fibroblasts (413). 
Repression of telomerase activity was observed upon E2F-l overexpression in 
human cells (83). Interestingly, there are three reported E2F DNA binding motifs 
in the hTERT core promoter region. Chromatin immunoprecipitation analysis 
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reveals that E2F/pocket proteinslHDAC complexes are key regulators of hTERT 
expression in human cells because disruption of the function of either protein 
derepresses hTERT gene expression (413). Moreover, a recent study demonstrates 
that endogenous p53 represses hTERT expression through a p21- and E2FlRb-
dependent pathway. The proposed model is as fonows. p53 induces p21 
expression, which decreases pRb phosphorylation. When hypophosphorylated, 
pRb interacts with E2F family members and histone deacetylases to form 
complexes that inhibit transcription (341). 
c. Regulation by growth factors 
Several growth factors are involved in telomerase regulation, like estrogen (210, 
280), EGF (48, 250) and TGF~. TGF13 inhibits telomerase activity and hTERT 
expression in various cell lines. Adenocarcinoma A549 cells treated with TGF~ 
show decreased telomerase activity. HCT116 cens (in which T~RII is mutated 
(253, 308)) have constitutive telomerase activity; expression of wt T~RII 
decreases telomerase and hTERT promoter activities (438). Moreover, TGF~ 
promotes loss of telomerase activity by specifically inducing alternative splicing 
of inactive forms of hTERT mRNA in HaCaT cens (53). It was proposed, but 
never confirmed, that TGF~ decreased hTERT expression indirectly through 
inhibiting c-Myc expression and activating Mad expression. However, the picture 
is more complex since SIP1, a corepressor that is induced by TGF~, seems to be 
involved in the TGF~ effect on hTERT expression (238). Also, published data 
suggest that Smad3 binds directly to hTERT promoter in response to TGF~ (231). 
Obviously, TGF~ regulates hTERT inhibition through several factors. 
d. Telomerase in cancer 
90% of cancer cells exhibit telomerase activity (198). This is by far the most 
commonly observed abnormality acquired by cancer cens. lndeed, it is used as a 
cancer diagnosis marker in pathology (342). The remaining 10% of cancer cens 
maintain their telomere length through the telomerase-independent mechanism 
named ALT (alternative lengthening of telomeres). The presence of one of either 
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process in advanced human cancers supports the hypothesis that cancer 
progression requires functional telomeres. These observations also lead to two 
questions: 1) How and when does hTERT gene reactivated in the tumorigenesis 
process? and 2) Is telomerase reactivation equivalent to ALT for tumor 
progression? 
Overexpression of the hTERT protein is unable to cause tumor formation, 
although it does greatly increase celllifespan (38). However, immortal cells have 
more of a chance to accumulate mutations favoring transformation simply 
because they replicate their DNA more often (increased mutation probability). 
Interestingly, advanced cancer cells are usually characterized by short telomeres, 
probably because they proliferate for a long time before acquiring telomerase 
activity (Fig.21). In normal cells, progressive telomere shortening would 
eventually trigger DNA damage response (32). However, in cancer cells 
characterized by loss of DNA damage-induced checkpoint (p53 mutation), short 
telomeres could contribute to the genomic instability usua1ly observed in cancer 
cells (343), further promoting acquisition of mutations within the cancer cells. 
Selection for cells with telomerase activity would then be favored and promote 
indefinite cell proliferation. Drugs inhibiting telomerase activity would 
preferentially affect cancer cells because they have shorter telomeres and they 
div ide more often than normal cells: DNA damage-induced response, such as 
apoptosis, would occur more rapidly in cancer cells than surrounding tissue (35). 
Interestingly, several recent studies indicate that telomerase possesses additional 
functions - not related to net telomere lengthening - that enhance survival and 
proliferation. The mouse appears to be a good model to study the role of 
telomerase activation on cell proliferation: because they have very long telomeres 
(25-40kb), the role of telomerase in lengthening short telomeres is less critical. 
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Figure 21: Telomeres length, telomerase and cancer. Changes in telomeres 
length over time during tumor progression. -: no telomerase activity, +: 
telomerase activity. Adapted from (35). 
During tumorigenesis in mice, telomerase activity increases even in the presence 
of very long telomeres (36, 44). First generation telomerase knockout mice (Tere· 
') develop 33% less skin tumors than wild-type mice when triggered with 
chemical carcinogens (132). In contrast, skin-specific transgenic hTERT mi ce are 
twice susceptible to develop skin tumors when exposed to carcinogens (131). 
Moreover, mice with constitutive expression of hTERT (under the control of the 
~-actin promoter) develop more tumors as they age, despite the presence of long 
telomeres (10). In summary, telomerase expression seems to cooperate with 
oncogenic insults (more frequent as the mice aged) to promote tumorigenesis in 
mice. This is supported by the observation that these transgenic mice, when 
young, have a normal phenotype in terms of viability and development. 
Overexpression of hTERT in human epithelial or neural cultured ceUs induces 
resistance to pro-apoptotic or anti-proliferative signaIs (245, 267, 424, 453), 
including TGF~ (364). In fibroblast ceUs maintaining their telomeres via ALT 
mechanisms, overexpression of hTERT with H-Ras produce the formation of 
tu mors in nude mice. Importantly, this is not observed in ceUs expressing H-Ras 
alone. This suggests that ALT- and hTERT-mediated mechanisms are not 
equivalent for promotion of cancer development. Again, this suggests that the 
hTERT effect on tumor progression includes non-telomere function. Indeed, 
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expression of a defective form of hTERT unable to lengthen telomeres is still able 
to cooperate with H-Ras in producing tumors (366). Recently, an elegant study 
using microarray technology demonstrates that telomerase is able to stimulate 
proliferation of epithelial cells by controlling expression of genes involved in cell 
proliferation (360). So, telomerase activation promotes cancer development in two 
ways: by inducing proliferation independently of telomere length at any step 
during tumorigenesis and by rescuing tumor cells with very short telomeres. 
In the two following chapters, the molecular mechanisms by which TGF~ and 
activin ligands repress two target genes are reported. These two genes are 
involved in the development of cancer, as explained in the review of the literature. 
Indeed, prolactinomas display unregulated production of PRL (Chapter 3), while 
hTERT is reactivated in 90% of all cancers (Chapter 4). 
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Chapter 3: Activin Inhibits Pituitary Prolactin Expression and Cell Growth 
through Smads, Pit-1 and Menin. 
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1. Abstract 
Activin, a member of the TGF~ superfamily, is a negative regulator of cell growth 
and prolactin (PRL) production in pituitary lactotrope cells. However, the 
mechanisms by which this growth factor exerts its growth inhibitory and 
repressive effect on PRL remain unclear. In this study, we show that activin 
negatively regulates PRL expression at the transcriptionallevel through the Smad 
pathway and the multiple endocrine neoplasia type 1 (MEN1) gene product, 
menin. Our results also demonstrate that the tumor suppressor menin is required 
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for activin-induced growth arrest of somatolactotrope cells. Moreover, we show 
that activin represses transcription and expression of Pit-l, a pituitary 
transcription factor that is essential for maintenance and development of 
lactotrope cells. We defined two Pit-l DNA-binding sites in the proximal region 
of the PRL promoter as critical for the activin-mediated inhibition. Together, our 
results highlight the Smad pathway and the tumor suppressor menin as key 
regulators of activin effects on PRL and Pit-l expression as well as on cell growth 
inhibition and emphasize the critical role of activin in the regulation of pituitary 
function. 
2. Introduction 
Prolactinomas, are the major type of human secretory pituitary tumors. In addition 
to their hyperproliferative capacity these cells secrete large amounts of prolactin 
(PRL) causing severe endocrine and reproductive disorders. Despite the high 
incidence of this type of cancer the moiecular basis for development of these 
pituitary tumors remain unknown. 
Pituitary gland function is controlled by a large array of hormones and growth 
factors. Activin, a member of the transforming growth factor ~ (TGF~) family, 
regulates the secretion of a variety of endocrine products (1) and plays an 
important role in regulating anterior pituitary gland function. Activin was first 
isolated from the gonads because of its ability to stimulate pituitary follic1e-
stimulating hormone (FSH) synthesis and secretion from the gonadotropes (2). 
The pituitary action of activin is not restricted to gonadotropes and activin also 
modulates the function of other pituitary cell types such as the somatotropes and 
lactotropes. In addition to stimulating FSH release from the gonadotropes, activin 
inhibits basal growth hormone (GH) and adrenocorticotropin (ACTH) secretion 
(2). Finally, activin acts as a negative regulator of PRL expression and secretion 
in pituitary primary culture and cell lines (3). In addition, activin regulates cell 
growth and differentiation of numerous cell types. The antiproliferative and 
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proapoptotic effects of activin have been observed in many different cell types 
such as erythroleukemia (4), capillary endothelial (5), immune (6, 7), breast 
cancer (8-10) and hepatocytes (11-15). Consistent with the critical role of activin 
in celI growth regulation, alterations of the activin signalling pathway such as 
mutation or truncation of the activin receptor are associated with human tumors 
(16, 17). 
Activin signaIs through a complex of two transmembrane serinelthreonine kinase 
receptors (type 1 and type il receptors) (18, 19). Upon ligand binding, the type il 
receptor phosphorylates the type 1 receptor and the activated receptor complex 
then recruits and phosphorylates the receptor-regulated Smad2 and Smad3 (18, 
20-22). These C-terminally phosphorylated Smads then undergo a change in 
conformation, which results in dissociation from the receptor complex and 
association with the common-partner Smad4 (23-25). The Smad complex 
translocates into the nucleus where it regulates transcription of target genes 
through DNA binding and functional recruitment of specific transcription factors 
and coregulators, thus providing tissue specificity (26, 27). However, the 
mechanisms and signaling pathways by which activin regulates lactotrope 
pituitary celI function and growth are not weIl characterized. 
An important player in regulating both PRL and GH expression is the pituitary-
specific transcription factor Pit-l (GHF-l) (28, 29). Pit-l is required for the 
generation and maintenance of three cell types (lactotropes, somatotropes and 
thyrotropes) in the anterior pituitary gland (30). While activin was reported to 
apparently not modulate Pit-I mRNA levels (31), it was shown to induce Pit-I 
degradation in MtTWI5 somatotrope cells (32). However, the mechanisms by 
which activin controls Pit-I activity are still not fully determined. 
Multiple endocrine neoplasia type 1 (MENt) is an autosomaI dominant disorder 
characterized by endocrine tumours of parathyroids, pancreatic islets, and anterior 
pituitary, especialIy prolactinomas (33). Interestingly, overexpression of menin, 
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the product of the MENl gene, leads to reduced PRL expression (34). Moreover, 
inactivation of menin expression suppresses TGF~-induced growth inhibition 
(35). We recently showed that menin physically interacts with Smad3 in 
somatolactotrope cells and its inactivation blocks TGF~ signalling (35). However, 
such a role for menin downstream of the activin receptor signalling pathway 
remains to be determined. 
The multiple effects of activin on hormone production and secretion highlight the 
important role played by this growth factor in regulating pituitary function. 
However, the me chanis ms remain unclear. In this study, we show that activin 
negatively regulates PRL gene transcription and that the Smad pathway is 
involved in the mediation of this effect. Moreover, we show for the first time that 
menin is required for activin-mediated inhibition of PRL expression. We also 
show that activin-mediated inhibition of PRL expression is mediated through 
reduction of Pit-l expression and we define two Pit-l sites in the proximal region 
of the PRL gene promoter as critical to activin-mediated PRL inhibition. Finally, 
we found that menin is also important for activin-induced cell growth inhibition in 
somatolactotrope cells. Together, our results clearly demonstrate a critical role for 
the growth factor activin in regulating inhibition of pituitary cell growth and Pit-
l/PRL expression through the Smads and menin. 
3. Materials and Methods 
a. Cell Culture 
GH4Cl cens, T47D, and CHû cens were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) (HyClone) in the presence of 10% fetai bovine serum 
(FBS) (Hyclone), and 2mM L-glutamine. 
b. Cell Viability Assay (MTT) 
Cens were plated in triplicate at 5 x 103 cens per 100 ~l in DMEM containing 2% 
FBS and cultured for three days in the presence or absence of 0.5 nM activin or 
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0.2 nM TGF~ (PeproTech). Cell viability was assessed using the non-radioactive 
MIT cell growth assay for eukaryotic cells (Cell Titer 96, Promega G4000). 
Absorbance was measured at 570nm with a reference wavelength at 450nm, using 
a Bio-tek Microplate reader. 
c. Transfection and Reporter Assays 
GH4Cl cells were stably transfected with antisense menin cDNA as described 
(27). For luciferase assays, 0.3 Ilg of the different promoter constructs (ratPRL-
lux 3kb, ratPRL-Iux 450, ratPRL-Iux mutants, humanPRL-Iux 5kb, human PRL-
lux 250, and Pit-l-Iux) were co-transfected in 106 cens with Lipofectamine 
(Invitrogen, Carlsbad, CA) with 0.3 Ilg of the pCHllO expression vector encoding 
~-galactosidase, in the presence or absence of various Smad expression plasmids, 
as described in the legend of fig.2. One day after transfection, cells were 
trypsinized, divided in three, allowed for recovery, and then serum-starved with or 
without activin (0.5nM) or TGF~ (0.2nM) for l8h. cens were then washed with 
PBS and lysed in 100 III of lysis buffer (1 % Triton X-lOO, l5mM MgS04, 4mM 
EGTA, ImM dithiothreitol, 25mM glycylglycine pH7.8) on ice. The luciferase 
activity of each sample was measured using 45 III of cell lysate (EG&G Berthold 
luminometer) and normalized to the relative ~-galactosidase activity. CHO cens 
were transfected using the calcium phosphate method. Briefly, lllg of the 
different reporter constructs were transfected with lllg ~-galactosidase expression 
vector. One day after transfection, cells were serum starved in the presence or 
absence of activin 0.5nM for l8h. Luciferase assays were performed as for the 
GH4Cl cells. 
d. Western blot Analysis 
For long time courses (0 to 24h), GH4Cl and T47D cells were plated at 106 
cells/ml in DMEM containing 2% FBS and stimulated in the presence or absence 
of activin 0.5nM. For short time courses (0 to 60 min.), cells were serum-starved 
overnight, and stimulated or not with activin 0.5nM. Cells were lysed on ice in 
lysis buffer (50mM Hepes at pH 7.5, l50mM sodium chloride, 100mM sodium 
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fluoride, lOmM sodium pyrophosphate, 5mM EDTA, 10% glycerol, 0.5% NP40 
and 0.5% sodium deoxycholate) supplemented with ImM phenyl 
methylsulphonyl fluoride (PMSF), 10llglml aprotinin, 10llglml leupeptin, and 
21lglml pepstatin. Total cell extracts were then separated on a polyacrylamide gel, 
transferred onto nitrocellulose, and incubated with the indicated specific antibody 
overnight at 4 OC [menin (66), stat3 (Santa Cruz), PRL, phospho-Smad2 (UBI), 
Smad2/3 (Santa Cruz), Tubulin (Sigma), Pit-l (Santa Cruz)]. Following 
incubation, membranes were washed twice for 10 min. in washing buffer (50mM 
Tris-Cl at pH 7.6, 200mM NaCl, 0.05% Tween20) and incubated with a 
secondary antibody coupled to horseradish peroxidase (from Sigma) at a 1/10 000 
dilution) for lh at room temperature. Then, membranes were washed four times 
for 15 min in the washing buffer. Immunoreactivity was normalized by 
chemiluminescence (Lumi-Light Plus Western blotting substrate, Roche 
Molecular Biochemicals) according to the manufacturer's instructions and 
revealed using an Alpha Innotech Fluorochem Imaging system (Packard 
Canberra). Densitometric analysis was performed using Fluorochem 8000 
software (Alpha Innotech) that allows normalization and quantitative analysis of 
chemiluminescence under non-saturating condition. 
e. Northern blot analysis 
GH4CI (106 cells/ml) were plated in DMEM containing 2% FBS and stimulated 
with activin 0.5nM for different periods of time. Total RNA was extracted using 
Trizol (Invitrogen). 20 Ilg of each sample were then separated on an agarose gel 
(1 % agarose in 0.04M MOPS, O.OIM sodium acetate, lOmM EDTA pH 8.0, and 
2.5M formaldehyde) and transferred to a nylon membrane. Membranes were 
rinsed twice in 10X SSC, crosslinked under UV light, and pre-hybridized in a pre-
hybridization solution (0.5M NaP04 pH 7.2, ImM EDTA pH 8.0, 7% SDS, 1 % 
BSA, and 200~glml salmon sperm DNA) for 2h at 60OC. Probes for PRL, Pit-l, 
and GAPDH were labeled using the Random Priming Kit (Roche), and then add 
to the pre-hybridization solution for an overnight incubation. Membranes were 
washed twice for 15 min. with wash A (40mM NaP04 pH 7.2, 5% SDS, ImM 
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EDTA, and 0.5% BSA), and four times with wash B (40rnM NaP04 pH 7.2, 1 % 
SDS, 1 mM EDTA). Results were revealed using a phosphorimager Cyclone 
Storage Phosphor Screen (Packard). 
f. Antisense oligonucleotide treatment 
Twenty-base pair phosphorothioate-derivatized antisense menin and control 
oligonucleotides (AS- and C-oligos) were synthetized. The AS oligo was 5'-
GGGCGGCCTICAGCCCCATG-3' and the C-oligo was 5'-TCAGACTGGCTC 
TCTCCATG-3'. Cells were plated in the presence or absence of 100 ~M menin 
AS-oligo or control C-oligo for 12h and then stimulated with activin O.5nM or 
TGF~ O.2nM. Luciferase activity was measured after 18h and cell growth after 
72h of ligand stimulation. 
g. Mutagenesis of the rPRL promoter 
The three Pit-l proximal binding sites in the wild-type PRL-3kb construct were 
mutated singly to disrupt DNA binding of Pit-l using the QuickChange 
mutagenesis kit (Stratagene). Oligonucleotides used for mutagenesis were: mut-
IP, 5'-GCCTGATIATATATATGGGAATGAAGGTGTCGAAGG-3' and 5'-
CCTICGACACCTICATTCCCATATATATAATCAGGC-3'; mut-2P, 5'-
GGCCACTATGTCTICCTGAATATTCCGAAGAAATAAAATACCATTIGA 
-3' and 5' -TCAAATGGTA TITI A TTICTICGGAATA TICAGGAAGACATA 
GTGGCC-3'; mut-3P, 5'-TCATTICCTITIGCTGTAATIGCGAAAAATCCT 
TCCTTICTGGCC-3' and 5' -GGCCAGAAAGGAAGGA TITITCGAAA TT AC 
AGCAAAAGGAAATGA-3'. The mutated nucleotides are indicated in boldo AlI 
mutant constructs were confirmed by sequencing. 
h. siRNA design and generation and transfection 
Three different siRNAs corresponding to distinct parts of the rat MEN 1 gene 
(GenBank accession no. 9506894) were designed using the "siRNA Selection 
Program" (Whitehead Institute for Biomedical Research. 2003). AlI siRNA 
sequences were BIast searched in the NCBI's search for short nearly exact 
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matches mode against aIl rat sequences of the GenBank database, and were not 
found to have significant homology to genes other then the rat MENl gene. 
siRNAs were synthetized using the Silencer siRNA Construction Kit (Ambion) 
according to the manufacturer's instructions. SiRNAs sequences were as follow: 
MlO 5'-AAGGCCGCCCAGAAGACGCTG-3'; M379 5'-AACAGCCTCAGCC 
GCTCCTAC-3'; M1073 5'-AAGAGATCTACAAGGAATICT-3'. GAPDH 
siRNA was provided with the kit. 5 x 104 GH4C 1 cells were transfected using the 
siPORT Lipid transfection agent (Ambion) according to the manufacturer' s 
instructions. Expression levels of menin, PRL, and Pit-l were analyzed by 
Western blot and RT-PCR. 
i. Statistical analysis 
Results are expressed as mean ± SD. Differences were assessed by oneway 
ANDV A or the unpaired t test, where appropriate. A P value less than 0.05 was 
considered significant. 
4. Results 
a. Activin inhibits PRL gene transcription. 
To first characterize the role of activin on PRL gene expression, we used rat 
somatolactotrope GH4C 1 cells, a highly differentiated neuroendocrine cell line 
that retains the capacity to synthesize and secrete GH and PRL in a hormone-
regulated manner (36, 37). The GH4 cells were established from rat pituitary 
tumor cells and are widely used as an in vitro model of pituitary tumors (38, 39). 
As shown in Fig.la (upper panel), PRL mRNA levels were rnarkedly reduced 
after 4h of activin treatment and had returned to basallevels by 24h. Reprobing of 
the stripped membrane for GAPDH mRNA showed equalloading (Fig. la, lower 
panel). To then evaluate whether the effect of activin on PRL rnRNA was 
followed by a decrease in PRL protein expression, ex tracts of GH4Cl cells treated 
or not with activin for different periods of time were analyzed by western blot. As 
shown in Fig.lb (upper panel), activin clearly inhibited PRL expression by 16h to 
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reach a maximum inhibition by 24h. Reprobing of the membrane for Stat3 protein 
showed equal loading (Fig. 1 b, lower panel). The results indicate that activin 
blocks PRL gene expression. The same results were obtained using another 
pituitary-derived prolactin-expressing tumor celI Hne (GH3), thus strengthening 
the conclusion (data not shown). To determine whether activin directly regulates 
PRL expression at the transcriptional level, GH4C1 celIs were transfected with 
reporter constructs containing either 3kb of the rat PRL promoter fused with the 
luciferase gene (rPRL-3kb) (40) or 5kb of the human PRL promoter (hPRL-5kb) 
(41) and stimulated or not with activin for 16h. As shown in Fig.1c, activin 
stimulation led to a 50% reduction in luciferase activity compared to control. 
Thus, activin exerts a direct transcriptional effect on PRL gene expression. 
The PRL gene promoter consists of distal and proximal regions that both contain 
important regulatory sequences. To explore further the promoter sequences 
mediating activin downregulation of PRL expression, constructs containing both 
distal and proximal regions of the rat (rPRL-3kb) and human (hPRL-5kb) PRL 
gene promoters and constructs containing only the proximal elements (rPRL-
450bp and hPRL-250bp) fused to the luciferase reporter gene were used. A 
construct, lacking both distal and proximal elements (rPRL-36bp) was also used. 
The constructs were transfected into GH4C 1 celIs and the luciferase activity was 
measured following activin treatment. As shown in Fig. 1 d, removal of the distal 
element of both rat and human promoters did not affect PRL induced repression 
(rPRL-450bp, hPRL- 250bp). The results indicate that activin mediates its 
inhibitory effect on PRL gene transcription through the proximal region of the 
PRL gene promoter. 
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Figure 1: Transcriptional regulation of PRL gene promoter by activin. a) 
Total RNA from GH4Cl ce11s stimulated with activin for the indicated periods of 
time were analyzed by Northern blot using specific probes for PRL and GAPDH. 
b) Whole ce11lysates from GH4Cl ce11s stimulated with activin for the indicated 
periods of time, were analyzed by Western blot using anti-PRL antibody. The 
membrane was reprobed with an anti-Stat3 antibody for loading control. c,d) 
GH4Cl ce11 were transfected with the rPRL-3kb or the hPRL-5kb c) or the 
indicated truncated promoter constructs d) with a ~-galactosidase expression 
plasmid and the activin response was measured by luciferase assay 18h after 
stimulation. In a11 panels *, P < 0.05 compared with no activin treatment. 
b. Smad pathway is critical for inhibition of PRL gene transcription by 
activin. 
The Smad pathway represents the canonical pathway downstream of activin 
receptors. Activin signaling via activation of Smads was demonstrated by 
immunoblot analysis using a specific antibody to phosphoSmad2. Activin 
treatment of GH4Cl ce11s led to an increase in endogenous Smad2 
phosphorylation (Fig.2a, upper panel). The membrane was stripped and reprobed 
with an anti-Stat3 antibody to show equal loading (Fig.2a, lower panel). To 
investigate the role of the Smads in the activin-induced PRL inhibition, we used 
the inhibitory Smad7 (42), the dominant-negative form of Smad2 (DNSmad2) 
(24) and Smad3 (DNSmad3) (43) in which the serine residues within the motif 
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SSXS, the target of Smad phosphorylation by the type 1 receptor, are mutated to 
alanine. GH4Cl cens were transiently co-transfected with the 3kb PRL gene 
promoter reporter construct and the cDNA encoding for either Smad7, DNSmad2 
or DNSmad3. As shown in Fig.2b, the activin-induced decrease in luciferase 
activity observed in control cens is blocked in GH4Cl cells overexpressing 
Smad7 or the dominant negative Smad2 or 3. These results clearly demonstrate 
the requirement of the Smad pathway in activin-mediated inhibition of PRL gene 
promoter activation. 
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Figure 2: The Smad pathway is critical for activin inhibition of PRL gene 
promoter activity. a) GH4Cl cens were treated with activin (0 to 60 min.) 
Whole cen lysates were analyzed by Western blot using a specific antibody to 
phospho-Smad2 (upper panel). The membrane was stripped and reprobed with an 
anti-Stat3 antibodyas a loading control. b) GH4Cl cens were transfected with the 
PRL-3kb reporter construct, the ~-galactosidase expression plasmid, and the 
different Smads expression plasmids, as indicated. cens were then stimulated 
with activin and assessed for luciferase activity. *, P < 0.05 compared with no 
activin treatment. 
c. Menin is required for activin-mediated inhibition of PRL expression. 
Interestingly, a recent study showed that overexpression of menin in GH3 
pituitary cens inhibits PRL gene expression (34). To explore the function of 
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menin m activin signalling, GH4Cl ceUs were treated with either antisense 
oligonucleotides to the 5' coding sequence of menin (AS-oligo) or a scrambled 
sequence as a control (C-oligo). To validate our system, we examined the ability 
of the antisense oligonucleotide to suppress menin expression. As shown in 
Fig.3a, treatment of GH4C 1 ceUs with the AS-oligo significantly inhibited menin 
protein expression by 40% as compared to the C-oligo. Densitometric analysis 
was performed using Fluorochem 8000 software that allows normalization and 
quantitative analysis of chemiluminescence under non-saturating condition. To 
then examine the effects of menin inactivation on activin-mediated PRL 
inhibition, GH4C 1 cells were treated with AS-oligo or C-oligo before being 
stimulated or not with activin. Total ceU lysates were then analyzed by Western 
blotting using antibodies to PRL or Stat3. As shown in Fig.3b, the inhibitory 
effect of activin on PRL protein expression is aboli shed in the presence of AS-
oligo, but not with the C-oligo. To further support the essential role of menin in 
the regulation of PRL, we generated and tested three different siRNAs 
corresponding to the rat MENI gene. We used, as a control, an unrelated siRNA 
specific for GAPDH gene. As illustrated in Fig.3c, transfection of MENI or 
GAPDH siRNAs in GH4Cl cells efficiently reduced their respective mRNA and 
protein expression levels (42% inhibition). We chose to use MIO siRNA for 
subsequent experiments since this siRNA was the most efficient in blocking 
menin rnRNA expression. As shown in Fig.3d, activin-mediated PRL expression 
inhibition was blocked in GH4Cl ceUs transfected with MIO siRNA but not 
affected in control ceUs or ceUs transfected with the GAPDH siRNA. Thus 
reducing menin expression levels by 40%, using siRNA or antisense approaches, 
is sufficient to efficiently block activin-mediated PRL inhibition, thus 
demonstrating the critical role played by menin in activin signal transduction in 
pituitary ceUs. We then analyzed the role of menin in activin-induced repression 
of the PRL gene promoter. For this, GH4Cl ceUs transfected with the 3kb rat PRL 
gene promoter construct were treated with the menin antisense or control 
oligonucleotide and ceUs were stimulated or not with activin. Interestingly, activin 
effects on the PRL gene promoter were completely blocked in the absence of 
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menin but not affected by the control oligonuc1eotide (Fig.3e). Therefore, menin 
is critical and required to mediate activin effects on inhibition of PRL expression 
in anterior pituitary cells. We also examined the role of activin on menin 
expression. As shown in Fig.3f, activin c1early induces an increase in menin 
expression in GH4Cl cells. As menin is required to mediate the activin effects 
(Fig.3b, c, d, e) this suggests that it may act in a positive feedback loop to 
transduce activin signalling. 
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Figure 3: Activin-mediated PRL inhibition requires menin. a,b,) GH4C 1 cells 
were cultured in the presence of menin antisense oligonuc1eotide or control 
oligonuc1eotide and stimulated or not with activin for 24h. Cell lysates were 
analyzed by Western blot using antibodies to menin, PRL and Stat3 as a loading 
control. c) Total RNA from GH4Cl cells transfected with menin (MIO) or 
GAPDH siRNA were analyzed by RT-PCR. Total celllysates from GH4Cl cells 
transfected with menin (MIO) or GAPDH siRNA were analyzed by Western blot 
using anti-menin and anti-Stat3 antibodies. d) GH4Cl cells transfected with MIO 
or GAPDH siRNA were cultured with or without activin for 24h. Cell lysates 
were analyzed by Western blot using anti-PRL and anti-menin antibodies. e) 
GH4Cl cells were transfected with the PRL-3kb reporter construct and the ~-
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galactosidase expression plasmid. Cells were treated with menin antisense 
oligonuc1eotide or control oligonuc1eotide and stimulated or not with activin for 
18h before being assessed for luciferase activity. *, P < 0.05 compared with no 
activin treatment. f), GH4Cl cells were cultured with activin for the indicated 
period of time. Proteins extracts were analyzed by Western blot using a specific 
antibody to menin. The membrane was stripped and reprobed with an anti-Stat3 
antibody. 
d. Activin-dependent down-regulation of PRL expression is pituitary cell 
specifie. 
Production of PRL is not limited to the pituitary and other sites such as the 
mammary gland (44) have been shown to produce PRL. Interestingly, the human 
breast cancer cellline T47D, that produces PRL (45) is also responsive to activin 
(46). However, as shown in FigAa, no change in PRL expression (upper panel) 
was observed in response to activin in these cens. The activin responsiveness of 
the cens was demonstrated by the c1ear increase in phosphoSmad2 in response to 
activin (FigAb). Moreover, CHû cells, transiently transfected with the rPRL-3kb 
or rPRL-450bp gene promoter construct showed no decrease in luciferase activity 
in response to activin (FigAc). As a positive control, cells were transfected with 
the activin responsive promoter construct (3TPLux). Together, these data indicate 
that a pituitary cell specific factor is involved in the activin-mediated 
downregulation of PRL rnRNA expression. 
e. Pit-! gene transcription, mRNA and protein levels are down-regulated 
byactivin. 
Analysis of both the rat and human PRL promoter proximal region reveals three 
Pit-l response elements, suggesting that activin-mediated PRL inhibition may be 
mediated via regulation of the pituitary specific transcription factor Pit-l. This 
prompted us to analyze the regulation of Pit-l gene expression by activin in 
GH4Cl cens. We first examined the activin effects on Pit-l mRNA levels in 
GH4CI cens. As shown in Fig.5a, Northern blotting analysis of activin-treated 
GH4Cl cells, indicated that Pit-l mRNA levels were significantly reduced 
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Figure 4: A pituitary cell-specific factor is involved in the activin-dependent 
down-regulation of PRL rnRNA. a) Breast cancer T47D cells were treated or 
not with aetivin for various time, as indieated. Cell lysates were analyzed by 
immunoblot using antibodies specifie to PRL or Stat3 as control. b) T47D cells 
were stimulated with activin for 0, 15, 30 and 60 minutes. Protein extraets from 
these cells were then subjeeted to western blot analysis with an 
antiphosphoSmad2 specific antibody. The membrane was stripped and reprobed 
with an anti-Smad2/3 specific antibody. c) CHO cells were transfected with the 
PRL-3kb, the PRL-450bp, or the 3TP-Iux reporter eonstruct as a positive control 
with the ~-galactosidase expression vector. Cells were then stimulated or not with 
activin and assessed for luciferase activity. *, P < 0.05 compared with no activin 
treatment. 
starting at 4h to reach a maximum at 16h following activin treatment. Pit-l levels 
then returned to normal by 24h. To then determine if this decrease in Pit-1 mRNA 
was followed by a deerease in Pit-1 protein expression, GH4C1 cells stimulated 
with activin for different periods of time were analyzed by Western blot. As 
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shown in Fig.5b, both PRL and Pit-l protein levels were strongly reduced upon 
activin treatment. To evaluate the role of menin in activin-mediated Pit-l down-
regulation, GH4Cl cens transfected with the menin siRNA (MlO) or GAPDH 
siRNA were stimulated or not with activin and the level of Pit-l protein 
expression was evaluated using a specifie anti-Pit-l antibody. As shown in Fig.5c, 
in the presence of menin siRNA, but not with GAPDH siRNA, activin lost its 
ability to repress Pit-l protein expression, similar to what observed for prolactin 
(Fig.3c), thus indieating that menin is required for activin to block Pit-l protein 
expression. 
Furthermore, in GH4Cl cens transfected with a construct in which the Pit-l gene 
promoter drives a luciferase reporter gene (47), activin caused a 50% inhibition of 
luciferase activity and this effect was blocked in cens expressing Smad7 (Fig.5d). 
These data indicate that activin modulates Pit-l rnRNA and protein expression in 
a Smad-dependent manner through inhibition of the Pit-l gene promoter. 
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Figure 5: Activin down-regulates Pit-l gene transcription, rnRNA and 
protein levels. GH4Cl cens were cultured with activin for the indieated periods 
of time. a) Total RNA from GH4Cl cens stimulated with activin for the indicated 
periods of time were analyzed by Northern blot using specific probes for Pit-l and 
GAPDH. b) GH4Cl cens were cultured with activin for the indieated periods of 
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time. Cells lysates were immunoblotted using anti-PRL and anti-Pit-l antibodies. 
Stripping and reprobing the blot with an anti-Stat3 antibody confrrmed equal 
loading. c) Cell lysates from GH4CI cells transfected with menin (MIO) or 
GAPDH siRNAs and treated or not with activin were immunoblotted using anti-
Pit-l and anti-stat3 antibodies. d) GH4Cl cells were transfected with the Pit-I-Iux 
reporter construct together with the ~- galactosidase expression plasmid. Cells 
were treated with activin for 18h and luciferase assays were performed. *, P < 
0.05 compared with no activin treatment. 
f. Pit-l response elements in the PRL gene proximal promoter are 
critical for activin-mediated repression. 
The proximal PRL gene promoter region contains three Pit-l sites (Fig.6a). These 
sites are involved in both positive and negative regulation of PRL gene promoter 
activity (48). To investigate the relative importance of these sites in mediating 
activin repression of the PRL promoter, four nucleotides of each Pit-l DNA 
response element were mutated in the rPRL-3kb gene promoter construct to 
disrupt Pit-l DNA binding activity (Fig.6a). Activin significantly inhibited the 
3kb parental promoter construct as well as the mutant promoter lacking the first 
Pit-l site (Fig.6b). However, removal of either site 2 or site 3 completely reversed 
the activin-mediated inhibition of the PRL gene (Fig.6b). These results indicate 
that the Pit-l sites 2 and 3, but not site 1, are important for activin-mediated 
repression of the PRL gene promoter activity. 
g. Activin inhibits pituitary cell growth through menin. 
Activin is known to induce growth inhibition of epithelial, endothelial, lymphoid, 
and hematopoietic cells (49, 50). Therefore, to next investigate the effect of 
activin on pituitary cell growth, GH4CI cells were stimulated or not with activin 
or TGF~ as a control. As shown in Fig.7a, both activin and TGF~ significantly 
inhibited cell growth of GH4Cl cells by 30%, thus indicating that activin acts as a 
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Figure 6: Pit-! response elements 2 and 3 in the proximal region of the PRL 
promoter are critical for the activin-mediated repression of PRL. a) 
Schematic representation of the rPRL-lux 3kb reporter construct. The proximal 
region contains three Pit-1 DNA-binding sites. For each of these sites, four 
nuc1eotides were changed to other bases as indicated to disrupt Pit-1 DNA 
binding. b) GH4C1 cells were transfected with either the wild type rPRL-Iux 3kb, 
Mut 1P, Mut 2P, or Mut 3P reporter constructs and the ~-galactosidase expression 
vector. Cells were stimulated or not with activin for 18h and luciferase activity 
was assessed. *, P < 0.05 compared with no activin treatment. 
potent cell growth inhibitor of lactotrope cells. To explore the function of menin 
in activin signalling, GH4C1 cells stably over-expressing antisense menin cDNA 
(GH4-AS), in which menin expression levels are strongly reduced (35), or control 
GH4C1 cells expressing the vector alone (GH4-V) were treated or not with 
activin or TGF~. Interestingly, both the activin and TGF~ effect on cell growth 
inhibition were totally blocked in the absence of menin (Fig.7a). To confirm these 
results we used another means of blocking menin expression by utilizing modified 
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phosphorothioate antisense oligonucleotide to menin. As shown in Fig.7b, the 
effects of activin and TGF~ on GH4Cl cell growth arrest are specifically 
antagonized and completely reversed in the presence of menin AS-oligo while not 
affected by the control oligonucleotide. These data demonstrate that activin acts 
as a potent pituitary tumor cell growth inhibitor and that this effect requires the 
tumor suppressor, menin. 
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Figure 7: Activin inhibits pituitary cell growth through the MENt gene 
product, menin. a) GH4Cl, GH4-V and GH4-AS cells were cultured with or 
without TGF~ or activin for 72h. and cell viability was assessed by MTT assay b) 
GH4Cl cells were cultured in the presence or the absence of menin antisense 
oligo or a control oligo and stimulated with or without TG~ or activin for 72h. 
Cell viability was measured by MTT assay. In all panels *, P < 0.05 compared 
with no activin treatment. 
5. Discussion 
Members of the activinffGFp family of growth factors are important in regulating 
cell growth and production of a variety of hormones from different pituitary cell 
types. Our study defines a critical role for activin in regulating the growth and 
function of pituitary lactotrope cells. We demonstrate for the first time the 
requirement of the Smad pathway and the tumor suppressor menin in transducing 
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activin signaIs to inhibition of PRL expression and cell growth arrest. Our results 
also indicate that activin-mediated effects on PRL production are pituitary 
specific. PRL transcription is controlled through a series of distal and proximal 
enhancer elements that contains several DNA binding sites for the transcription 
factor Pit-l which are required to regulate ceIl-specific expression (51). Our 
results clearly indicate that activin exerts a direct negative effect on Pit-l gene 
expression. Thus, inhibition of Pit-l expression by activin contributes to the 
decreased PRL level. Our data strongly support previous observations showing 
that extinction of PRL and growth hormone gene expression in somatic cell 
hybrids is correlated with the repression of the pituitary-specific transcription 
factor Pit-l (52, 53). 
Interestingly, previous work showed that activin could contribute to reduced 
intracellular Pit-l levels by decreasing its stability (32). Together with our results, 
this indicates that activin is able to down-regulate intracellular Pit-l and PRL 
levels through different parallel mechanisms, highlighting the critical role played 
by activin in regulating pituitary hormone levels. A previous study in GR3 
pituitary ceIls, found no apparent change in Pit-l rnRNA level foIlowing activin 
stimulation of the cells for 24h (31). Based on our study, activin-mediated 
repression on Pit-l rnRNA is a transient event that occurs within hours of 
stimulation and has returned to normal by 24h, thus explaining why Tamura et al. 
failed to observe any change in Pit-l mRNA in activin-treated celIs (31). A 
previous study indicated that activin's inhibitory effect on GR production is 
mediated through rapid phosphorylation of Pit-l, resulting in loss of DNA binding 
activity and protein instability (32). Together with our results this suggests that 
activin acts at multiple levels to regulate Pit-l and hormonal levels in pituitary 
cells. 
We also show that the proximal but not the distal region of the PRL gene 
promoter mediates the activin inhibitory effects. This proximal region of the PRL 
gene promoter contains 3 Pit-l response elements and we show here that sites 2 
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and 3 are each required for activin to repress PRL gene expression. Therefore, this 
suggests that activin-mediated inhibition of PRL expression is not only mediated 
through a direct down-regulation of Pit-l gene expression but also through 
prevention of the pre-existing pool of Pit-l to bind DNA on site 2 and 3 of the 
PRL gene promoter. Such interference with DNA binding and activating function 
of Pit-l has been described as a mechanism by which glucocorticoids inhibit PRL 
expression (48). 
Interestingly, negative regulation of PRL expression by glucocorticoids involves 
the same proximal Pit-l sites 2 and 3, suggesting that this may represent a general 
mechanism of negative regulation of the PRL gene transcription. It is also 
possible that activin induces recruitment of a co-repressor to the Pit-l complex 
bound to DNA. Activin and TGFp are known to recruit histone deacetylases to 
sorne of their target genes, thereby inhibiting their transcription (54). Pit-l has 
also been shown to mediate transcriptional activation and repression by 
recruitment of co-activators or co-repressors (55, 56). It will therefore be 
interesting in future studies to determine whether the Smads physically interact 
with Pit-l and/or histone deacetylase activity can be found in these complexes. 
While Smads, menin and Pit-l are critical to activin inhibition of PRL gene 
expression, a previous study suggested that the inhibitory effect of TGFp on the 
rat PRL gene promoter is Pit-I-independent (57). Therefore, our results also 
highlight significant differences in the intracellular signalling pathways of these 
two growth factors leading to PRL gene regulation in pituitary cells. 
Inactivating alterations in the activinffGFp signalling pathways have been 
described underlying many human cancers (58). For instance, Smad2 and Smad4 
are frequently mutated in colorectal cancers and pancreatic carcinomas, 
respectively (58). Truncated activin receptor forms are often found in human 
pituitary adenomas and function as dominant negative receptors, contributing to 
pituitary tumorigenesis by blocking the growth inhibitory effect of activin (59). 
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MEN 1 is an autosomal dominant disorder characterized by parathyroid 
hyperplasia, pancreatic endocrine tumours, and pituitary adenomas (33). Pituitary 
tumors occur in 30% of MENI patients, with prolactinomas being the most 
common type (60). Twenty-six percent of mice heterozygous for deletion of the 
MENI gene develop large pituitary tumors by 16 months of age (61). Here, we 
demonstrate that inactivation of menin through three different antisense 
technologies (cDNA antisense, oligonucleotide antisense, and siRNA) blocks 
activin signalling. This results in an increase in PRL gene expression, Pit-l gene 
expression, and the loss of pituitary cell growth inhibition by activin. This is 
consistent with our previous work showing that inactivation of menin interrupts 
Smad3 binding to DNA, thereby bloc king TGFp signalling (35). Thus, menin 
appears as a novel activin downstream signalling effector molecule and its 
inactivation leads to the loss of activintrGFp responses, emphasizing the critical 
role played by these growth factors in maintaining cellular homeostasis. Pituitary 
adenoma is the most frequent adult intracranial neoplasm accounting for 10 % of 
brain tu mors and compared to other neoplasms, they occur in younger patients. 
Prolactinomas are the most common hormone-secreting pituitary tumor 
accounting for two-thirds of the patients in a pituitary tumor registry across the 
fourth decades (62). Prolactinomas often develop sporadically as a monoclonal 
proliferation but the molecular mechanisms underlying the formation of these 
tu mors remain largely unknown. Gene expression of Pit-l has been explored in 
pituitary adenoma but revealed no mutation of the Pit-l gene in these tumors, 
despite up to 5-fold higher levels of Pit-l as compared to normal (63). To date, 
standard primary treatment using dopamine agonists showed suppressive but not 
tumoricidal effects with side effects and varying remission rates (64, 65). As for 
patients with therapeutic intolerance or insensivity to dopamine agonists, surgery 
remains the last resort. Our study sheds light on the mechanisms by which activin 
regulates PRL, Pit-l levels and cell growth arrest in lactotrope cells, through the 
Smad pathway and the tumor suppressor menin, and opens new avenues for future 
therapies to combat human pituitary adenomas. 
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Chapter 4: Transforming Growth Factor-~ Tumor Suppressor EfTect on 
hTERT Expression are Mediated through Increase of E2F-l Expression in a 
Smadlp38~rk-dependentmanner 
Annie Lacerte, Juliana Korah, Mélanie Roy, Xiang-Jiao Yang, Serge Lemay, 
Jean-Jacques Lebrun 
1. Abstract 
Tumors will develop when barriers that inhibit cell proliferation are overcome. 
One such barrier is the length of the telomeres. In 90% of cancers, the telomere 
length is maintained by the enzyme telomerase. The expression of hTERT, the 
protein component of telomerase, is closely associated with telomerase activity 
and is increased in most cancer cells. Transforming growth factor-~ (TGF~), a 
well-known inhibitor of cell proliferation, has been recently shown to decrease 
hTERT expression. The aim of the present work is to understand how TGF~ 
inhibits hTERT expression at the transcriptionallevel. To test this, we cloned the 
2.0kb promoter region of the hTERT gene in front of the luciferase gene. In the 
keratinocyte HaCaT cell line, we showed that TGF~ inhibits hTERT expression 
within 8 hours and hTERT promoter activity by 80%. This inhibition required 
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HDAC activity. As TGF~ classicaIly signaIs through the Smad pathway, we then 
evaluated its involvement using the inhibitory Smad7, dominant negative forms of 
Smads (DNSmads) or siRNAs against Smad2, Smad3 and Smad4. Smad7 
overexpression and Smads siRNAs reversed the TGF~-mediated decrease of 
hTERT promoter activity. Our data also indicated that the Erk1l2 and p38 kinases 
pathways play a direct role in TGF~ regulation of hTERT expression and 
promoter activity. Moreover, we showed that TGF~ repressed hTERT expression 
through induction of the expression of an intermediate signaling molecule. Using 
truncation and deletion mutant forms of the hTERT promoter construct, we found 
that TGF~ repressed hTERT promoter activity through the -252 to the +3 region, 
proximal to the start site. Interestingly, we found that several binding sites for E2F 
family members were critical for TGF~-mediated inhibition of the hTERT 
promoter. Furthermore, interfering with E2F activity also resulted in reversaI of 
TG~-mediated hTERT inhibition. FinaIly, we showed that TGF~ rapidly 
increased the expression of the transcription factor E2F-I, identifying E2F-I as 
the intermediate factor required by TGF~ to repress hTERT expression. 
Understanding the mechanism by which the hTERT gene is upregulated in cancer 
ceIls suggests new avenues for the development of cancer therapy. 
2. Introduction 
In humans, tumor formation and progression rely on several hallmarks that are 
found in aIl human cancers (33). Cancer ceIls acquire the ability to become 
resistant to growth arrest signaIs, such as TGF~, to proliferate in the absence of 
growth factors, to induce the development of new blood vessels, to escape 
apoptosis and the immune system, to metastasize and to achieve immortalization. 
Immortalization is achieved through the preservation of the length of ends of 
chromosomes, which are called telomeres. Telomeres consist of DNA repeats 
associated with proteins. The telomere structure protects chromosomes from 
recombination, end-to-end fusion, and recognition as damaged DNA (6). With 
each somatic cell division, the so-called end-replication problem occurs, i.e. 
97 
telomeres shorten by 50-200bp because conventional DNA polymerases are 
unable to completely replicate the ends of chromosomes. As a result, telomeres 
will shorten upon cen division until their minimal lengths are not maintained 
leading to cen death or a permanent cell cycle arrest (replicative senescence). 
Telomere shortening thus functions as a clock that monitors the proliferation 
history of cens (16). To complete the replication of telomeres, the enzyme 
telomerase is needed, whieh adds telomeric DNA repeats at the ends of newly 
duplicated telomeres. However, telomerase activity is undetectable in most human 
somatic cens, whereas highly proliferative cens, such as activated lymphocytes, 
germ cens and stem cens display telomerase activity (76). The telomerase enzyme 
minimally contains an RNA component, the human telomerase RNA template or 
hTER and a protein component, the human telomerase reverse transcriptase or 
hTERT (11). Between these two components of telomerase, only hTERT seems to 
be the key determinant of telomerase activity, as hTERT expression is strongly 
suppressed in somatie cens (66). 
90% of cancer cens exhibit telomerase activity (47). This is by far the most 
commonly observed abnormality acquired by tumor cens and is used in pathology 
as a marker for diagnosis of cancer (76). The prevalence of telomerase 
reactivation in tumorigenesis strongly supports the hypothesis that cancer 
progression requires functional telomeres. Reactivation of telomerase activity is 
mainly due to the loss of repression of the hTERT gene in cancer cells. Although 
telomerase activity is regulated at various levels, such as rnRNA splicing and 
accessibility of the telomeres, the transcriptional control of the hTERT gene is the 
major player involved in the apparition of telomerase activity in cancer cens (16). 
Several studies have been done to uncover the mechanisms regulating hTERT 
gene transcription in normal and tumor cells. Repression of hTERT expression 
requires histone deacetylase (HDAC) activity (15, 87). The minimal hTERT 
promoter sequence required for activity is contained within the 330bp upstream of 
the translation start site (ATG) (14). This region contains DNA binding elements 
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for several transcription factors, such as the MyclMadIMax family, SpI and E2F 
transcription factors. The c-Myc transcription factor, in collaboration with SpI, is 
a positive regulator of hTERT gene transcription (48), while Mad transcription 
factors repress hTERT expression and counteract c-Myc effects (32, 95). 
Interestingly, the E2F-l transcription factor was shown to repress hTERT gene 
expression (17, 75, 90). The presence of so many DNA binding elements support 
the hypothesis that hTERT gene is under multiple levels of regulation and is most 
likely regulated by different transcription factors in a cell specific manner. 
TGF~ is part of the TGF~ superfamily of ligands that contains among others 
TGF~l, 2, 3, and activins. TG~ ligands have a profound impact on cell 
homeostasis, through regulation of cell growth arrest, apoptosis and cell 
migration, among others. TGF~ ligands signal through serine/threonine kinase 
receptors. Following TGF~ binding to a dimer of type II receptors (T~RII), the 
TGF~-T~RII complex recruits a dimer of the TGF~ type 1 receptor (T~RI). T~RII 
activates the kinase activity of T~RI through phosphorylation of serine residues in 
the GS domain of T~RI. Once activated, T~RI binds to and phosphorylates the 
receptor-regulated Smads, Smad2 and Smad3. When phosphorylated, Smad2 and 
Smad3 interact with Smad4 (Co-Smad), and this complex translocates to the 
nucleus to form transcriptional complexes with a multitude of DNA-binding 
factors, co-activators and/or co-repressors that target hundreds of different genes 
for activation or repression (63). Smad7 expression is quickly increased following 
stimulation by TGF~ family members in most ceIllines (2,42, 71) and acts in a 
negative feedback loop to block TGF~ signaling. In addition to compete wîth the 
receptor-regulated Smads for binding to the receptors (34), Smad7 is also able to 
recruît an E3 ubiquitin-ligase complex, through its association with Smurf2, 
which targets the receptors for degradation (45). TGF~ binding to receptors also 
activates several other pathways such as Erk1l2, p38, JNK and RhoA (19, 68). 
The activation and the physiological importance of these pathways on TG~­
regulated genes appear to be highly cell-type specific. 
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TGF~ inhibits telomerase activity and hTERT expression in various cell lines. 
The Adenocarcinoma A549 celI line treated with TGF~ shows decreased 
telomerase activity. Expression of wild type T~RII in telomerase-positive 
HCT116 celIs, a celI line expressing a non-functional T~RII (62, 72), results in 
inhibition of telomerase and hTERT promoter activities (99). Moreover, TGF~ 
decreases telomerase activity by specificalIy inducing alternative splicing of 
inactive forms of hTERT rnRNA in HaCaT. It has also been proposed that TGF~ 
decreases human and rat TERT expression indirectly through inhibiting c-Myc 
expression (38, 99). However, hTERT regulation may be much more complicated. 
ln fact, a recent study in MCF-7 breast cancer cells suggested that the TG~ 
inhibitory effect on hTERT was not mediated through inhibition of c-myc 
expression, but involved the direct action of Smad3 on the hTERT promoter. This 
repression effect of Smad3 requires interaction with c-myc, then potentially 
inhibiting c-myc transcriptional activity (52). A recent paper also suggests that 
Smad interacting protein-l or SIPl is involved in TGF~ effect on hTERT 
expression (54). Obviously, TGF~ inhibition of hTERT gene transcription is not 
fully resolved. 
In this paper, we used the HaCaT human keratinocyte cell tine as a model to 
analyze the signaling pathways triggered by TGF~ in epithelial cells to repress 
hTERT expression. We show here that TGF~ inhibits hTERT expression and 
promoter activity with the help of HDAC proteins. Blocking the Smad pathway 
by three different approaches reversed TGF~-mediated inhibition of hTERT 
promoter activity. Our data also indicate that the Erkl/2 and p38 kinases 
pathways play a direct role in TGF~ regulation of the hTERT promoter. We also 
demonstrate that hTERT repression following TGF~ stimulation occurs via the 
induction of an intermediate signaling factor. Truncations of the hTERT promoter 
reveal that TGF~ acts through the -252 to the +3 region of the promoter. Within 
this region, several binding elements for E2F transcription factors are critical for 
inhibition of hTERT promoter activity in response to TGF~. Furthermore, 
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interfering with E2F activity also results in reversaI of TGF~-mediated hTERT 
inhibition. Finally, we show that TG~ induces the expression of the 
transcription factor E2F-l to control hTERT expression. A better understanding of 
the mechanisms regulating hTERT gene expression in normal and cancer cells is 
important because it may pave the way to novel strategies to inhibit telomerase 
activity in tumors. 
3. Experimental Procedures 
a. Plasmid constructions and Exonuclease III deletion 
hTERT-2k GFP reporter construct was digested with BarnHI and KpnI to separate 
the hTERT promoter insert (-1934 to +78, ATG as +1, GenBank sequence gi: 
4210970) from the pGFP vector. This hTERT promoter insert was ligated into 
pGL3-basic vector eut with BglII and KpnI. The resulting hTERT(-1934)-lux 
reporter construct was confirmed by sequencing. Sequential deletion mutants of 
hTERT promoter reporter were done using Erase-a-Base System (Promega, 
Madison, WI, USA) according to manufacturer instructions. E2F-decoy and TA-
decoy constructs were produced by digesting E2F-TA-Iuc and TA-lue (Clontech) 
with Hindill and SphI to disrupt the luciferase gene. Once blunted and gel-
purified, the digestion product was ligated and transformed. The proper disruption 
of the luciferase gene was checked by digestion and luciferase assays. The 
dominant negative Smad2 (SSMS to SAMA) and Smad3 (SSVS to SA V A) were 
generated by PCR, using wt Smads as templates and oligonucleotides that 
contained the mutations with flanking EcoRIIXhoI sites and a flag tag. 
Oligonuc1eotides used for production of the dominant negative Smad were as 
follows: Smad2: 5' -TT ACGAA TTCATGGACTACAAAGACGACGACGACAA 
ATCGTCCATCTTGCCATTCACT-3' and 5' -ATTGCTCGAGTTAGGCCATG 
GCTGAGCATCGCACTGACGGG-3'; Smad3: 5'-TTACGAATTCATGGACTA 
CAAAGACGACGACGACAAATCGTCCATCCTGCCCTTCACC-3' and 5'-
ATTGCTCGAGCTAAGCCACCGCGGAACAGCGGATGCTGGGG-3'. The 
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PCR products were cloned into pcDNA3.l+neo (Invitrogen). AIl constructs were 
confirmed by sequencing. 
b. Mutagenesis of hTERT promoter 
Mutagenesis of hTERT promoter was performed using the QuickChange site-
directed mutagenesis kit (Stratagene) using the hTERT(-1934)-lux construct as a 
template. The two E-boxes and the five GC-box binding elements were changed 
to the same mutations that were previously shown to disrupt DNA binding (48). 
Oligonucleotides used for mutagenesis were: E-box (-35): 5'-
GCGTCCTGCTGCGCACGAAGGAAGCCCTGGCCCCGG-3' and 5'-
CCGGGGCCAGGGGTTCCTTCGTGCGCAGCAGGACGC-3'; E-box (-242): 
5' -CCCAGGACCGCGCTTCCAAAGTGGCGGAGGGACTGGG-3' and 5'-
CCCAGTCCCTCCGCCACTTTGGAAGCGCGGTCCTGGG-3'; GC-box (-85): 
5'-CCTTCCTTTCCGCGGCCCATACCTCTCCTCGCGGCGCG-3' and 5'-
CGCGCCGCGAGGAGAGGTATGGGCCGCGGAAAGGAAGG-3'; GC-box (-
108) 5'-GGGCCCTCCCAGCCCCATTCCTTCCTTTCCGCGGCCC-3' and 5'-
GGGCCGCGGAAAGGAAGGAA TGGGGCTGGGAGGGCCC-3'; GC-box (-
165) 5'-TCCTCCGCGCGGACCCATACCCGTCCCGACCCCTC-3' and 5'-
GAGGGGTCGGGACGGGTATGGGTCCGCGCGGAGGA-3'; GC-box (-185) 
5'-CCCCTTCACCTTCCAGCTCAACCTCCTCCGCGCGGACC-3' and 5'-
GGTCCGCGCGGAGGAGGTTGAGCTGGAAGGTGAAGGGG-3'; GC-box (-
132) 5'- CCCGGGTCCCCGGCCCAAACCCCTCCGGGCCCTCCC-3' and 5'-
GGGAGGGCCCGGAGGGGTTTGGGCCGGGGACCCGGG-3'; E2F (-96): 5'-
CTCCCAGCCCCTCCCCTTCCGAATTCCCCCGCCCTCTCCTCGCG-3' and 
5' -CGCGAGGAGAGGGCGGGGGAATTCGGAAGGGGAGGGGCTGGGAG-
3'; E2F (-251): 5'-GGGCACAGACGCCCAGGACGAATTCTTCCCACGTGG 
CGGAGGGA-3' and 5' -TCCCTCCGCCACGTGGGAAGAA TTCGTCCTGGG 
CGTCGTTGCCC-3'; E2F (-175): 5' -CTTCCAGCTCCGCCTCCTCGAATTCG 
GACCCCGCCCCGTCCC-3' and 5' -GGGACGGGGCGGGGTCCGAATTCGA 
GGAGGCGGAGCTGGAAG-3'; E2F (-68): 5'-CCCCGCCCTCTCCTCGCGG 
AATTCGTTTCAGGCAGCGCTGCGTC-3' and 5' -GACGCAGCGCTGCCTG 
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AAACGAATTCCGCGAGGAGAGGGCGGGG-3'. The mutated nucleotides are 
indicated in boldo InternaI deletions of hTERT(-1934)-lux were done using the 
same system with the foUowing oligonucleotides . .1(-116, +3): 5'-CCCAGCCCC 
CTCCGGGCCCGCGCGCTCCCCGCTG-3' and 5' -CAGCGGGGAGCGCGCG 
GGCCCGGAGGGGGCTGGG-3'; .1(-252, -116): 5'-CGGGCACAGACGCCCA 
GGACCTCCCAGCCCCTCCCCTT-3' and 5'-AAGGGGAGGGGCTGGGAGG 
TCCTGGGCGTCTGTGCCCG-3'; .1(-252, +3): 5'-GCAGCGGGGAGCGCGCG 
GTCCTGGGCGTCTGTGCCC-3' and 5' -CGGGCACAGACGCCCAGGACCG 
CGCGCTCCCCGCTGC-3' . AU mutant constructs were confirmed by 
sequencing. 
c. Cell Culture 
HaCaT, HuH7, MCF-7 and CHû ceUs were cultured in DMEM (Hyclone 
Laboratories Inc., Logan, UT) in the presence of 10% fetal bovine serum (FBS) 
(HyClone) and 2mM L-glutamine. AU stimulations were done in serum-free 
media containing 100pM TGF~ (Peprotech), for the periods of time indicated in 
the figures. 
d. RT-PCR 
For reverse transcription reactions, total RNA was prepared from ceUs treated or 
not with TG~, using Trizol reagent (Invitrogen) according to the manufacturer' s 
protocol. When used, inhibitors were added to the starvation media 30 minutes 
prior to starting the time course, as indicated in figures 2b, 4c & 5a. cDNA 
synthesis was carried out using Superscript First Strand Synthesis System for RT-
PCR (Invitrogen) using random primers and 5Jlg of total RNA. Primers sequences 
used for the PCR reactions of the different human genes were as foUows: hTERT 
(LT5: 5'CGGAAGAGTGTCTGGAGCAA-3'; LT6: 5'-GGATGAAGCGGAGTC 
TGGA-3'); GAPDH (sense: 5'-ACCACCATGGAGAAGGCTGG-3'; antisense: 
5'-CTCAGTGTAGCCCAGGATGC-3'); C-MYC (sense: 5'-TTCGGGTAGTGG 
AAAACCAG-3'; antisense: 5'-CAGCAGCTCGAATTTCTTCC-3'); MAX 
(sense: 5'- GAACGAAAACGTAGGGACCA-3'; antisense: 5'-TGCTGGTGTGT 
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GTGG'ITI1T-3'); E2F-l (sense: 5'-TGCAGAGCAGATGGTTATGG-3'; 
antisense: 5'-ATCTGTGGTGAGGGATGAGG-3'); E2F-2 (sense: 5'- GGCCAA 
GAACAACATCCAGT-3'; antisense: 5'-TGTCCTCAGTCAGGTGCTTG-3'); 
E2F-3 (sense: 5'-TGGGGTCAAGACAGATGACA-3'; antisense: 5'-CCCCAAT 
GCTTCATCTAGGA-3'); E2F-4 (sense: 5'-GTGCCACCACCTGAAGATTT-3'; 
antisense: 5'-TGAGCTCACCACTGTCCTTG-3'); E2F-5 (sense: 5'-CTGGAGG 
TACCCATTCCAGA-3'; antisense: 5'-TGTTGCTCAGGCAGATTTTG-3') 
Smad2 (sense: 5'-CGAAATGCCACGGTAGAAAT-3'; antisense: 5'-CTGCCTT 
CGGTATTCTGCTC-3'); Smad3 (sense: 5'-CCCCAGAGCAATATTCCAGA-3'; 
antisense: 5'-CCTGTTGACATTGGAGAGCA-3'); Smad4 (sense: 5'-CCATTTC 
CAATCATCCTGCT-3'; antisense: 5'-ACCTTTGCCTATGTGCAACC-3'); 
Smad7 (sense: 5' -TCCTGCTGTGCAAAGTGTTC-3'; antisense: 5' -CAGGCTC 
CAGAAGAAGTTGG-3'). SYBR Green staining following migration on non-
denaturing PAGE detected hTERT RT-PCR products. AIl other PCR products 
were revealed by ethidium bromide staining of agarose gels. Densitometry 
analysis was performed using Alpha Innotech Corporation (San Leandro, CA) 
Fluorochem 8000 software version 3.04. The linear amplification range of each 
PCR was tested on the adjusted cDNA. The conditions were chosen so that none 
of the RNA analyzed reached a plateau at the end of the amplification protocol, 
i.e. they were in the exponential phase of amplification. 
e. siRNAs transfections 
Smad2, Smad3 and Smad4 siRNAs that are specifie for human Smads were 
purchased from Ambion. These siRNAs were introduced in HaCaT by reverse 
transfection using Lipofectamine 2000 reagent (Invitrogen). Briefly, lOnM of 
each siRNA was mixed with Lipofectamine 2000 reagent and Optimem media 
(Invitrogen) directly into 60mm2 plates. 7.5 x 105 HaCaT cells were then added to 
each transfection mix and incubated 72 hours at 37°C in a 5% C02 incubator. 
Cells were then trypsinized and fed into 6-well plates for 16 hours. siRNA 
transfected cells were then incubated in serum-free media 30 minutes before 
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adding TGF~ for the periods of time indicated in the figures. Cells were then 
harvested and extracts were used for immunoblotting, as described below. 
f. Immunoblotting 
1.5 x106 cells were stimulated with TGF~ for the indicated times in serum-free 
DMEM. For figures 4a and 8d, cells were incubated with inhibitors 30 min prior 
to the addition of TGF~. Cells were harvested in RIPA buffer supplemented with 
l00mM sodium vanadate, ImM phenyl methylsulphonyl fluoride (PMSF), 
lOJ.Lglml aprotinin, lOJ.Lg/ml leupeptin and 2J.Lglml pepstatin. Whole-cell lysates 
were separated on a polyacrylamide gel, transferred to nitrocellulose and 
incubated with the indicated specific antibody ovemight at 4°C: [anti-hTERT 
(Calbiochem); anti-~-tubulin, anti-flag (Sigma); anti-phospho-Erk, anti-Erk, anti-
phospho-p38, anti-p38 (Cell Signaling Technology), anti-phospho-Smad3 
(BioSource); anti-E2F-l (LabVision) anti-Smad4 and anti-Smad2/3 (SantaCruz)]. 
After the primary antibody incubation, membranes were washed twice in TBST 
(50 mM Tris-Cl at pH 7.6, 200 mM NaCl, 0.05% Tween 20), and incubated with 
the proper secondary antibody coupled to horseradish peroxidase (Sigma) at 
1: 10,000 dilution) for one hour at room temperature. Then, membranes were 
washed four times for 15 min in TBST. Immunoreactivity was normalized by 
chemiluminescence (ecl from Roche) according to the manufacturer' s instructions 
and revealed using an Alpha Innotech Fluorochem Imaging system (Packard 
Canberra, Montreal, Quebec, Canada). Densitometry analysis was performed 
using Fluorochem 8000 software (Alpha Innotech, San Leandro, CA) that allows 
quantitative analysis of chemiluminescence under non-saturating conditions. 
g. Luciferase Assays 
One day before transfection, HaCaT cells were plated at a density of 3.5x105 
cells/well in 6-well plates. The cells were transfected using Lipofectamine 2000 
(Invitrogen) and incubated ovemight. 2J.Lg of total DNA including 0.5J.Lg of 
luciferase reporter construct, 0.5J.Lg of ~-galactosidase (pCMV -lacZ) expression 
vector and O.1J.Lg to 0.8J.Lg of the different Smad expression vectors completed to 
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IJlg with filler vector were transfected into the cells and repeated independently 
six times in duplicate for each condition shown. For siRNA transfection (Fig.3g, 
h), lOnM of each Smad siRNAs was added to 0.5Jlg 3TP-Iux or hTERT(-1934)-
lux and 0.5Jlg ~-galactosidase expression vector. The day after, the cells were 
split in two, allowed to attach in 24-well plates and stimulated, or not, with TG~ 
(lOOpM) in starvation media. When inhibitors were used, they were added 30min 
prior to TGF~ treatment (figures 2a, 4b, 7c). In all experiments, ~-galactosidase 
activity was measured to normalize for transfection efficiency. 
h. Statistical analysis 
Results are expressed as mean ± standard deviation. Differences were assessed by 
one-way ANDV A or the unpaired t test, where appropriate. p < 0.05 was 
considered significant. 
4. Results 
a. TGF~ family members decrease hTERT protein, hTERT mRNA and 
hTERT promoter activity. 
To study the effect of TGF~ family members on hTERT expression, we used 
three human epithelial cell lines originating from three different tissues (skin, 
breast and liver) , as well as CHû cells. These cell lines are known to be 
responsive to TGF~, activin or both (27, 36, 39, 50, 65). We first analyzed the 
effect of TGF~ on hTERT promoter activity. For this, 2kb (-1978 to +73, ATG 
being +1) of the hTERT promoter region was c10ned in front of the luciferase 
gene. The resulting hTERT-lux construct was then introduced into four different 
cell lines, which were then stimulated with TGF~. As shown in Fig.la, TGF~ 
strongly decreased hTERT promoter activity in HaCaT (76% ± 8% inhibition), 
more modestly in HuH7 cells (32% ± 13% inhibition) and CHû cells (46% ± 24% 
inhibition). TG~ effect was much weaker in MCF-7 cells (24% ± 4% inhibition). 
Thus, the human HaCaT keratinocytes cell line was selected as a good model to 
study the TGF~ effect. 
106 
To examine if this decrease of hTERT promoter activity translated into a reduced 
level of hTERT rnRNA, we first performed RT-PCR on HaCaT cens treated for 
up to 24 hours with TGF~. As illustrated in Fig.l b (upper panel), TGF~ treatment 
resuIts in a decrease of hTERT rnRNA levels after 8 hours in HaCaT cens and this 
inhibition was still observed after 24 hours. Since the hTERT mRNA decrease 
was already complete at eight hours and did not further increase for longer TGF~ 
incubation times, we checked if hTERT mRNA was decreased by TG~ treatment 
before eight hours by doing a short time course of two, four, and eight hours. 
Indeed, we observed that hTERT mRNA levels diminished quickly in HaCaT 
cens within 2-4 hours of TGF~ stimulation (Fig. 1 b, lower panel). 
To then evaluate whether the decrease of hTERT mRNA was fonowed by a 
reduction of hTERT protein level, whole cell extracts from HaCaT, CHû and 
HuH7 ceIls, treated for different periods of time with TGF~, were analyzed by 
western blot. As shown in Fig.lc, hTERT protein level is decreased in aIl three 
ceIl lines following TGF~ treatment. Interestingly, this effect is not restricted to 
TGF~ al one as activin, another member of the TGF~ superfamiIy, also 
significantly repressed hTERT protein level in HuH7 cells (Fig.lc). These 
observations show that TGF~ and activin act as inhibitors of hTERT expression in 
epithelial cell Hnes originating from different tissues. Since we observed the 
strongest hTERT promoter inhibition in the human HaCaT ceIlline, we decided to 
focus on the use of this cellline for the rest of the study. 
b. TGF~ requires HDAC activity to repress hTERT gene expression. 
hTERT promoter repression is known to depend on HDAC activity since 
telomerase-negative ceIls, treated with trichostatin A (TSA), an inhibitor of class 1 
and II HDAC, results in the apparition of telomerase activity (15, 82, 95). So, to 
assess whether inhibition of hTERT expression by TGF~ requires HDAC activity, 
we examined the effect of TSA on hTERT promoter activity. Increasing 
concentrations of TSA reversed the inhibitory effect of TGF~ on hTERT. 
107 
hi 
Ha('.T 
TGFP " l' 
11111 
1 
" 1 
1 
~~111~~ .••. ·····;._.·. _1 c _, "",.~" ,,". 
, ... 
1 
Figure 1: TGF~ family members decrease hTERT protein, mRNA level, and 
hTERT promoter activity. a) HaCaT, HuH7, MCF-7 and CHO cells were 
transfected with the hTERT( -1934 )-lux reporter construct with a ~-galactosidase 
expression plasmid. The TGF~ response was measured by luciferase assays 18 
hours after stimulation. Differences were assessed by the unpaired t test. p < 0.05 
was considered significant. b) RT-PCR analysis was performed using total RNA 
extracted from HaCaT cells stimulated or not with TG~ as indicated. hTERT 
mRNA level and GAPDH rnRNA level were arnplified with specifie 
oligonucleotides. c) HaCaT, HuH7 and CHO cells were treated with TGF~ or 
activin for the indicated times. The level of expression for each protein was 
deterrnined by immunoblotting using hTERT or ~-tubulin antibodies. 
promoter activity (Fig.2a, upper panel). To control for specificity, TSA had no 
significant effect on a known TGF~ responsive promoter construct, 3TP-Iux (91), 
following TGF~ stimulation (Fig.2a, lower panel). Furthermore, TSA was also 
able to overcome the TGF~ inhibitory effect on endogenous hTERT rnRNA, as 
shown in Fig.2b. 
108 
HDAC proteins are classified into three different classes based on their homology 
to yeast HDACs. Class 1 HDAC consists of HDACl, HDAC2, HDAC3 and 
HDAC8, which are homologous to the RPD3 yeast HDAC. These proteins are 
generally nuclear and ubiquitously expressed. Class II HDAC, such as HDAC4, 
HDAC5, HDAC6, HDAC7, HDAC9 and HDACIO, are differentially regulated in 
human tissues and are cytoplasmic proteins that shuttle to the nucleus when their 
functions are required. Class III HDACs are homologous to yeast Sir2 gene and 
the HDAC activity of this class is dependent upon NAD+ (83, 85). The Smad 
proteins have been described to interact with class 1 and class II family members, 
yet no studies reported Smadlclass III HDAC interactions (84). So, we decided to 
focus on classes 1 and II. To unveil which class of HDAC is mediating the TGF~ 
effect, we overexpressed one class 1 and two class II HDAC and analyzed their 
effect on hTERT promoter inhibition by TGF~. Class 1 HDACI did not have any 
significant effect on hTERT promoter activity (Fig.2c). Interestingly, the two 
class II HDAC4 and HDAC5 repressed hTERT promoter activity. Importantly, 
this effect was not enhanced by TGF~ stimulation, suggesting that other signaling 
components need to be expressed along with class II HDAC. AIl together, these 
results suggest that TGF~ requires HDAC, more specifically class II HDAC, to 
repress hTERT expression. 
c. TGF~ requires the Smad pathway to inhibit hTERT promoter 
activity. 
TGF~ transduces its signal through activation of the canonical Smad pathway, but 
also through activation of other intracellular signalling cascades such as p38, 
JNK, Erkl/2 and RhoA, in a tissue-specifie manner (68). To first investigate 
whether TGF~ could activate the Smad pathway in HaCaT keratinocytes celIs, we 
examined the phosphorylation of Smad3 in response to TGFI3. As shown in 
Fig.3a, TGF~ rapidly and transiently increased phospho-Smad3 level, while the 
total level of Smad3 remained constant (Fig.3a, lower panel). To address the 
involvement and relative contribution of the Smad pathway in the regulation of 
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Figure 2: TGFp requires HDAC activity to repress bTERT gene expression. 
a) hTERT(-1934)-lux or 3TP-Iux were transfected in HaCaT ceUs with a p-
galactosidase expression vector. Transfected ceUs were pre-treated with the 
indicated concentrations of TSA 30 minutes before the addition of TGFp for 16 
hours. Luciferase assays were then performed. Differences were assessed by one-
way ANOY A. P < 0.05 was considered significant. b) FoUowing a pre-incubation 
of 30 minutes with TSA ImM, HaCaT ceUs were stimulated with TGFp for the 
indicated periods and RNA samples were used for RT-PCR analysis. hTERT and 
GAPDH were amplified using specifie primers. c) HDACl, HDAC4 and HDAC5 
expression vectors were co-transfected with hTERT(-1934)-lux, and luciferase 
assays were done foUowing 16 hours of TGFp stimulation of the transfected 
HaCaT ceUs. Differences were assessed by one-way ANOY A. P < 0.05 was 
considered significant. 
hTERT expression, we first used Smad7 as a general inhibitor of the TGF13 
signaling pathway. Smad7 is a potent activinffGFp inhibitor as it restrains Smad2 
and Smad3 phosphorylation by TpRI through TpRI binding competition (34, 71). 
Moreover, Smad7 is now known to act as an adaptor to recruit Smurf2, an E3 
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ubiquitin-ligase, to the TGF~ receptors and thus targets the receptor complex for 
degradation (21, 45). We thus cotransfected increasing amounts of Smad7 
expression vector with hTERT-lux and performed luciferase assays. As seen in 
Fig.3b, Smad7 expression completely reversed the inhibition of hTERT promoter 
by TGF~, suggesting that functional receptor complexes are required for 
inhibiting hTERT expression. 
We then used mutant forms of Smad2 and Smad3 that still bind to, but cannot be 
phosphorylated by, T~Rl because the two serine residues that are targeted by 
T~Rl are mutated to alanine. Thus, these mutants are expected to behave as 
dominant negative proteins when overexpressed (1, 55, 59). We first addressed 
the ability of these mutants to reverse TGF~-induced transcriptional activity on 
3TP-Iux. As shown in Fig.3c, both DNSmad2 and DNSmad3 were able to 
significantly reverse TGF~-induced 3TP-Iux activity. We then tested the effect of 
these DNSmads on TGF~-mediated inhibition of the hTERT gene promoter. 
When DNSmad2 or DNSmad3 was cotransfected with hTERT-Iux, we did 
observe a 50% reversai of the TGF~ effect on hTERT promoter activity (Fig.3d, 
e). A combination of both DNSmads did not further increase the reversai on the 
TGF~ effect, suggesting that DNSmad2 and DNSmad3 can antagonize both 
Smad2 and Smad3 responses when expressed individually (Fig.3f). 
To further address the role of the Smad pathway and address the relative 
contribution of Smad2 versus Smad3, we use specifie siRNAs to block the 
expression of the Smad components of the TG~ signaling pathway. As 
illustrated in Fig.3g, transfection of siRNAs targeted against human Smad2, 
Smad3 and Smad4 resulted in protein level reductions of 46%, 49% and 68%, 
respectively. Importantly, the siRNAs against Smad2 and Smad3 were highly 
specifie since Smad2 siRNA did not affect the expression of the Smad3 protein 
and vice versa (Fig.3g, two upper panels). Interestingly, blocking expression of 
Smad3, but not Smad2 or Smad4, led to a reversaI of the TGF~ inhibitory effect 
of hTERT promoter activity (Fig.3h). This suggests that even though the Smad 
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pathway is required for TGF~ to inhibit hTERT promoter activity, this response is 
Smad3-dependent but Smad2-independent. This is also consistent with a recent 
study indicating that TGF~-mediated inhibition of hTERT is Smad3-specific (52). 
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Figure 3: TGF~ requires the Smad pathway to inhibit hTERT promoter 
activity. a) HaCaT cells were starved priOf to stimulation with TGF~ for 0 to 4 
hours. Protein phosphorylation level was then monitored by immunoblotting with 
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anti-phospho-Smad3. Equal protein levels were verified by immunoblotting with 
anti-Smad2/3. b) HaCaT cells were transfected with hTERT(-1934)-lux, the ~­
galactosidase expression vector and increasing amounts of Smad7 expression 
vector (0.1 to 0.8J,lg). 24 hours after transfection, cells were stimulated or not with 
TGFj3 for 16 hours. Luciferase assays were then performed. c) HaCaT cells were 
transfected with 3TP-Iux, pCMV -lacZ and increasing amounts of the different 
dominant negative Smads (0.4J,lg and 0.8J,lg). Cells were then stimulated with 
TGF~ and assessed for luciferase activity. d) and e) HaCaT cells were 
cotransfected with hTERT(-1934)-lux, pCMV-lacZ and increasing amounts 
(O.1J,lg to 0.8J,lg) of the dominant negative forms of Smad2 (d) or Smad3 (e). 16 
hours after TGF~ stimulation, luciferase activity was assessed. Proper expression 
of the dominant negative Smads were revealed by an anti-flag Western blot. f) 
HaCaT cells were co-transfected with hTERT(-1934)-lux, the ~-galactosidase 
vector and a combination of both dominant negative Smad2/Smad3 (0.2J,lg each 
and O.4J,lg each). Cells were then stimulated with TGFj3 and assessed for 
luciferase activity. g) HaCaT cells were transfected with siRNAs against human 
Smad2, Smad3 and Smad4. The efficiency of these siRNAs was measured by 
Western blot analysis using antibodies against Smad2/3 and Smad4. h) HaCaT 
cells were cotransfected with hTERT(-1934)-lux and Smads siRNAs, as indicated. 
16 hours post TGF~ stimulation, luciferase activity was measured. Differences 
were assessed by one-way ANOV A. P < 0.05 was considered significant. 
d. TGF~ reduces hTERT expression through the Erk and p38 MAPK 
pathways. 
As shown above, blocking Smad3 signaling reversed TGF~ inhibition of hTERT 
expression, but only partially (Fig.3). This strongly suggested that other pathways 
are activated by TGF~ in HaCaT cells and required for TGF~ to fully inhibit 
hTERT expression. Indeed, different signaling pathways are activated following 
TGF~ stimulation in various cell line models (68). Among them, the MAPK 
pathways Erk and p38 have been shown to be involved in TGFj3 signaling, with 
the physiological outcome being largely cell type-specifie. We first investigated if 
these pathways were activated following TGF~ stimulation by looking at the 
phosphorylation state of these two kinases. In HaCaT cells, TGF~ stimulated the 
phosphorylation of p38 and Erk1l2 within 30 minutes, with a peak at 60 minutes 
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(Fig.4a). To inhibit signaling from these kinases, we analyzed the efficiency of 
three chemical inhibitors of these pathways on HaCaT cells. Treatment with 
PD98059, an inhibitor of MEKl, ultimately led to Erk inhibition (Fig.4a). Finally, 
PD169316 and SB202190, two chemical inhibitors of p38 kinase, greatly 
decreased the phosphorylation state of p38 following TGF~ signaling, as 
illustrated in Fig.4a. 
To study the involvement of these kinases in TGF~-mediated regulation of the 
hTERT promoter, we treated HaCaT cells that were transfected with hTERT-Iux 
with increasing concentrations of chemical inhibitors, with or without TGF13 
stimulation. As shown in Fig.4b, the effect of TGF~ treatment on the hTERT 
promoter were reversed when cells were pretreated with the MEKI inhibitor 
PD98059. We then anaIyzed the effect of SB202474, which is a non-functional 
anaIog of the PD169316 inhibitor. Treatment with the SB202474 inhibitor did not 
reverse TGF~-induced downregulation of hTERT promoter activity. Thus, the 
reversaI of the TGF~-mediated hTERT promoter inhibition observed in the 
presence of the PD169316 inhibitor is specifie (Fig.4b). Moreover, we observed 
the same level of reversaI with the SB202190 inhibitor (Fig.4b). We then 
determined if this effect on the hTERT promoter was also observed at the mRNA 
level. Pre-treatment of HaCaT cells with PD98059 or PD169316 blocked the 
ability of TGF~ to decrease hTERT rnRNA level (Fig.4c), suggesting a role of 
Erk and p38 kinase in the regulation of hTERT in response to TGF~. 
Several chemical inhibitors of p38 kinase have been described as inhibitors of 
other serine/threonine kinases, including T~R, depending on the concentrations 
used (97). To exclude the possibility that chemical inhibitors we used had a non-
specifie effect on T~R kinase activities, we checked the level of phospho-Smad3 
in the presence of a PD98059 or PD169316 inhibitor. As illustrated in Fig.4d, 
TGF~ treatment results in the rapid phosphorylation of Smad3 and both PD98059 
and PD169316 inhibitors did not interfere with the increase of phospho-Smad3 
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level in response to TGF~. Together, these results suggest that, in addition to the 
Smad pathway, both Erk and p38 kinase pathways are important for TG~ 
regulation of hTERT promoter activity and mRNA expression. 
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Figure 4: TGF~ reduces hTERT expression through the Erk and p38 MAPK 
pathways. a) HaCaT cells were starved and treated with PD98059, PDl69316 or 
SB202190 as indicated, before stimulation with TG~ for 0 to 4h. Protein 
phosphorylation levels were then monitored by anti-phosphoErk and anti-
phospho-p38 Western blot. Equal protein levels were verified by immunoblotting 
with anti-Erk1l2 and anti-p38. b) HaCaT were transfected with hTERT-lux and 
the ~-galactosidase expression vector. 24 hours post-transfection, cens were 
incubated with the different MAPK inhibitors at the indicated concentrations for 
30 min in starvation media, and then stimulated or not with TGF~. Luciferase 
assays were performed 16 hours later. Differences were assessed by one-way 
ANOY A. P < 0.05 was considered significant.c) Following a pre-incubation of 30 
minutes with PD98059 10J.lM or PDl69316 10J.lM, HaCaT cens were stimulated 
with TGF~ for the indicated periods and RNA samples were used for RT-PCR 
analysis. hTERT and GAPDH were amplified using specifie primers. d) HaCaT 
cens were starved, with or without PD98059 or PD169316, before addition of 
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-TGF~ for 0 to 4 hours. Protein phosphorylation levels and equal loading were 
then monitored by immunoblotting with anti-phospho-Smad3 and anti-Smad2/3. 
e. TGF~ inhibits hTERT expression through the induction of an 
intermediate protein that acts on the hTERT core promoter region. 
Previous studies failed to find a precise mechanism by which TGF~ regulates 
hTERT expression. In fact, only Smad3 was recently shown to be involved in the 
decrease of hTERT expression following TGF~ treatment (52). However, as 
shown in Fig.4, other signaling pathways that are activated by TGF~ are required 
for hTERT inhibition, suggesting the existence of an intermediate signaling 
protein necessary for hTERT regulation. So, to identify if the hTERT gene is a 
direct or indirect target gene regulated by TG~, we used cyc10heximide (CHX), 
which inhibits translation. HaCaT cells were stimulated with TGF~ for up to 8 
hours in the presence or absence of CHX. Fig.5a (left panel and graph) c1early 
indicates that TGF~ rapidly reduced hTERT mRNA levels and this effect is 
reversed in the presence of CHX. As a positive control, the rnRNA expression 
level of a direct TGF~ target gene, the Smad7 gene, was examined in the presence 
or in the absence of CHX. As shown in Fig.Sa (middle panel and graph), CHX did 
not affect TGF~-mediated increase of Smad7 rnRNA. This suggests that TG~ 
needs to induce the synthesis of new proteines) to inhibit hTERT gene expression. 
Moreover, TGF~ stimulation did not lead to hTERT downregulation in cells pre-
treated with actinomycin D, an inhibitor of transcription, whereas actinomycin D 
completely blocked Smad7 rnRNA expression (Sa right panel). An together, these 
results indicate that TGF~ requires transcription and translation of an intermediate 
proteines) to inhibit hTERT gene expression, thus hTERT is an indirect target 
gene of TGF~ signaling. 
To further investigate the nature of such an intermediate signaling molecule 
required for TG~ inhibitory effects on hTERT expression, progressive deletion 
of the hTERT promoter DNA sequence was performed using the exonuc1ease III 
system. The generated truncation mutants were transfected in HaCaT cens and 
116 
cell lysates were used for luciferase assays. As shown in Fig.5b, truncated 
promoters from -1121 to -252 are inhibited by TGF~ treatment to the same extent 
as the hTERT(-1934)-lux construct. However, the hTERT-Iux (+3) construct is 
not responsive to TGF~ treatment (Fig.5b). We therefore conc1uded that the 
important regulatory region for TGF~-mediated inhibition of hTERT promoter 
activity is located between the nuc1eotides -252 to +3, which approximately 
corresponds to the previously reported minimal promoter sequence necessary for 
its activity (14). 
To further characterize this important regulatory region, internaI deletions within 
-252 to +3 bp region were performed in the hTERT(-1934)-lux construct. The 
hTERT(.1-252, +3)-lux construct had almost lost complete responsiveness to 
TGF~ when compared to full length hTERT(-1934)-lux construct (Fig.5c), thus 
confirming the importance and criticaI role of the -252 to +3 region in conferring 
TGF~ its ability to repress the hTERT gene promoter. We then eut this region in 
two and deleted each half from the hTERT(-1934)-lux construct. This created the 
two following internai deletion mutants: hTERT(.1-252, -116)-lux and hTERT(.1-
116, +3)-lux, as illustrated in Fig.5c. Surprisingly, the hTERT(.1-252, -116)-lux 
and hTERT(.1-116, +3)-lux constructs are both inhibited by TGF~ treatment, as is 
the fulliength hTERT(-1934)-lux (Fig.5c). AIl together, these results suggest that 
TGF~ mediates its inhibitory effect through several DNA regions within the 
hTERT core promoter region. Two hypotheses can explain these observations. 
First, these DNA binding elements are redundant on each half of the -252 to +3 
region: interfering with these binding sites on one haIf would not produce any 
change in the TGF~ inhibition of hTERT promoter as the binding sites of the 
other half would maintain the inhibition. Second, the DNA binding elements on 
each side of the -252 to +3 region are important and not redundant: interfering 
with these binding sites would gradually reverse the ability of TG~ to repress 
hTERT promoter activity. 
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Figure 5: TGFJ3 inhibits hTERT expression through the induction of an 
intermediate protein that acts on the hTERT -252 to +3 promoter region. a) 
HaCaT cells, pretreated or not for 30 min with cyc10heximide 10J.lM or 
actinomycinD IJ.lM, were then stimulated with TGFJ3 as indicated. RNA were 
extracted and analyzed by RT-PCR. A graph view of the RT-PCR results in the 
right panel. b) Progressive deletion mutants were transfected in HaCaT together 
with the J3-galactosidase expression vector. 24hours after transfection, cells were 
stimulated or not with TGFJ3 for 16 hours. Luciferase assays were then performed. 
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c) HaCaT ceUs were transfected with internal deletion mutants of the core 
promoter region, as indicated. Luciferase assays were done 16 hours after TGF~ 
stimulation. Differences were assessed by one-way ANOV A. P < 0.05 was 
considered significant 
f. E2F DNA binding elements are involved in TGF~·mediated inhibition 
of the hTERT promoter. 
The -252 to +3 hTERT promoter region contains 2 E-box DNA binding sites 
surrounding 5 GC-boxes, as previously published (Fig.6a and (14, 37, 81, 89». E-
box DNA elements of the hTERT promoter are recognized by the MyclMadIMax 
transcription factor family (31, 48, 92). In many cases, c-Myc expression paraUe1s 
hTERT expression, in that both are increased in highly dividing ceUs and 
downregulated during differentiation. On the other hand, Mad overexpression 
results in decreased hTERT promoter activity (32). Both c-myc and Mad protein 
expression levels are known to be controUed by TGF~ signaling (25, 77, 96). For 
this reason and as it was previously suggested that TGF~ inhibits hTERT through 
a decrease of c-myc protein (99), we evaluated the importance of each E-box in 
the TGF~-mediated decrease of hTERT promoter activity by changing the 
sequence in order to disrupt DNA binding (48). As shown in Fig.6b, individual 
mutations of each E-box located at -242 and -35 in the complete hTERT-Iux 
construct did not attenuate TGF~ inhibition of the promoter activity. Furthermore, 
an hTERT -lux construct bearing mutations in both E-boxes was inhibited as the 
wild type promoter foUowing TGF~ stimulation (Fig.6b). On the other hand, GC-
boxes are DNA binding elements for the SpI transcription factor family. SpI 
transcription factor is known to cooperate with Smad proteins to regulate several 
target genes (18, 23, 69, 102). In our case, individual mutations of each GC-box in 
the core promoter region did not affect TGF~-mediated decrease of hTERT 
promoter activity (data not shown). 
Importantly, no canonica15'-GTCT-3' Smad binding elements (63) were found in 
the -252 to +3 region. However, doser examination of this region revealed the 
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presence of four E2F DNA binding elements (Fig.6a). The E2F DNA binding 
sites located at -251, -175, and -68 have been previously described (17, 90). 
These DNA elements were involved in repression of hTERT expression. Analysis 
using Mat Inspector software also revealed the presence of an additional putative 
E2F binding element at -96. The E2F transcription factor farnily members are able 
to recognize and bind these DNA binding elements. E2F family members are also 
known to be important for TGF~-mediated downregulation of c-myc (12, 25) and 
cdc25A (40,41). We thus evaluated the role ofthese DNA binding sites in TG~­
induced hTERT repression by individually mutating the four E2F elements within 
the hTERT(-1934)-lux construct. As illustrated in Fig.6c, individual mutation of 
any of the E2F binding sites did not alter the TGF inhibitory effect of the hTERT 
gene promoter. However, since our previous results (Fig.5c) indicated that several 
sites located within the -252 to +3 region could be involved in the regulation of 
the hTERT gene promoter by TGF~, we next mutated aIl the possible 
combinations of two E2F DNA binding elements. When hTERT -lux constructs 
containing two mutations of E2F sites located at -96 and -68, -175 and -96, -
175 and -68, or -251 and -68 were introduced into HaCaT ceIls, we observed a 
50% reversai of the TGF~ effect when compared to the wt hTERT promoter 
(Fig.6d). An E2F triple mutant (-251, -96, and -68) hTERT-Iux was also 50% less 
inhibited by TGF~ treatment when compared to the wt hTERT-Iux (Fig.6e). 
Finally, when a hTERT-Iux construct bearing mutations within the four E2F DNA 
binding elements was transfected into HaCaT cells and stimulated, or not, with 
TGF~, we observed a complete reversai of the TGF~ inhibitory effect on hTERT 
promoter activity (Fig.6f). These results suggest that aIl E2F DNA binding 
elements in the hTERT proximal promoter region promote repression of hTERT 
expression in response to TGF~ stimulation. 
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Figure 6: E2F DNA binding elements are involved in TGF~-mediated 
inhibition of hTERT promoter. a) DNA sequence of the -252 to +3 region. 
Orange: E-box binding element. Blue: E2F binding element. Green: GC-box 
binding element. b) hTERT(-1934)-lux construct containing either single 
mutations of the E-boxes (-35 or -242) or both mutated E-boxes (-35 and -242) 
were transfected in HaCaT cells with the ~-galactosidase vector. Luciferase 
assays were performed 16 hours post TG~ stimulation. c) to f) hTERT(-1934)-
lux construct containing either (c) individu al mutations of E2F binding element, 
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(d) double mutations of all possible combinations of E2F binding sites, (e) triple 
mutations of aIl the possible combinations of E2F DNA binding elements, or, (f) 
aIl E2F DNA binding elements mutated were introduced in HaCaT cells. 24 hours 
post transfection, ceIls were stimulated or not with TGF~ for 16 hours and 
luciferase activity was assessed. Differences were assessed by one-way ANOV A. 
P < 0.05 was considered significant. 
g. E2F transcription factor activity is required for TGF~-mediated 
inhibition of hTERT. 
We used two different approaches to elucidate whether E2F transcription factors 
were important in hTERT promoter regulation by the TGF~ ligand. We first 
performed a competition assay by co-transfecting hTERT-Iux with a vector 
containing four repeats of the canonical E2F DNA binding element (E2F-decoy). 
If E2F family members are required for hTERT promoter downregulation by 
TGF~, the presence of increasing amounts of E2F DNA-binding sites will 
decrease E2F transcription factor availability for TGF~ inhibition. This will 
translate into a loss of the TGF~ effect on hTERT promoter activity. As a control 
we also used the same vector that does not contain the E2F DNA binding 
elements (TA-decoy). As illustrated in Fig.7a, the presence of increasing amounts 
of E2F-decoy reversed the effect of TGF~ stimulation on hTERT promoter 
activity by 50%. This effect is due specifically to the presence of E2F DNA 
binding elements since a vector without E2F binding sites had no effect on TGF~­
induced inhibition of hTERT promoter activity. Moreover, the E2F-decoy effect 
is specifie to the hTERT promoter since 3TP-lux activity was unchanged in 
response to TGF~ in the presence of E2F decoy (Fig.7a). These results indicate 
that quenching E2F transcription factors away from the hTERT promoter reduces 
the ability of TGF~ to repress hTERT expression. 
We then performed luciferase assays on HaCaT cells transfected with hTERT-lux 
and a mutant form of E2F-l (E2F-l(1-374» that contains the DNA binding 
domain but lacks the transactivation domain as well as the pocket protein-binding 
site. This mutant was previously shown to act as a dominant negative protein and 
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displace wt E2F-complexes from E2F DNA binding sites (58). Likewise, in the 
presence of increasing amounts of DN-E2F-I, TGF~ lost 50% of its ability to 
repress transcription from the hTERT promoter (Fig.7b), suggesting that E2F 
family members are required for TGF~-mediated inhibition of hTERT promoter 
activity. 
The transcriptional activity of E2F family members is negatively regulated by 
interactions with pocket proteins (Rb, p107, p130) that recruit HDAC proteins to 
repress target genes (13, 20). We thus tested whether TGF~ required interaction 
between E2F factors and pocket proteins. For this, we used a mutated form of 
E2F-l, E2F-l (Y 411 C), which is unable to bind pocket proteins (58). As shown in 
Fig. 7 c, increasing amounts of E2F-l (Y 411 C) reversed TGF~-mediated inhibition 
of hTERT promoter activity. These observations indicate that proper complex 
formation of E2F/pocket proteins is necessary for TGF~ to repress hTERT 
transcription gene from its promoter. 
The ability of E2F family members to repress hTERT expression depends on their 
association with pocket and HDAC proteins (90). Since TGF~ repressed hTERT 
expression through involvement of HDAC proteins (Fig.2), we then investigated 
whether TGF~ treatment has a positive or a negative effect on the transcription al 
activity of E2F family members. For this, we transfected an artificial promoter 
construct containing four E2F-binding sites (E2F-TA-Iuc) in HaCaT cells. 
Stimulation with TGF~ decreased the transcriptional activity of E2F transcription 
factors (Fig.7d). To delineate if this effect was due to a passive loss of 
transcription al activity or to the formation of an active repressor complex 
containing HDAC activity, we evaluated the effect of TSA treatment on TGF~ 
capacity to decrease transcriptional activity of E2F-TA-luc. Importantly, in the 
presence of TSA, TGF~ is no longer able to have an effect on the E2F-dependent 
promoter(Fig.7d), strongly suggesting that TG~ induces the active formation of 
a repressor complex containing E2F family members and HDAC activity on E2F 
binding sites, and not simple inactivation of E2F function. An together, these 
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results support the hypothesis that E2F family members are required for hTERT 
promoter inhibition by TGF~. 
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Figure 7: E2F transcription factor activity is required for TGF~-mediated 
inhibition of hTERT. a) 3TP-lux was co-transfected in HaCaT cells with TA-
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decoy or E2F-decoy. Luciferase assays were performed after 16 hours of TGF~ 
stimulation. hTERT(-1934)-lux was co-transfected with either TA-decoy or 
increasing amounts of E2F-decoy. 24 hours after transfection, HaCaT cells were 
stimulated with TGF~ for 16 hours and luciferase assays were done. b) and c) 
hTERT( -1934 )-lux construct was introduced in HaCaT along with increasing 
amounts of (b) DN-E2F-l or (c) E2F-l (Y411C) expression constructs. Luciferase 
activities were measured 16 hours after the addition of TGF~. d) E2F-TA-lue was 
co-transfected with a ~-galactosidase expression vector and luciferase assays were 
performed following 16 hours incubation with TGF~. Differences were assessed 
by one-way ANOVA or the unpaired t test (only in d). p < 0.05 was considered 
significant. 
h. E2F-l expression is induced by TGF~ stimulation. 
Our data indicate that the E2F transcription factors are critical to TGF~-mediated 
downregulation of hTERT expression. Moreover, the results from Fig.5a clearly 
show that TGF~ requires the expression of an unidentified intermediate to repress 
hTERT expression. To see if E2F family members expression is activated by 
TGF~ treatment, we first performed RT-PCR analysis. We focus on E2F-l since 
it was previously shown to be important in hTERT repression on its own. As 
shown in Fig.8a, E2F-l mRNA levels increased within 30 minutes to up to 4 
hours following TGF~ addition to HaCaT cells, as did the positive control Smad7. 
This mRNA accumulation results in a fast E2F-l protein level increase, also 
within 30 minutes to up to 4 hours (Fig.8b). As hTERT expression is rapidly 
downregulated, the fast upregulation of E2F-l expression goes along with the 
hypothesis that E2F-I is the required protein that is induced by TGF~ to reduce 
hTERT expression. 
As we previously showed that Smad, Erk and p38 signaling cascades were 
required for TGF~ inhibition of hTERT, we next assessed the contribution of 
these pathways in the regulation of E2F-l by TGF~. We evaluated the 
involvement of the Smad pathway in E2F-l upregulation by using Smad to 
knockdown Smad expression. In the presence of siRNAs against Smad3, 
Smad2/Smad3 or Smad2/Smad3/Smad4, TGF~ treatment of HaCaT cells did not 
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lead to an increase of E2F-l protein level, as it was observed in the mock-
transfected cells (Fig.8c). Finally, blocking the Erk pathway using the PD98059 
inhibitor or the p38 kinase pathway with PD169316 inhibitor also blocked 
TGFWs ability to activate E2F-l expression (Fig.8d). AIl together, these results 
show that the upregulation of E2F-l by TGF~ is dependent on an intact Smad 
pathway and functional Erk and p38 pathways. All together, our findings indicate 
that TGF~ represses hTERT expression by inducing the expression of the 
transcription factor E2F-l, which in turn represses hTERT promoter activity 
through a functional interaction with HDAC proteins. For E2F-l induction, TG~ 
necessitates the activation of the Smad pathway, as well as Erk and p38 kinases 
signaling cascades. 
i. TGF~-mediated repression of hTERT is lost in embryonic fibroblasts 
E2F-l null mutant mice. 
We have shown that TGF~ acts as a potent repressor of hTERT expression in a 
variety of cancer cell Hnes, and mediates its effects through up-regulation of the 
transcription factor E2F-l. To precisely define the role and contribution of E2F-l 
downstream of TG~ in normal cells, we used mouse embryonic fibroblasts 
(MEFs) isolated from the E2F-l knockout mice (98). Wild type (+1+) or E2F-l(-I-) 
null mutant MEFs were stimulated or not with TGF~ and the level of Smad 
phosphorylation assessed by Western blot. As shown in Fig.9a, the wild type and 
E2F-l(-I-) MEFs equally responded to TGF~. We next analyzed the contribution of 
E2F-l to TGF~- mediated inhibition of mTERT rnRNA levels. MEFs from wild 
type and E2F-l nuIl mice were stimulated with TGF~ for different periods of time 
and mTERT mRNA levels were analyzed by RT-PCR. As shown in Fig.9b, TG~ 
strongly inhibited mTERT mRNA levels in wild type cells, indicating that TG~ 
is a strong suppressor of telomerase activity in normal cells. However, this effect 
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Figure 8: E2F-l expression is induced by TGF~ stimulation. a) HaCaT cells 
were stimulated for the indicated periods of time with TGF/3 in starvation media. 
RNA ex tracts were then used for RT-PCR analysis. E2F-l, Smad7 and GAPDH 
were amplified with specifie primers. b) Following TGF/3 stimulation of HaCaT 
cells for the indicated times, protein extracts were used for Western blot analysis 
with specifie antibodies against E2F-l and ~-tubulin. c) HaCaT cells were 
transfected with the indicated siRNAs, either individually or in combination. 72 
hours post transfection, cells were incubated with TGF~ for the indicated times. 
Protein extracts were then used for immunoblotting with anti-E2F-l and anti-~­
tubulin. d) HaCaT cells were pre-incubated with 1 O~M PD98059 or 1 O~M 
PD 169316 for 30 minutes followed by TGF~ treatment for the indicated periods 
of time. Protein ex tracts were then used for Western blot analysis with anti-E2F-I 
and anti-~-tubulin. 
was lost in the E2F-l knockout cells, demonstrating the requirement of E2F-I in 
TGF~- mediated inhibition of mTERT. We also examined the TGF~ effects on 
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mTERT expression at the protein level and as shown in Fig.9c, TGF~ stimulation 
of the wild type cens led to a clear decrease in mTERT protein, while this effect is 
completely blocked in the E2F-l (-1-) MEFs, further highlighting the critical role 
played by E2F-l in TGF~-mediated repression of mTERT expression. The 
requirement of E2F-l for TGF~-mediated inhibition of hTERT transcription was 
also assessed by transfecting the hTERT -lux construct in both wild type and E2F-
1 knockout cens. As shown in Fig.9d, TGF~ inhibited hTERT promoter activity 
by 20% in normal MEFs, however this effect was totany reversed in the E2F-l 
deficient cens. Together, our results show that TGF~ potently inhibits TERT 
expression in both normal and cancer cens and that these effects are mediated by 
the transcription factor E2F-l. 
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Figure 9: TGF~-mediated repression of hTERT is lost in the E2F-l null 
mutant mice. Wild type and E2F-l (-1-) MEFs were stimulated or not with TGF~ 
for the indicated times and phospho- Smad3 (a), hTERT mRNA (b) and hTERT 
protein (c) levels were assessed by Western blotting and RT-PCR. d) Wild type 
and E2F-l (-1-) MEFs were transfected with hTERT-Iux, stimulated or not with 
TGF~ and assessed for luciferase activity. 
128 
5. Discussion 
In this paper, we showed that TGF~ ligand stimulation rapidly represses hTERT 
expression in various cell types, within two to four hours. We further 
demonstrated that the TGF~ inhibitory effect on hTERT expression requires class 
II HDAC activities. We also showed that these effects are mediated through the 
canonical Smad pathway but also require the activation p38 and Erk kinases. 
Activation of these three pathways is necessary to decrease hTERT expression in 
response to TGF~. FinaIly, we showed that TG~ requires the rapid induction of 
expression of a transcription factor, the E2F-l transcription factor. We further 
identified the critical E2F binding sites in the hTERT promoter responsible for the 
TGF~ effect. FinaIly, using the E2F-l (-1-) MEFs we demonstrate that the 10ss of 
E2F-l abolishes the TGF~ inhibitory effect on TERT expression in normal mouse 
embryonic fibroblasts. Together, our results highlight the prominent role pIayed 
by TGF~ ligand in regulating telomerase activity and the E2F-l transcription 
factor as the critical player for this effect (Fig.lO). 
Signaling pathways induced by TGF~ to regulate hTERT expression 
We provide evidence that the Smad, Erk, and p38 pathways play a role in the 
regulation of hTERT. Expression of dominant negative Smad2 and Smad3 
proteins that cannot he phosphorylated could partially reverse hTERT repression 
by TGF~. We di mini shed Smad2, Smad3 and Smad4 expression levels using 
specific human siRNAs. Interestingly, TGF~-induced repression of the hTERT 
promoter was partially reversed only when Smad3 siRNA, alone or in 
combination, was present. This suggests that proper level of Smad3 protein is 
important for hTERT gene regulation by TGF~. This was also observed by Li, et 
al. (52). Since only Smad3 siRNA reverses the TGF~ effect on the hTERT 
promoter, it suggests that proper expression of Smad2 and Smad4 proteins are 
accessory to hTERT repression by TGF~. Although we cannot exclude that the 
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Figure 10: Model of TGFp-mediated repression of hTERT expression. TGFJ3 
requires activation of the Smad pathway, Erk, and p38 kinases to rapidly induce 
E2F-I expression, which then cooperate with class II HDAC proteins, and maybe 
Smad complexes to repress hTERT expression. 
remaining expressed Smad2 and Smad4 proteins are not involved in hTERT 
regulation, the fact that the combination of the three siRNAs did not further 
increase the reversaI effect of the individu al Smad3 siRNA strongly supports the 
theory that hTERT is indeed a Smad3-specific target gene. Other genes are known 
to be specifically regulated by Smad2 or Smad3: induction of matrix 
metalloproteinase-2 by TGF~ was selectively dependent on Smad2, whereas 
induction of c-fos, Smad7, and TGFJ3 relied on expression of Smad3 (73). 
Furthermore, the goosecoid gene is activated by the Smad2/Smad4 complex while 
inhibited by the Smad3/Smad4 complex (49). 
The Smad3 specific requirement was not observed when DNSmads were used, 
since DNSmad2 had the same reversing effect as DNSmad3. This is probably 
because DNSmad2, through its binding to the receptors, not only blocks 
endogenous Smad2 recruitment and phosphorylation, but also endogenous Smad3 
phosphorylation. Indeed, Smad2 and Smad3 binding specificity to T~R complex 
is due to interactions between the lA5 loop of T~RI and the L3 loop of the R-
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Smad (22, 56), which are identical for Smad2 and Smad3 proteins. Since both 
Smad2 and Smad3 share the same mechanism of recruitment to T~RI, using one 
DNSmad is expected to block activation of both R-Smads. Supporting this 
explanation, we showed that the co-expression of DNSmad2 and DNSmad3 does 
not increase the reversaI effect of the individual expression of DNSmad2 or 
DNSmad3. 
One Smad binding element (SBE) located between -262 and -259, through which 
TGF~ inhibits hTERT promoter activity (52), was shown to mediate TGF~ effect 
in MCF-7 cells. Our results suggest rather that this particular SBE is not critical 
for TGF~-mediated hTERT repression, at least in HaCaT and HuH7 ceUs 
(unpublished data). First, the truncated hTERT(-252) promoter fragment, which 
does not contain the SBE(-262, -259), is repressed following TGF~ treatment as 
is the hTERT(-1934) promoter, which contains the SBE (-262, -259). Moreover, 
the hTERT promoter construct with the internai deletion -252 to +3, is no longer 
responsive to TGF~ stimulation, even though the SBE(-262, -259) is present. We 
can conc1ude, from aU of our data, that TGF~ requires several DNA binding 
elements within the -252 to +3 region, as deletion of this complete region 
abrogates the TGF~ repressive effect on the hTERT promoter. And we c1early 
showed that E2F DNA binding sites are critical for TG~ effect on hTERT 
repression. TGF~ represses hTERT expression through more than one 
mechanism. Indeed, severa! other molecules, such as SIP1, have been described as 
being important for the TGF~ effect on hTERT promoter regulation (54). 
We used Smad7 to block signaling from T~R complexes. Smad7 overexpression 
results in the complete reversaI of hTERT promoter inhibition that is induced by 
TGF~. The discrepancy between the results with Smad7 and 
DNSmad2/DNSmad3 can be explained by the different mechanisms used by 
Smad7 and DNSmads to inhibit signaling. Smad7 has been described to bind to 
the receptors to compete with Smad2/3 recruitment. However, the picture seems 
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to be more complex. Indeed, T~RI defective in Smad phosphorylation because of 
mutations in the L45 loop of the receptor can still bind Smad7 (43), suggesting 
that Smad2/3 and Smad7 do not share the same T~RI binding interface, although 
Smad7 and Smad2/3 binding to T~RI are mutually exclusive. Moreover, Smad7 is 
involved in the degradation of the receptor complexes, a role that is not shared by 
the DNSmads, which are thought to act by binding to the receptors and thus 
blocking the recruitment of endogenous Smad2/Smad3 to the activated receptors. 
In conclusion, Smad7 is a potent inhibitor of T~R signaling that include the Smad 
and other signaling pathways directly induced by TGF~IT~R complexes (8, 34, 
100), while DNSmads specificalIy inhibit the activation of the Smad pathway (1, 
55,59). 
Moreover, the partial reversaI observed with the DNSmads or Smad siRNA 
strongly suggests that TGF~ requires other signaling pathways to downregulate 
hTERT expression. The activation of Erk and p38 activation folIowing T~R 
activation appears to be celI-type dependent (44). In our celI model system, we 
effectively showed that p38 and Erk kinase activity are needed to diminish 
hTERT expression. In telomerase-positive celIs, Erk kinase was previously shown 
to mediate hTERT promoter upregulation, through the involvement of Ets 
transcription factors, in response to Epidermal Growth Factor (6l)or oncogenic 
HER2, Ras or Raf (30). Moreover, the activity of the p38 kinase is also involved 
in the USF1I2-dependent upregulation of hTERT promoter activity (29). It is 
probably the crosstalk that occurs between Erk, p38 and Smad pathways 
following TGF~ stimulation that produce the negative effect on hTERT 
expression. In other cell systems, such crosstalk between these three pathways 
have been described to be important for the activation of the aggrecan gene (88) 
and the collagenase-3 gene (74) by TGF~. Although we cannot exclude a direct 
effect of Erk and p38 kinases on hTERT promoter, our results suggest that 
crosstalk between these three pathways occurs at the E2F-l regulation lev el. 
Indeed, Erk and p38 kinases activities are required for E2F-l upregulation by 
TGF~, as well as the Smad proteins, thus explaining the requirement of these two 
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kinases in hTERT regulation. Further, the relationship between Erk and p38 
activation in response to TGF13 is not weIl characterized. Preliminary data from 
our laboratory suggest that Erk kinase activation necessitates prior p38 kinase 
activation, since that in the presence of PDl693l6, Erk phosphorylation induced 
by TGF~ is lost (data not shown). 
Telomerase expression, TGF~, and cell cycle regulation 
TGF~ is a very potent negative regulator of the cell cycle. To inhibit the cell 
cycle, TGF~ activates the expression of the cyclin-dependent kinase inhibitor pIS 
and p21, and represses Id proteins and c-myc in most cell types. c-myc, through 
its binding to the E-boxes -242 and -35, is also known to be required for hTERT 
expression. The downregulation of c-myc protein has been suggested as the 
mechanism by which TGF~ regulates hTERT and rat TERT, since c-Myc 
downregulation correlates with hTERT repression in response to TGF~. Our 
results suggest that it is not the case. Instead, we showed that TGF~ was still able 
to repress transcription from hTERT promoters containing either individual or 
both mutated E-boxes. These findings demonstrate that the E-boxes are not 
needed by TGF~ to repress hTERT expression. A recent paper suggests that 
Smad3 interacts with c-myc in order to reduce hTERT expression in MCF-7. 
However, this Smad3/c-myc effect was clearly independent of the downregulation 
of c-myc by TGF~. Although our data cannot exclude that Smad3/c-myc 
interaction plays a role in hTERT reduction, we can exclude that the c-myc effect 
is mediated through binding to the E-boxes. Moreover, we showed that TGF~ 
rather quickly activates expression of an intermediate protein in order to repress 
hTERT. Mad family members are known repressors of the hTERT promoter, 
through the same E-boxes and Mad1 is a target gene of TGF~ (77). Even though 
Madl protein is indeed upregulated by TGF~ in HaCaT cells (data not shown), 
the fact that the E-boxes are not required for the TGF~ effect indicate that Madl 
is not the intermediate molecule required by TGF~. 
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Repression of c-myc by TGF~ has been extensively characterized. It involves 
interactions between Smad3, E2F4/5 and the co-repressor p107 that is known to 
interact with HDAC. Moreover, repression of cdc25A also implicated E2F and 
HDAC (40, 41). It is interesting to note that c-myc and cdc25A, two important 
genes in the regulation of the cell cycle, are regulated by TGF~ through 
cooperation between the Smad proteins and E2F transcription factors, as hTERT. 
Intriguingly, recent studies indicate that telomerase possesses additional functions 
that are not related to net telomere lengthening. In fact, increased telomerase 
expression enhances tumor formation even in the presence of very long telomeres 
in mice(3, 7, 9, 28). Overexpression of hTERT in human epithelial or neural 
cultured cells induces resistance to pro-apoptotic or anti-proliferative signaIs (57, 
64, 93, 103), including TGF~ (79). In fibroblast cells maintaining their telomeres 
via ALT mechanisms, overexpression of hTERT with H-Ras produced the 
formation of tumors in nude mice. Importantly, this is not observed in cells 
expressing H-Ras alone. This suggests that ALT- and hTERT-mediated 
mechanisms are not equivalent for promotion of cancer development. Moreover, 
this suggests again that the hTERT effect on tumor progression includes non-
telomere function. Indeed, expression of a defective form of hTERT unable to 
lengthen telomeres is still able to cooperate with H-Ras in producing tumors (80). 
Recently, an elegant study using microarray technology demonstrated that 
telomerase is able to stimulate proliferation of epithelial cells by controlling 
expression of genes involved in cell proliferation (78). So, it makes sense to 
hypothesize that hTERT downregulation by TGF~ is actually an important 
component of the cytostatic program induced by this ligand to inhibit cell 
proliferation. Moreover, the involvement of E2F family members, with the 
Smads, in the repression of these three genes suggest that they might be involved 
in the repression of other genes regulating cell cycle progression. 
E2F-I is well known for its regulatory role in the transition of the cell cycle from 
G 1 to S phase as it activates genes required for DNA synthesis, cell-cycle control 
and possesses oncogenic properties (60). However, mice studies revealed that 
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E2F-l could actually act as a tumor suppressor gene. E2F-l knockout mice 
exhibit apoptosis defects in thymocytes and develop numerous tumors (24, 98), 
whereas transgenic mice expressing E2F-l display aberrant cell apoptosis (86). 
E2F-l promotes apoptosis in both a p53-dependent and independent manner. E2F-
1 increases the expression of ARF, which in turn stabilize p53 by blocking its 
MDM2-mediated ubiquitination and degradation (4). E2F-l also upregulates the 
expression of the ATM kinase which phosphorylates p53, thus enhancing its 
transcriptional activity (5). E2F-l is also able to induce apoptosis in the absence 
of p53, primarily through the induction of apoptotic genes such as Apaf-l (26, 
67), caspases (10,70), Bim (35), ASKI (46) and SmaclDIABLO (94). 
As TGF~ signaling, E2F-l has a dual effect on cancer development. It is thus 
intriguing to see that TGF~ induces E2F-l expression within 30 minutes and that 
E2F-l is critical for hTERT downregulation, thus regulating the number of 
divisions a cell can do. E2F-l upregulation could also be involved in the 
regulation of apoptosis by TG~. A previous study shows a decrease of E2F-l 
mRNA following 12 hour exposure to TG~ in HaCaT cells (53). The different 
time points used can easily explain this discrepancy. Several papers reported that 
E2F family member are involved in transcriptional repression in response to 
TGF~ stimulation (12, 53, 101). Whether E2F-l activated or represses its target 
gene depend on its interactions with pocket family members. In normal human 
fibroblasts, E2F-pocket protein-HDAC complexes repress hTERT expression 
(90). Moreover, we showed that an E2F-l mutant protein that is unable to interact 
with pocket protein is blocking the TGF~ effect on the hTERT promoter. E2F 
repressive activity on the hTERT promoter could be induced by TG~ through (1) 
the expression of E2F-l and (2) the hypophosphorylation of pocket proteins, as 
TGFi3 is known to maintain Rb in a hypophosphorylated form (51). As a result, 
pocket proteins would tightly bind to E2F-l to form a repressive transcriptional 
complex. Obviously, this needs further investigation. 
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Telomerase activation seems to promote cancer development in two ways: by 
inducing proliferation independently of telomere length at any step during 
tumorigenesis and by rescuing tumor cens with very short telomeres. It is thus 
critical to understand the detailed mechanisms that control telomerase activation 
in cancer cells. First, a better comprehension of telomerase regulation would 
increase our understanding of the molecular events occurring for its reactivation 
in 90% of cancers. Second, telomerase is thought to be a good target for 
therapeutic intervention. Indeed, inhibition of telomerase activity wou Id lead to 
specific killing of tumor cells because these cens are usually characterized by 
shorter telomeres than normal cens. Being shorter, telomeres from cancer cens 
would trigger induction of crisis and cen death more rapidly than normal cells. 
Third, sorne therapeutic strategies are based on the hTERT promoter because the 
activity of the hTERT promoter is higher in a large spectrum of cancer cells. This 
characteristic makes the hTERT promoter a good candidate to specifically drive 
the expression of genes encoding cell-killing agents in cancer cells. 
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Chapter 5: Discussion and Conclusion 
As the results presented in Chapter 3 and 4 have been thoroughly discussed in the 
previous sections, 1 will use this space to discuss the general impacts of these 
studies of TGFj3 and activin signaling, sorne of the general questions that remain 
to be clarified, and their significance on the knowledge we have on cancer 
development. 
As illustrated in the review of literature, TGF~ ligands activate a very linear 
signaling pathway, the Smad pathway. Despite the simple nature of the Smad 
signaling pathway, TGF~ ligands elicit a great diversity of effects on cell 
homeostasis, controlling cell proliferation, apoptosis, differentiation, and 
migration in a cell and tissue specific manner. We illustrated this aspect in 
Chapter 3, Fig.4, where activin was shown to repress PRL expression specifically 
in pituitary cells. This is due to the downregulation of Pit-l transcription factor 
The repression was first observed at the mRNA levels of both proteins and then 
followed in time by decreased protein levels (Chapter 3, Fig.l and 5). Moreover, 
this effect was transient as the mRNAs encoding both proteins were back to 
control levels 24 hours after activin treatment. We did not observed the same 
effect at the protein levels, probably b Pit-l is only expressed in cells originating 
from the pituitary. As a result, activin had no effect on PRL expression in 
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mammary epithelial cells. However, this is only one example of a cell-type 
specific effect of activin and TGF~. Much more work is necessary to delineate the 
complete set of target genes that are differently regulated in epithelial cells 
originating from different tissues. This cou Id be achieved by doing microarray 
studies using epithelial cells originating from different tissues, treated or not with 
TGF~ ligands. This would delineate sets of genes that are specifically regulated 
by TGF~ in a cell and tissue specific fashion. It is likely that the set of genes will 
vary greatly from cell type to cell type, explaining the diversity of TGF~ ligand 
responses. Identification of the se target genes would be of great help to 
understand how TGF~ ligands elicit so many different outcomes depending on the 
cell type, as it is the protein products of these genes that are mediating the 
physiological effects. 
Also important will be the identification of genes that are systematically regulated 
by TGF in all cell types, no matter what is the tissue they are coming from, as the 
function of these genes downstream of TGF~ is likely to be critical. One such 
ex ample of this last category is the Smad7 gene. While Smad7 has been shown to 
be inhibitory to TGF~ signaling, recent observations suggest that it may play 
additional roles and obviously, its function seems much more complex then 
previously thought. A specific role of Smad7 in the regulation of immune cells, 
especially B cells, is suggested by a recent study reporting the phenotype of mice 
with partial loss of Smad7(235). For this, a complete Smad7 knockout mice 
model would be of great help, since to my knowledge, it has not been reported 
yet. 
Additionally, the transcriptional mechanisms by which TGF~ and activin regulate 
their target genes remain an intense research area. Studies on specific TGF~ and 
activin target genes have identified numerous non-Smad proteins that cooperate 
with the Smad to control expression of target genes. It would now be interesting 
to study the groups of genes that are controlled by every given Smad/Smad 
partner complexes. In particular, and based on the work and results presented in 
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this thesis, it would be interesting to analyze the involvement of E2F transcription 
factor family, downstream of TGF~, in the regulation of genes that are controlling 
cell proliferation. E2F-l is particularly intriguing since it has been reported to act 
both as a tumor suppressor and as an oncogene. This is, in fact, very reminiscent 
to the biphasic role played by TGF~ signaling cascade as a tumor suppressor but 
also tumor promoter, depending on the grade of the cancer. Thus, it would be 
interesting to unveil what is the group of genes controlled by E2F-I, possibly in 
cooperation with the Smads, in response to TGF~. One way to do this is to 
perform a chromatin immunoprecipitation using anti-E2F-l antibody on cells that 
are treated or not with TGF~, followed by a microarray experiment to discover to 
which promoters E2F-l binds upon stimulation with TGF~. This experiment 
would be of great help to delineate what genes are under the control of E2F-l and 
TGF~ signaling, and what functions these target genes are involved in. 
Signaling from the Smads is exquisitely important for TGF~ ligands effects. 
However, this occurs in parallel with other ligands and pathways impinging on the 
cell. Furthermore, TGF~ and activin stimulation themselves can activate several 
other signaling pathways, as described in Chapter 4, FigA. Indeed, we showed 
that Smad proteins, Erk and p38 kinases cooperate to repress hTERT expression. 
However, in other contexts, these other pathways can either enhance, suppress or 
modify the Smad signaling pathway. AIl together, this creates a vast signaling 
network that integrates the different inputs of the cellular environment that allows 
the cell to respond properly to its changing milieu. Several issues remain to be 
clarified about the role and importance of each of these different pathways. First, 
mechanisms of activation of non-Smad signaling cascade, like Erk and p38, by 
TGF~ ligand receptors are not weIl defined yet, as they appear to be largely cell-
type specifie. Second, whether non-Smad cascades truly exist downstream of 
TGF~ receptors remain to be clarified. Most of the so-called Smad-independent 
signaling cascades were uncovered using cells that lack Smad4 proteins. 
However, the absolute requirement of Smad4 in Smad signaling itself remains an 
open question. Cells lacking Smad4 are often characterized by elevated levels of 
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R-Smad(273). AIso, R-Smad signaling independently of Smad4 is plausible. First, 
phospho-Smad2 is able to form homotrimers in solution(420). Second, Smad2 
knockout mice display a more severe phenotype when compared to Smad4-1- mice, 
suggesting that sorne functions of Smad2 can occur even in the absence of Smad4. 
Our results of Chapter 4, Fig.3, also suggest that Smad4 is not required for 
hTERT downregulation, although we cannot exclude that the remaining Smad4 
protein cooperate with Smad3 to repress hTERT. 
Perhaps the most intriguing aspect of TGF~ signaling is its dual role on cancer 
progression. What make TGF~ signaling switch from being a tumor suppressor 
pathway to an oncogenic pathway is the topic of extensive research. In this thesis, 
1 focused on the tumor suppressor function of TGF~ cascade. However, as we 
know more about its signaIing cascade, it is becoming easier to study the 
oncogenic aspect of TGF~ signaling. Severallines of evidence suggest that partial 
failure of TGF~ signaIs is allowing tumor development. However, there is no 
selective pressure in tumor cells to lose TGF~ signaIing completely. ActuaIly, 
sorne residual TGF~ effects might be needed for selection of more metastatic 
cancers(103). We can hypothesize that in many tumors, the pathways that links 
TGF~ signaIs to ceIl growth arrest or apoptosis have been interrupted through the 
loss of components other then the receptors and the Smads. One possible example 
found in this thesis is the MEN! gene, but other oncogenes have been described to 
affect TGF~ signaling, like Ski, SnoN, and Evi-l. Other examples are likely to be 
discovered. So, cross-talk mechanisms are probably the key to understand the 
switch occurring around TGF~ signaling that change it from a tumor suppressor 
to an oncogenic pathway. Indeed, TGF~/Smad pathway cross-talk with oncogenic 
pathway, such as the RAS pathway. Moreover, the tumor suppressor effect of 
TGF~ signaling might be tissue specific as the tumor suppressor role is 
particularly prominent in colon and pancreatic cancers. In other tissues, TGF~ 
very often lost its cell growth inhibition ability through uncharacterized 
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mechanisms as very few mutations affecting the receptors or the Smad have been 
found. 
The observation that TGF~ is both a tumor suppressor and a tumor promo ter 
makes it hard to predict the final outcome of targeting TGF~ signaling for tumor 
treatment. Enhancing TGF~ signaling by exogenous TGF~ treatment could be 
used, in principle, to prevent cancer progression because TGF~ inhibit cell 
growth, telomerase activity and promote apoptosis. However, TGF~ also 
stimulates other signaling pathways that are associated with cell transformation, 
like Ras/Erk and PI3K/Akt. In sorne case, TGF~ synergizes with oncogenes, 
especially Ras, to induce transformation. Thus enhancing TGF~ signaling to 
prevent or treat cancer might not be effective and might even be associated with a 
tu mor-permissive effect, a strategy that is highly not efficient in the treatment of 
cancer. 
On the other hand, blocking TGF~ functions might be more useful for the 
treatment of cancer. Indeed, mice studies provide evidence that blocking TGF~ 
negatively affects tumor growth(103), probably by blocking induction of 
angiogenesis, EMT and immune cells. Inhibition of TGF~ can be achieved 
through several mechanisms. One strategy is to block ligand access to the receptor 
by using antibodies against TGF~ ligands. Another approach to prevent TGF~ 
ligands binding to the receptor is to use recombinant fusion protein bearing the 
extracellular ligand-binding do main of T~RII fused to Fc. Lastly, another strategy 
is to use chemical inhibitor to block the kinase activity of T~RI. However, 
inhibiting TGF~ may induce at least two main side effects. Inhibiting TGF~ could 
induce inflammatory and autoimmune disorders and potentially accelerate cancers 
in which TGF~ still exert growth inhibition. For these two reasons and probably 
sorne more to be discovered, it is thus important to continue to characterize TGF~ 
signaling pathways. This will increase our understanding of the final effect of 
targeting TGF~ signaling for the treatment of cancers. 
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Appendix 1: Tansgenic and Knockout mice of TGF~ signaling components 
Genes KnockoutlKnockin phenotypes References 
Perigastrulation lethality (297, 400, 410) 
Defects in extraembryonic ectoderm and 
Smad2-KO mesoderm formation 
Abnormalities in anterior/posterior axis 
formation 
Die between 1-10 months (13,87,439, 
Severe mucosal infection and immune 454) 
dysregulation 
Smad3-KO Colon cancer 
Accelerated wound healing 
Osteoporosis, osteoarthritis, skeletal 
defects 
Perigastrulation lethality (358, 374, 440) 
Defects in extraembryonic ectoderm and 
Smad4-KO mesoderm formation Lack of ectodermal cell proliferation 
Abnormalities in anterior/posterior axis 
formation 
Multiple cardiovascular abnormalities. (125) 
Hyperplasia of the cardiac valves and 
Smad6-KO outflow tract septation defects. In the adult cardiovascular system: 
development of aortic ossification and 
elevated blood pressure in viable mutants. 
Partial KO: defects in B cell immune (204,235) 
responses 
Smad7 Pancreas specific transgenic: at six months 
of age, mice develop premalignant ductal 
lesions in the pancreas 
50% die at EIO.5 due to defects in (101,227) (40, 
hematopoiesis and differentiation of 70, 205, 206, 
TGF~I-KO extraembryonic tissue. 228,353) TGF~ 1-1- mice die approximately at 4 
weeks of age from massive infiltration of 
lymphocytes and macrophages in tissues. 
Die from congenital cyanosis before or (331) 
during birth. 
TGF~2-KO Craniofacial (deft palate), eye, spinal 
column, inner ear, cardiac, lung, limb, and 
urogenital malformations 
Die within 24h of birth. (190,317,378) 
TGF~3-KO Cleft palate and delay in pulmonary 
development/lung maturation 
185 
Genes KnockoutlKnockin phenotypes References 
T~Rr/- mi ce die at midgestation with (218) 
T~RI-KO severe defects in vascular development of 
the yolk sac and placenta, and an absence 
of circulating red blood cells 
Lethal around EIO.5. (304) 
T~RII-KO Defect in yolk sac hematopoiesis and 
vasculogenesis. 
Endoglin-f - mice die around EI0.5 due to (11) (52) 
Endoglin-KO failure to form mature blood vessels in the 
yolk sac. 
TBRIII-f- mice are not viable, dying (365) 
Betaglycan-KO between E16.5 and birth with defects in 
hepatic and cardiovascular development. 
Activin~A -I-mice die within 24 h of birth. (272) 
Lack of whiskers and lower incisors and 
Activin~A-KO defects in their secondary palates, 
including cleft palate, so defects in 
craniofacial development. 
Pailure of eyelid fusion during late (324,394) 
embryonic development led to eye les ions 
Activin~B-KO in mutant animaIs. ~B-I- females are unable to lactate, thus 
causing perinatallethality of their 
offspring. 
Viable. (219) 
Activin~C-KO No obvious abnormalities and normal 
reproductive capacities 
Viable. (73,234,268, 
Infertility in females and secondary 269,271) 
Inhibin (X-KO infertility in males (granulosa/Sertoli cells 
and adrenal tumors). 
Cachexia-like syndrome 
Embryonic lethality. (149) 
ActRIB-KO Disorganization of epiblast and 
extraembryonic ectoderm. 
Suppression of PSH production. (270) 
ActRII-KO Defect in reproduction: delayed maturation 
of testes and female sterility 
ActRIIB-KO Defect in axial patteming. (301) Disturbance of left-right asymmetry 
ActRIIJ ActRIIB- Embryonic lethality. (361) 
KO Abrogation of mesoderm formation before ~astrulation 
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Appendix 2: Celllines used in this thesis 
'ùéïf':Une '., .", " ;:~.:' -'~, 'l ,',).';":;':< " f':Ongi!l:'::;',' '. ;;,':";,,",!;. <> k ."ùhm.:~cieiistics,." .. 
,",7 ,., '" h,,"'~ 1"',,. d, . ,,;,., 
CHû Cricetulus griseus (Chinese hampster) • Adherent 
ûvary • Epithelial 
T47D Homo Sapiens (human) • Adherent 
Breast, mammary gland • Epithelial 
• Ductal 
carcinoma 
GH4CI Rattus norvegicus (rat) • Adherent 
Pituitary • Epithelial 
• Tumor cells 
HaCaT Homo Sapiens (human) • Adherent 
Skin, keratinocytes • Epithelial 
HuH7 Homo Sapiens (human) • Adherent 
Li ver, hepatocytes • Epithelial 
• carcinoma 
MCF-7 Homo Sapiens (human) • Adherent 
Breast, mammary gland • Epithelial 
• adenocarcinoma 
WtMEFs Mus Musculus (mouse) • Adherent 
Embryonic fibroblasts • fibroblasts 
E2F-I (-1-) MEFs Mus Musculus (mouse) • Adherent 
Embryonic fibroblasts • fibroblasts 
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Aetivin, a member of the TGFfJ superfamily, is a 
negative regulator of cell growth and prolaetin 
(PRL) production in pituitary lactotrope cells. How-
ever, the mechanisms by which this growth factor 
exerts its growth-inhibitory and -repressive effect 
on PRL remain unclear. In this study, we show that 
activin negatively regulates PRL expression at the 
transcriptional level through the Smad pathway 
and the multiple endocrine neoplasia type 1 gene 
product, menin. Our results also demonstrate that 
the tumor suppressor menin is required for activin-
induced growth arrest of somatolactotrope cells. 
Moreover, we show that activin represses tran-
P ROLACTINOMAS ARE THE major type of human secretory pituitary tu mors. In addition to their hy-
perproliferative capacity, these cells secrete large 
amounts of prolactin (PRL) causing severe endocrine 
and reproductive disorders. Despite the high inci-
dence of this type of tumors, the molecular basis for 
development of these pituitary disorders remains 
unknown. 
Pituitary gland function is controlled by a large array 
of hormones and growth factors. Activin, a member of 
the TGF/3 family, regulates the secretion of a variety of 
endocrine products (1) and plays an important role in 
regulating anterior pituitary gland function. Activin was 
first isolated from the gonads because of its ability to 
stimulate pituitary FSH synthesis and secretion from 
the gonadotropes (2). The pituitary action of activin is 
not restricted to gonadotropes, and activin also mod-
ulates the function of other pituitary cell types such as 
the somatotropes and lactotropes. In addition to stim-
ulating FSH release from the gonadotropes, activin 
inhibits basal GH and ACTH secretion (2). Finally, ac-
Abbreviations: AS-oligo, menin antisense oligonucleotide; 
CHO, Chinese hamster ovary; C-oligo, control oligonucleo-
tide; GAPOH, glyceraldehyde-3-phosphate dehydrogenase; 
h, human; MEN1, multiple endocrine neoplasia type 1, MTT, 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide; 
PRL, prolactin; r, rat; SOS, sodium dodecyl sulfate; siRNA, 
small interfering RNA; Stat, signal transducer and activator of 
transcription. 
Mo/ecu/ar Endocrin%gy is published monthly by The 
Endocrine Society (http://www.endo-society.org), the 
foremost professional society serving the endocrine 
community. 
seription and expression of Pit-1, a pituitary tran-
scription factor that is essential for maintenance 
and development of lactotrope cells. We defined 
two Pit-1 DNA-binding sites in the proximal region 
of the PRL promoter as critieal for the activin-
mediated inhibition. Together, our results highlight 
the Smad pathway and the tumor suppressor me-
nin as key regulators of activin effects on PRL and 
Pit-1 expression, as weil as on cell growth inhibi-
tion, and emphasize the critical role of activin in the 
regulation of pituitary function. (Mo/eeu/ar Endo-
erin%gy 18: 1558-1569, 2004) 
tivin acts as a negative regulator of PRL expression 
and secretion in pituitary primary culture and celltines 
(3). In addition, activin regulates cell growth and dif-
ferentiation of numerous cell types. The antiprotifera-
tive and proapoptotic effects of activin have been 
observed in many different cell types such as erythro-
leukemia (4), capillary endothelial (5), immune (6, 7), 
breast cancer (8-10), and hepatocytes (11-15). Con-
sistent with the critical role of activin in cell growth 
regulation, alterations of the activin signaling pathway, 
su ch as mutation or truncation of the activin receptor, 
are associated with human tumors (16, 17). 
Activin signais through a complex of two transmem-
brane serine/threonine kinase receptors (type 1 and 
type \1 receptors) (4, 18). Upon ligand binding, the type 
\1 receptor phosphorylates the type 1 receptor, and the 
activated receptor complex then recruits and ph os-
phorylates the receptor-regulated Smad2 and Smad3 
(18-21). These C-terminally phosphorylated Smads 
th en undergo a change in conformation, which results 
in dissociation from the receptor complex and asso-
ciation with the common-partner Smad4 (22-24). The 
Smad complex translocates into the nucleus where it 
regulates transcription of target genes through DNA 
binding and functional recruitment of specifie tran-
scription factors and coregulators, th us providing tis-
sue specificity (25, 26). However, the mechanisms and 
signaling pathways by which activin regulates lacto-
trope pituitary cell function and growth are not weil 
characterized. 
An important player in regulating both PRL and GH 
expression is the pituitary-specific transcription factor 
Lacerte et al. • Activin Signaling in Somatolactotrope Cells 
Pit-1 (GH factor-1) (27, 28). Pit-1 is required for the 
generation and maintenance of three cell types (lacto-
tropes, somatotropes, and thyrotropes) in the anterior 
pituitary gland (29). A1though activin was reported to 
apparently not modulate Pit-1 mRNA levels (30), it was 
shown to induce Pit-1 degradation in MtTW15 somato-
trope ceUs (31). However, the mechanisms by which 
activin controls Pit-1 activity are still not fuUy determined. 
Multiple endocrine neoplasia type 1 (MEN1) is an 
autosomal dominant disorder characterized by endo-
crine tumors of parathyroids, pancreatic islets, and 
anterior pituitary, especially prolactinomas (32). Inter-
estingly, overexpression of menin, the product of the 
MEN1 gene, leads to reduced PRL expression (33). 
Moreover, inactivation of menin expression sup-
presses TGFj3-induced growth inhibition (34). We re-
cently showed that menin physically interacts with 
Smad3 in somatolactotrope cells, and its inactivation 
blocks TGFj3 signaling (34). However, such a role for 
menin downstream of the activin receptor signaling 
pathway remains to be determined. 
The multiple effects of activin on hormone produc-
tion and secretion highlight the important role played 
by this growth factor in regulating pituitary function. 
However, the mechanisms remain unclear. In this 
study, we show that activin negatively regulates PRL 
gene transcription and that the Smad pathway is in-
volved in the mediation of this effect. Moreover, we 
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show, for the tirst time, that menin is required for 
activin-mediated inhibition of PRL expression. We also 
show that activin-mediated inhibition of PRL expres-
sion occurs through reduction of Pit-1 expression, and 
we define two Pit-1 sites in the proximal region of the 
PRL gene promoter as critical to activin-mediated PRL 
inhibition. Finally, we found that menin is also impor-
tant for activin-induced cell growth inhibition in soma-
tolactotrope cells. Together, our results clearly dem-
onstrate a critical role for the growth factor activin in 
regulating inhibition of pituitary cell growth and Pit-V 
PRL expression through the Smads and menin. 
RESULTS 
Activin Inhibits PRL Gene Transcription 
To tirst characterize the role of activin on PRL gene 
expression, we used rat somatolactotrope GH4C1 
cells, a highly differentiated neuroendocrine cell line 
that retains the capacity to synthesize and secrete GH 
and PRL in a hormone-regulated manner (35, 36). The 
GH4 cells were established from rat pituitary tumor 
cells and are widely used as an in vitro model of 
pituitary tumors (37, 38). As shown in Fig. 1A (upper 
pane~, PRL mRNA levels were markedly reduced after 
4 h of activin treatment and had returned to basal 
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Fig. 1. Transcriptional Regulation of PRL Gene Promoter by Activin 
A, Total RNA from GH4C1 cells stimulated with activin for the indicated periods of time were analyzed by Northern blot using 
specifie probes for PRL and GAPDH. B, Whole-ceillysates from GH4C1 cells stimulated with activin for the indicated periods of 
time were analyzed by Western blot using anti-PRL antibody. The membrane was reprobed with an anti-Stat3 antibody for loading 
control. C and D, GH4C1 cells were transfected with the rPRL -3kb or the hPRL -5kb (panel C) or the indicated truncated promoter 
constructs (panel D) with a l3-galactosidase expression plasmid, and the activin response was measured by luciferase assay 18 h 
after stimulation. " P < 0.05 compared with no activin treatment (al/ panels). 
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levels by 24 h. Reprobing of the strippOO membrane for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA showed equalloading (Fig. 1 A, lower panen. To 
then evaluate whether the effect of activin on PRL 
mRNA was foUowed by a decrease in PRL protein 
expression, extracts of GH4C1 ceUs treatOO or not with 
activin for different periods of time were analyzed by 
Western blot. As shown in Fig. 1 B (upper panen, ac-
tivin clearly inhibitOO PRL expression by 16 h to reach 
a maximum inhibition by 24 h. Reprobing of the mem-
brane for signal transducer and activator of transcrip-
tion (Stat)3 protein showOO equal loading (Fig. 1 B, 
lower panen. The data indicate that activin blocks PRL 
gene expression. The same results were obtained us-
ing another pituitary-derived PRL-expressing tumor 
ceUline (GH3), thus strengthening the conclusion (data 
not shown). 
To determine whether activin directly regulates PRL 
expression at the transcriptional level, GH4C1 ceUs 
were transfected with reporter constructs containing 
either 3 kb of the rat PRL promoter fusOO with the 
luciferase gene (rPRL-3kb) (39) or 5 kb of the human 
PRL promoter (hPRL-5kb) (40) and stimulatOO or not 
with activin for 16 h. As shown in Fig. 1C, activin 
stimulation 100 to a 50% rOOuction in luciferase activity 
comparOO with control. Thus, activin exerts a direct 
transcriptional effect on PRL gene expression. 
The PRL gene promoter consists of distal and prox-
imal regions that both contain important regulatory 
sequences. To explore further the promoter se-
quences mOOiating activin down-regulation of PRL 
expression, constructs containing both distal and 
proximal regions of the rat (rPRL-3kb) and human 
(hPRL-5kb) PRL gene promoters and constructs con-
taining only the proximal elements (rPRL-450bp and 
hPRL-250bp) fusOO to the luciferase reporter gene 
were used. The constructs were transfectOO into 
GH4C1 ceUs, and the luciferase activity was measurOO 
after activin treatment. As shown in Fig. 1 D, removal of 
the distal element of both rat and human promoters 
did not affect PRL-induced repression (rPRL-450bp, 
hPRL-250bp). The results indicate that activin medi-
ates its inhibitory effect on PRL gene transcription 
through the proximal region of the PRL gene promoter. 
Smad Pathway Is Critical for Inhibition of PRL 
Gene Transcription by Activin 
The Smad pathway represents the canonical pathway 
downstream of activin receptors. Activin signaling via 
activation of Smads was demonstratOO by immuno-
blot analysis using a specifie antibody to phospho-
Smad2. Activin treatment of GH4C1 ceUs 100 to a rapid 
increase in endogenous Smad2 phosphorylation (Fig. 
2A, upper panen. The membrane was strippOO and 
reprobOO with an anti-Stat3 antibody to show equal 
loading (Fig. 2A, lower panen. 
To investigate the role of the Smads in the acti-
vin-induced PRL inhibition, we used the inhibitory 
Smad7 (41), the dominant-negative forms of Smad2 
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Fig. 2. The Smad Pathway Is Critical for Activin Inhibition of 
PRL Gene Promoter Activity 
A, GH4C1 cens were treated with activin (0-60 min.) 
Whole-cell Iysates were analyzed by Western blot using a 
specifie antibody to phospho-Smad2 (upper pane~. The 
membrane was stripped and reprobed with an anti-Stat3 
antibody as a loading control. B, GH4C1 cens were trans-
fected with the PRL-3kb reporter construct, the j3-galactosi-
dase expression plasmid, and the different Smad expression 
plasmids, as indicated. Cens were then stimulated with ac-
tivin and assessed for luciferase activity .• , P < 0.05 com-
pared with no activin treatment. 
(DNSmad2) (23), and Smad3 (DNSmad3) (42) in which 
the serine residues within the motif SSXS, the target of 
Smad phosphorylation by the type 1 receptor, are mu-
tatOO to alanine. GH4C1 ceUs were transiently cotrans-
fectOO with the 3-kb PRL gene promoter reporter con-
struct and the cDNA encoding for either Smad7, 
DNSmad2, or DNSmad3. As shown in Fig. 2B, the 
activin-induced decrease in luciferase activity ob-
servOO in control ceUs is blocked in GH4C1 cells over-
expressing Smad7 orthe dominant negative Smad2 or 
3. These results clearly demonstrate the requirement 
of the Smad pathway in activin-mediated inhibition of 
PRL gene promoter activation. 
Menin Is Required for Activin-Mediated Inhibition 
of PRL Expression 
Interestingly, a recent study showed that overexpres-
sion of menin in GH3 pituitary ceUs inhibits PRL gene 
expression (33). To explore the function of menin in 
activin signaling, GH4C1 ceUs were treatOO with either 
antisense oligonucleotides to the 5' -coding sequence 
of menin (AS-oligo) or a scramblOO sequence as a 
control (C-oligo). To validate our system, we examinOO 
the ability of the antisense oligonucleotide to suppress 
menin expression. As shown in Fig. 3A, treatment of 
GH4C1 ceUs with the AS-oligo significantly inhibitOO 
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Fig. 3. Activin-Mediated PRL Inhibition Requires Menin 
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A and B, GH4C1 ceUs were cultured in the presence of menin antisense or control oligonucleotides and stimulated or not with 
activin for 24 h. CeUlysates were analyzed by Western blot using antibodies to menin, PRL, and Stat3 (as a loading control). C, 
Total RNA from GH4C1 ceUs transfected with menin (M10) or GAPDH siRNA were analyzed by RT-PCR. Total ceUlysates from 
GH4C1 ceUs transfected with menin (M10) or GAPDH siRNA were analyzed by Western blot using antimenin and anti-Stat3 
antibodies. D, GH4C1 ceUs transfected with M1 0 or GAPDH siRNA were cultured with or without activin for 24 h. CeUlysates were 
analyzed by Western blot using anti-PRL and antimenin antibodies. E, GH4C1 ceUs were transfected with the PRL-3kb reporter 
construct and the (3-galactosidase expression plasmid. CeUs were treated with menin antisense or control oligonucleotides and 
stimulated or not with activin for 18 h before being assessed for luciferase activity. " P < 0.05 compared with no activin treatment. 
F, GH4C1 ceUs were cultured with activin for the indicated period of time. Protein extracts were analyzed by Western blot using 
a specific antibody to menin. The membrane was stripped and reprobed with an anti-Stat3 antibody. 
menin protein expression by 75% as compared with 
the C-oligo. Densitometric analysis was pertormed us-
ing Fluorochem 8000 software that aUows normaliza-
tion and quantitative analysis of chemiluminescence 
under nonsaturating condition. To th en examine the 
effects of menin inactivation on activin-mediated PRL 
inhibition, GH4C1 ceUs were treated with AS-oligo or 
C-oligo before being stimulated or not with activin. 
Total ceUlysates were then analyzed by Western blot-
ting using antibodies to PRL or Stat3. As shown in Fig. 
3B, the inhibitory effect of activin on PRL protein ex-
pression is abolished in the presence of AS-oligo, but 
not with the C-oligo. 
To further support the essential role of menin in the 
regulation of PRL, we generated and tested three dif-
ferent siRNAs corresponding to the rat MEN1 gene. 
We used, as a control, an unrelated siRNA specific for 
GAPDH gene. As iIIustrated in Fig. 3C, transfection of 
MEN1 or GAPDH siRNA in GH4C1 ceUs efficiently 
reduced their respective mRNA and protein expres-
sion levels (55% inhibition). We chose to use M10 
siRNA for subsequent experiments because this par-
ticular smaU intertering RNA (si RNA), which corre-
spond to nucleotides 10-21 of the rat MEN1 coding 
sequence, was the most efficient in blocking menin 
mRNA expression. As shown in Fig. 3D, activin-medi-
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ated PRL expression inhibition was blocked in GH4C1 
cells transfected with M10 siRNA but not affected in 
control cells or cells transfected with the GAPOH 
siRNA. Thus, reducing menin expression levels using 
siRNA or antisense approach, is sufficient to block 
activin-mediated PRL inhibition, demonstrating the 
critical role played by menin in activin signal transduc-
tion in pituitary cells. 
We then analyzed the role of menin in activin-in-
duced repression of the PRL gene promoter. For this, 
GH4C1 cells transfected with the 3-kb rat PRL gene 
promoter construct were treated with the menin anti-
sense or control oligonucleotide, and cells were stim-
ulated or not with activin. Interestingly, activin effects 
on the PRL gene promoter were completely blocked in 
the absence of menin but not affected by the control 
oligonucleotide (Fig. 3E). Therefore, menin is critical 
and required to mediate activin effects on inhibition of 
PRL expression in anterior pituitary cells. We also ex-
amined the role ofactivin on menin expression. As 
shown in Fig. 3F, activin clearly induces an increase in 
menin expression in GH4C1 cells. As menin is required 
to mediate the activin effects (Fig. 3, B-E), this sug-
gests that it may act in a positive feedback loop to 
transduce activin signaling. 
Activin-Dependent Down-Regulation of PRL 
Expression Is Pituitary Cell Specifie 
Production of PRL is not limited ta the pituitary, and 
other sites su ch as the mammary gland (43) have been 
shown ta produce PRL. Interestingly, the human 
breast cancer ceilline T 470, which produces PRL (44), 
is also responsive to activin (10). However, as shown in 
Fig. 4A, no change in PRL expression (upper panen 
was observed in response to activin in these cells. The 
activin responsiveness of the cells was demonstrated 
by the clear increase in phospho-Smad2 in response 
to activin (Fig. 4B). Moreover, Chinese hamster ovary 
(CHO) ceUs, transiently transfected with the rPRL -3kb 
or rPRL -450bp gene promoter constructs, showed no 
decrease in luciferase activity in response to activin 
(Fig. 4C). As a positive control, ceUs were transfected 
with the activin responsive promoter construct 
(3TPLux). Together, these data indicate that a pituitary 
cell-specific factor is involved in the activin-mediated 
down-regulation of PRL mRNA expression. 
Pit-1 Gene Transcription and mRNA and Protein 
Levels Are Down-Regulated by Activin 
Analysis of both the rat and human PRL promoter-
proximal region reveals three Pit-1 response elements, 
suggesting that activin-mediated PRL inhibition may 
be mediated via regulation of the pituitary-specific 
transcription factor Pit-1. This prompted us to analyze 
the regulation of Pit-1 gene expression by activin in 
GH4C1 ceUs. We tirst examined the activin effects on 
Pit-1 mRNA levels in GH4C1 ceUs. As shown in Fig. 
5A, Northem blotting analysis of activin-treated 
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Fig. 4. A Pituitary CeU-Specific Factor Is Involved in the Ac-
tivin-Dependent Down-Regulation of PRL mRNA 
A, Breast cancer T 470 ceUs were treated or not with activin 
for various times, as indicated. CeUlysates were analyzed by 
immunoblot using antibodies specifie to PRL or Stat3 as 
control. B, T47D ceUs were stimulated with activin for 0,15, 
30, and 60 min. Protein extracts from these ceUs were then 
subjected to Westem blot analysis with an anti-phospho-
Smad2-specific antibody. The membrane was stripped and 
reprobed with an anti-Smad2/3-specific antibody. C, CHO 
ceUs were transfected with the PRL-3kb, the PRL-450bp, or 
the 3TP-lux reporter construct as a positive control with the 
f3-galactosidase expression vector. CeUs were then stimu-
lated or not with activin and assessed for luciferase activity. 
" P < 0.05 compared with no activin treatment. 
GH4C1 ceUs indicated that Pit-1 mRNA levels were 
significantly reduced starting at 4 h to reach a maxi-
mum at 16 h after activin treatment. Pit-1 levels th en 
returned to normal by 24 h. T 0 then determine wh ether 
this decrease in Pit-1 mRNA was foUowed by a de-
crease in Pit-1 protein expression, GH4C1 ceUs stim-
ulated with activin for different periods of time were 
analyzed by Western blot. As shown in Fig. 5B, both 
PRL and Pit-1 protein levels were strongly reduced 
upon activin treatment. To evaluate the role of menin in 
activin-mediated Pit-1 down-regulation, GH4C1 ceUs 
transfected with the menin siRNA (M10) or GAPOH 
siRNA were stimulated or not with activin, and the level 
of Pit-1 protein expression was evaluated using a spe-
cifie anti-Pit-1 antibody. As shown in Fig. 5C, in the 
presence of menin siRNA, but not with GAPOH siRNA, 
activin lost its ability to repress Pit-1 protein expres-
sion, similar to that observed for PRL (Fig. 3C), thus 
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Fig. 5. Activin Down-Regulates Pit-1 Gene Transcription and mRNA and Protein Levels 
GH4C1 cells were cultured with activin for the indicated periods of time. A, Total RNA from GH4C1 cells stimulated with activin 
for the indicated periods of time were analyzed by Northem blot using specific probes for Pit-1 and GAPDH. B, GH4C1 cells were 
cultured with activin for the indicated periods of time. Ceillysates were immunoblotted using anti-PRL and anti-Pit-1 antibodies. 
Stripping and reprobing the blot with an anti-Stat3 antibody confirmed equalloading. C, Ceillysates from GH4C1 cells transfected 
with menin (M10) or GAPDH siRNAs and treated or not with activin were immunoblotted using anti-Pit-1 and anti-stat3 antibodies. 
D, GH4C1 cells were transfected with the Pit-1-lux reporter construct together with the l3-galactosidase expression plasmid with 
or without Smad7 expression construct. Cells were treated with activin for 18 h, and luciferase assays were performed. " P < 
0.05 compared with no activin treatment. 
indicating that menin is required for activin to block 
Pit-1 protein expression. 
Furthermore, in GH4C1 cells transfected with a con-
struct in which the Pit-1 gene promoter drives a lucif-
erase reporter gene (45), activin caused a 50% inhibi-
tion of luciferase activity, and this effect was blocked 
in cells expressing Smad7 (Fig. 50). These data indi-
cate that activin modulates Pit-1 mRNA and protein 
expression in a Smad- and menin-dependent manner 
through inhibition of the Pit-1 gene promoter. 
Pit-1 Response Elements in the PRL Gene 
Proximal Promoter Are Critical for Activin-
Mediated Repression 
The proximal PRL gene promoter region contains 
three Pit-1 sites (Fig. 6A). These sites are involved in 
both positive and negative regulation of PRL gene 
promoter activity (46). To investigate the relative im-
portance of these sites in mediating activin repression 
of the PRL promoter, four nucleotides of each Pit-1 
ONA response element were mutated in the rPRL-3kb 
gene promoter construct to disrupt Pit-1 ONA binding 
activity (Fig. 6A). Activin significantly inhibited the 3-kb 
parental promoter construct as weil as the mutant 
promoter lacking the tirst Pit-1 site (Fig. 68). However, 
removal of either site 2 or site 3 completely reversed 
the activin-mediated inhibition of the PRL gene (Fig. 
68). These results indicate that the Pit-1 sites 2 and 3, 
but not site 1, are important for activin-mediated re-
pression of the PRL gene promoter activity. 
Activin Inhibits Pituitary Cell Growth 
through Menin 
Activin is known to induce growth inhibition of epithe-
liai, endothelial, Iymphoid, and hematopoietic cells. 
Therefore, to next investigate the effect of activin on 
pituitary cell growth, GH4C1 cells were stimulated or 
not with activin or TGF{3 as a control. As shown in Fig. 
7A, both activin and TGF{3 significantly inhibited cell 
growth of GH4C1 cells by 30%, thus indicating that 
activin acts as a potent cell growth inhibitor of lacto-
trope cells. To explore the function of menin in activin 
signaling, GH4C1 cells stably overexpressing anti-
sense menin cONA (GH4-AS), in which menin expres-
sion levels are strongly reduced (34), or control GH4C1 
ce Ils expressing the vector alone (GH4-V) were treated 
or not with activin or TGF{3. Interestingly, both the 
activin and TGF{3 effect on cell growth inhibition were 
totally blocked in the absence of menin (Fig. 7A). To 
confirm these results, we used other means of block-
ing menin expression by utilizing modified phospho-
rothioate antisense oligonucleotides to menin. As 
shown in Fig. 78, the effects of activin and TGF{3 on 
GH4C1 cell growth arrest were specitically antago-
nized and completely reversed in the presence of me-
nin AS-oligo whereas they were not affected by the 
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Fig. 6. Pit-1 Response Elements 2 and 3 in the Proximal Region of the PRL Promoter Are Critical for the Activin-Mediated 
Repression of PRL 
A, Schematic representation of the rPRL-lux 3kb reporter construct. The proximal region contains three Pit-1 DNA-binding 
sites. For each of these sites, four nucleotides were changed to other bases as indicated to disrupt Pit-1 DNA binding. B, GH4C1 
cells were transfected with either the wild-type rPRL-lux 3kb, Mut 1P, Mut 2P, or Mut 3P reporter constructs and the 
f3-galactosidase expression vector. Cells were stimulated or not with activin for 18 h, and luciferase activity was assessed .• , P < 
0.05 compared with no activin treatment. 
control oligonucleotide. These data demonstrate that 
activin acts as a potent pituitary tumor cell growth 
inhibitor and that this effect requires the tumor sup-
pressor, menin. 
DISCUSSION 
Members of the activin/TGFj3 family of growth factors 
are important in regulating cell growth and production 
of a variety of hormones from different pituitary cell 
types. Our study defines a critical role for activin in 
regulating the growth and function of pituitary lacto-
trope cells. We demonstrate for the first time the re-
quirement of the Smad pathway and the tumor sup-
pressor menin in transducing activin signais to 
inhibition of PRL expression and cell growth arrest. 
Our results also indicate that activin-mediated ef-
fects on PRL production are pituitary specifie. PRL 
transcription is controlled through a series of distal 
and proximal enhancer elements that contain several 
DNA binding sites for the transcription factor Pit-1 that 
are required to regulate cell-specific expression (47). 
Our results clearly indicate that activin exerts a direct 
negative effect on Pit-1 gene expression. Thus, inhi-
bition of Pit-1 expression by activin contributes to the 
decreased PRL levaI. Our data strongly support pre-
vious observations showing that extinction of PRL and 
GH gene expression in somatic cell hybrids is corre-
lated with the repression of Pit-1 (48, 49). Interestingly, 
previous work showed that activin could contribute to 
reduced intracellular Pit-1 levels by decreasing its sta-
bility (31). Together with our results, this indicates that 
activin is able to down-regulate intracellular Pit-1 and 
PRL levels through different parallel mechanisms, 
highlighting the critical role played by activin in regu-
lating pituitary hormone levels. 
A previous study in GH3 pituitary cells found no 
apparent change in Pit-1 mRNA levels after activin 
stimulation of the cells for 24 h (30). Based on our 
study, activin-mediated repression of Pit-1 mRNA is a 
transient event that occurs within hours of stimulation 
and returns to normal by 24 h, thus explaining why 
Tamura et al. (30) failed to observe any change in Pit-1 
mRNA in activin-treated cells. 
Moreover, the inhibitory effect of activin on GH pro-
duction is mediated through rapid phosphorylation of 
Pit-1, resulting in loss of DNA binding activity and 
protein instability (31). Together with our results, this 
suggests that activin acts at multiple levels to regulate 
Pit-1 and hormonal levels in pituitary cells. 
We also show that the proximal, but not the distal, 
region of the PRL gene promoter mediates the activin-
inhibitory effects. This proximal region of the PRL gene 
promoter contains three Pit-1 response elements, and 
we show here that sites 2 and 3 are each required for 
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Fig. 7. Activin Inhibits Pituitary GeU Growth through the 
MEN1 Gene Product, Menin 
A, GH4C1, GH4-V, and GH4-AS ceUs were cultured with or 
without TGFI3 or activin for 72 h, and ceU viability was as-
sessed by MTT assay. B, GH4C1 ceUs were cultured in the 
presence or the absence of menin antisense oligo or a control 
oligo and stimulated with or without TGFI3 or activin for 72 h. 
CeU viability was measured by MTT assay. *, P < 0.05 com-
pared with no activin treatment (al/ panels). 
activin to repress PRL gene expression. Therefore, this 
suggests that activin-mediated inhibition of PRL ex-
pression is not only mediated through a direct down-
regulation of Pit-1 gene expression but also through 
prevention of DNA binding of the preexisting pool of 
Pit-1 on sites 2 and 3 of the PRL gene promoter. Su ch 
interference with DNA binding and activating functions 
of Pit-1 has been described as a mechanism by which 
glucocorticoids inhibit PRL expression (46). Interest-
ingly, negative regulation of PRL expression by glu-
cocorticoids involves the same proximal Pit-1 sites 2 
and 3, suggesting that this may represent a general 
mechanism of negative regulation of PRL gene 
transcription. 
It is also possible that activin induces recruitment of 
a corepressor to the Pit-1 complex bound to DNA. 
Activin and TGFt3 are known to recruit histone 
deacetylases to some of their target genes, inhibiting 
their transcription (50). Pit-1 has also been shown to 
mediate transcriptional activation and repression by 
recruitment of coactivators or corepressors (51, 52). It 
will therefore be interesting in future studies to deter-
mine whether the Smads physically interact with Pit-1 
and/or histone deacetylase activity can be found in 
these complexes. 
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Whereas Smads, menin and Pit-1, are critical to 
activin inhibition of PRL gene expression, a previous 
study suggested that the inhibitory effect of TGFt3 on 
the rat PRL gene promoter is Pit-1-independent (53). 
Therefore, our results also highlight significant differ-
ences in the intracellular signaling pathways of these 
two growth factors leading to PRL gene regulation in 
pituitary cells . 
Inactivating alterations in the activin/TGFt3 signaling 
pathways have been described to form the basis of 
many human cancers (54). For instance, Smad2 and 
Smad4 are frequently mutated in colorectal cancers 
and pancreatic carcinomas, respectively (54). Trun-
cated activin receptor forms are often found in human 
pituitary adenomas and function as dominant negative 
receptors, contributing to pituitary tumorigenesis by 
blocking the growth-inhibitory effect of activin (17) . 
MEN1 is an autosomal dominant disorder character-
ized by parathyroid hyperplasia, pancreatic endocrine 
tumors, and pituitary adenomas (32). Pituitary tumors 
occur in 30% of MENI patients, with prolactinomas 
being the most common type (56). Twenty-six percent 
of mice heterozygous for deletion of the MEN1 gene 
develop large pituitary tumors by 16 months of age 
(57). Here, we demonstrate that inactivation of menin 
through three different antisense technologies (cDNA 
antisense, oligonucleotide antisense, and siRNA) 
blocks activin signaling. This results in an increase in 
PRL gene expression, Pit-1 gene expression, and the 
loss of pituitary cell growth inhibition by activin. This is 
consistent with our previous work showing that inac-
tivation of menin interrupts Smad3 binding to DNA, 
thereby blocking TGFt3 signaling (34). Thus, menin 
appears as a novel activin downstream signaling ef-
fector molecule, and its inactivation leads to the loss of 
activin/TGFt3 responses, emphasizing the critical role 
played by these growth factors in maintaining cellular 
homeostasis. 
Pituitary adenoma is the most frequent adult intra-
cranial neoplasm, accounting for 10% of brain tumors, 
and, in contrast to other neoplasms, occurs in younger 
patients. Prolactinomas are the most common hor-
mone-secreting pituitary tumor, accounting for two-
thirds of the patients in a pituitary tumor registry 
across the fourth decade (58). Prolactinomas often 
develop sporadically as a monoclonal proliferation, 
but the molecular mechanisms underlying the forma-
tion of these tumors remain largely unknown. Gene 
expression of Pit-1 has been explored in pituitary ad-
enomas but revealed no mutation of the Pit-1 gene in 
these tumors, despite an up to 5-fold higher level of 
Pit-1 as compared with normal (59). To date, standard 
primary treatment using dopamine agonists showed 
suppressive, but not tumoricidal, effects with side ef-
fects and varying remission rates (60, 61). As for pa-
tients with therapeutic intolerance or insensitivity to 
dopamine agonists, surgery remains the last resort. 
Our study sheds light on the mechanisms by which 
activin regulates PRL, Pit-1 levels, and cell growth 
arrest in lactotrope ceUs, through the Smad pathway 
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and the tumor suppressor menin, and opens new av-
enues for future therapies to combat human pituitary 
adenomas. 
MATERIALS AND METHODS 
Cell Culture 
GH4C1 cells, T47D, and CHO cells were cultured in DMEM 
(HyClone Laboratories, Inc., Logan, UT) in the presence of 
10% fetal bovine serum (FBS) (HyClone), and 2 mM 
L-glutamine. 
Cell Viability Assay [3-(4,5-Dimethylthiazolyl-2)-2,5 
Diphenyltetrazoliumbromide (MTT)] 
Cells were plated in triplicate at 5 X 103 cells per 100 p.1 in 
DMEM containing 2% FBS and cultured for 3 d in the pres-
ence or absence of 0.5 nM activin or 0.2 nM TGFj3 (PeproTech, 
Rocky Hill, NJ). Cell viability was assessed using the nonra-
dioactive MTT cell growth assay for eukaryotic cells (Cell Titer 
96, promega G4000; Promega Corp., Madison, WI). Absor-
bance was measured at 570 nm with a reference wavelength 
at 450 nm using a Bio-Tek Microplate reader (Bio-Tek Instru-
ments, Inc., Winooski, VD. 
Transfection and Reporter Assays 
GH4C1 cells were stably transfected with antisense menin 
cDNA as described (34). For luciferase assays, 0.3 p.g of the 
different promoter constructs (rat PRL-Iux 3kb, rat PRL-Iux 
450, rat PRL-Iux mutants, human PRL-Iux 5kb, human PRL-
lux 250, and Pit-1-lux) were cotransfected in 106 cells with 
Lipofectamine (Invitrogen, Carlsbad, CA) with 0.3 p.g of the 
pCH110 expression vector encoding j3-galactosidase, in the 
presence or absence of various Smad expression plasmids, 
as described in the legend of Fig. 2. Cells were trypsinized 1 d 
after transfection, divided in three, allowed to recover, and 
then serum-starved with or without activin (0.5 nM) or TGFj3 
(0.2 nM) for 18 h. Cells were then washed with PBS and Iysed 
in 100 p.llysis buffer (1 % Triton X-100; 15 mM MgS04; 4 mM 
EGTA; 1 mM dithiothreitol; 25 mM glycylglycine, pH 7.8) on 
ice. The luciferase activity of each sample was measured 
using 45 pl cell Iysate (Iuminometer trom EG&G Berthold, 
Badwildbad, Germany) and normalized to the relative j3-ga-
lactosidase activity. CHO cells were transfected using the 
calcium phosphate method. Briefly, 1 p.g of the different 
reporter constructs were transfected with 1 p.g j3-galactosi-
dase expression vector. Cells were serum-starved 1 d after 
transfection, in the presence or absence of 0.5 nM activin, for 
18 h. Luciferase assays were performed as for GH4C1 cells. 
Western Blot Analysis 
For long time courses (0-24 h), GH4C1 and T47D ceUs were 
plated at 106 cells/ml in DMEM containing 2% FBS and 
stimulated in the presence or absence of 0.5 nM activin. For 
short time courses (0-60 min), ceUs were serum starved 
ovemight, and stimulated or not with 0.5 nM activin. CeUs 
were Iysed on ice in Iysis buffer [50 mM HEPES at pH 7.5, 150 
mM sodium chloride, 100 mM sodium fluoride, 10 mM sodium 
pyrophosphate, 5 mM EDTA, 10% glycerol, 0.5% Nonidet 
P40, and 0.5% sodium deoxycholate] supplemented with 1 
mM phenylmethylsulfonyl fluoride, 10 p.g/ml aprotinin, 10 
p.g/ml leupeptin, and 2 p.g/ml pepstatin. Total cell extracts 
were then separated on polyacrylamide gels, transferred to 
nitrocellulose, and incubated with the indicated specifie an-
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tibody ovemight at 4 C [menin (62), stat3 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA), PRL, phospho-Smad2 
(Upstate Biotechnology, Inc., Lake Placid, NY), Smad2l3 
(Santa Cruz), tubulin (Sigma Chemical Co., St. Louis, MO), 
Pit-1 (Santa Cruz)]. After incubation, membranes were 
washed twice for 10 min in washing buffer (50 mM Tris-CI at 
pH 7.6, 200 mM NaCl, 0.05% Tween 20) and incubated with 
a secondary antibody cou pied to horseradish peroxidase 
(Sigma) at 1:10,000 dilution) for 1 h at room temperature. 
Then, membranes were washed four times for 15 min in 
washing buffer. Immunoreactivity was normalized by chemi-
luminescence (Lumi-Light Plus Westem blotting substrate, 
Roche Molecular Biochemicals, Indianapolis, IN) according 
to the manufacturer's instructions and revealed using an 
Alpha Innotech Fluorochem Imaging system (Packard Can-
berra, Montreal, Ouebec, Canada). Densitometric analysis 
was performed using Fluorochem 8000 software (Alpha In-
notech, San Leandro, CA) that allows normalization and 
quantitative analysis of chemiluminescence under nonsat-
urating condition. 
Northem Blot Analysis 
GH4C1 (106 cells/ml) were plated in DMEM containing 2% 
FBS and stimulated with 0.5 nM activin for different periods of 
time. Total RNA was extracted using Trizol (Invitrogen). Each 
sample (20 p.g) was then separated on agarose gels (1 % 
agarose in 0.04 M 3-(N-morpholino)propanesulfonic acid; 
O.01M sodium acetate; 10 mM EDTA, pH 8.0; and 2.5M form-
aldehyde) and transferred to nylon membranes. Membranes 
were rinsed twice in 10X standard saline citrate, cross-linked 
under UV light, and prehybridized in a prehybridization solu-
tion (0.5M NaP04' pH 7.2; 1 mM EDTA, pH 8.0; 7% sodium 
dodecyl sulfate (SOS); 1 % BSA; and 200 p.g/ml salmon 
sperm DNA) for 2 h at 60 C. Probes for PRL, Pit-1, and 
GAPDH were labeled using the Random Priming Kit (Roche), 
and then add to the prehybridization solution for an ovemight 
incubation. Membranes were washed twice for 15 min with 
wash A (40 mM NaP04, pH 7.2; 5% SOS; 1 mM EDTA; and 
0.5% BSA), and four times with wash B (40 mM NaP04' pH 
7.2; 1 % SOS; 1 mM EDTA). Results were revealed using a 
phosphor imager Cyclone Storage Phosphor Screen (Pack-
ard Instruments, Meriden, CT). 
Antisense Oligonucleotide (AS-Oligo) Treatment 
Phosphorothioate-derivatized antisense menin and control 
oligonucleotides (C-oligos) (20 bp) were synthesized. The 
AS-oligo was 5'-GGGCGGCCTTCAGCCCCATG-3', and the 
C-oligo was 5'-TCAGACTGGCTCTCTCCATG-3'. Cells were 
plated in the presence or absence of 100 p.M menin AS-oligo 
or control C-oligo for 12 h and then stimulated with 0.5 nM 
activin or 0.2 nM TGFj3. Luciferase activity was measured 
after 18 h and cell growth was measured after 72 h of ligand 
stimulation. 
Mutagenesis of the rPRL Promoter 
The three Pit-1 proximal binding sites in the wild-type PRL-
3kb construct were mutated singly to disrupt DNA binding of 
Pit-1 using the OuikChange mutagenesis kit (Stratagene, 
La Jolla, CA). Oligonucleotides used for mutagenesis were: 
mut-1 P, 5' -GCCTGATTATATATATGGGAATGAAGGTGTCG-
AAGG-3' and 5' -CCTTCGACACCTTCATTCCCATATATATA-
ATCAGGC-3'; mut-2P, 5'-GGCCACTATGTCTTCCTGAAT-
ATTCCGAAGAAATAAAATACCATTTGA-3' and 5'-TCAAA-
TGGTATTTTATTTCTTCGGAATATTCAGGAAGACATAGTG-
GCC-3'; mut-3P, 5'-TCATTTCCTTTTGCTGTAATTGCGAAA-
AATCCTTCCTTTCTGGCC-3' and 5' -GGCCAGAAAGGAAG-
GATTTTTCGAAATT ACAGCAAAAGGAAATGA-3'. The mu-
tated nucleotides are indicated in bold. Ail mutant constructs 
were confirmed by sequencing. 
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siRNA Design, Generation, and Transfection 
Three different siRNAs corresponding to distinct parts of the 
rat MEN1 gene (GenBank accession no. 9506894) were de-
signed using the siRNA Selection Program (Whitehead Insti-
tute for Biomedical Research, Cambridge, MA). Ail siRNA 
sequences were Blast searched in the National Center for 
Biotechnology Information search for short-nearly exact-
matches mode against ail rat sequences of the GenBank 
database and were not found to have significant homology to 
genes other than the rat MEN1 gene. siRNAs were synthe-
tized using the Silencer siRNA Construction Kit (Ambion, Inc., 
Austin, TX) according to the manufacturer's instructions. 
SiRNAs sequences were as follows: M10 5'-AAGGCCGC-
CCAGAAGACGCTG-3'; M379 5'-AACAGCCTCAGCCGC-
TCCTAC-3'; M1073 5'-AAGAGATCTACAAGGAATTCT-3'. 
GAPDH siRNA was provided with the kit. GH4C1 cells (5 x 
104) were transfected using the siPORT Llpid transfection 
agent (Ambion) according to the manufacturer's instructions. 
Expression levels of menin, PRL, and Pit-1 were analyzed by 
Western blot and RT-PCR. 
Statistical Analysis 
Results are expressed as mean ± 50. Differences were as-
sessed by one-way ANOVA or the unpaired t test, where 
appropriate. P < 0.05 was considered significant. 
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increase the hazards? 
NO 
8. Do the specifie procedures to be employed involving genetically engineered organisms have a history of safe use? 
YES 
9. What precautions will be taken to reduce production of infectious drop lets and aerosols? 
Work done in safety hood in room HS.84. 
~o. List the biological safety cabinets to be used. 
~llilding RoomNo. Manufacturer ModelNo. SeriaI No. 
RVH Hersey Pavillon HS.84 Forma Scientific. 1286 type A/B3 185170 
Date Certified 
July7,2005 
